



US006340583B1

(12) **United States Patent**
Yan et al.

(10) Patent No.: **US 6,340,583 B1**
(45) Date of Patent: **Jan. 22, 2002**

(54) **ISOLATED HUMAN KINASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING
HUMAN KINASE PROTEINS, AND USES
THEREOF**

(75) Inventors: **Chunhua Yan, Boyds; Karen A.
Ketchum, Germantown; Valentina Di
Francesco, Rockville; Ellen M.
Beasley, Darnestown, all of MD (US)**

(73) Assignee: **PE Corporation (NY), Norwalk, CT
(US)**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/813,817**

(22) Filed: **Mar. 22, 2001**

(51) Int. Cl.⁷ **C12N 9/12; C12N 1/20;
C12N 15/00; C12N 5/00; C07H 21/04**

(52) U.S. Cl. **435/194; 435/320.1; 435/252.3;
435/325; 536/23.2**

(58) Field of Search **435/194, 252.3,
435/325, 320.1; 536/23.2**

(56) **References Cited**

PUBLICATIONS

GenEmbl Database, Accession No. D45906, Feb. 1999.*

Sambrook et al., Molecular Cloning Manual, 2nd edition,
Cold Spring Harbor Laboratory Press, 1989.*

* cited by examiner

Primary Examiner—Rebecca E. Prouty

Assistant Examiner—M. Monshipouri

(74) *Attorney, Agent, or Firm*—Celera Genomics; Robert
A. Millman; Justin D. Karjala

(57) **ABSTRACT**

The present invention provides amino acid sequences of
peptides that are encoded by genes within the human
genome, the kinase peptides of the present invention. The
present invention specifically provides isolated peptide and
nucleic acid molecules, methods of identifying orthologs
and paralogs of the kinase peptides, and methods of iden-
tifying modulators of the kinase peptides.

9 Claims, 41 Drawing Sheets

1 CCCAGGGCGC CGTAGGCGGT GCATCCCGTT CGCGCCTGGG GCTGTGGTCT
51 TCCCGCGCCT GAGGCGGCGG CGGCAGGAGC TGAGGGGAGT TGTAGGGAAC
101 TGAGGGGAGC TGCTGTGTCC CCCGCCTCCT CCTCCCCATT TCCGCGCTCC
151 CGGGACCATG TCCGCGCTGG CGGGTGAAGA TGTCTGGAGG TGTCCAGGCT
201 GTGGGGACCA CATTGCTCCA AGCCAGATAT GGTACAGGAC TGTCAACGAA
251 ACCTGGCAGG GCTCTTGCTT CCGGTGAAAG TGATGCGCAG CCTGGACCAC
301 CCCAATGTGC TCAAGTTCAT TGGTGTGCTG TACAAGGATA AGAAGCTGAA
351 CCTGCTGACA GAGTACATTG AGGGGGGCAC ACTGAAGGAC TTTCTGCGCA
401 GTATGGATCC GTTCCCCTGG CAGCAGAAGG TCAGGTTTGC CAAAGGAATC
451 GCCTCCGGAA TGGACAAGAC TGTGGTGGTG GCAGACTTTG GGCTGTCACG
501 GCTCATAGTG GAAGAGAGGA AAAGGGCCCC CATGGAGAAG GCCACCACCA
551 AGAAACGCAC CTTGCGCAAG AACGACCGCA AGAAGCGTA CACGGTGGTG
601 GGAAACCCCT ACTGGATGGC CCCTGAGATG CTGAACGGAA AGAGCTATGA
651 TGAGACGGTG GATATCTTCT CCTTTGGGAT CGTTCTCTGT GAGATCATTG
701 GGCAGGTGTA TGCAGATCCT GACTGCCTTC CCCGAACACT GGACTTTGGC
751 CTCAACGTGA AGCTTTTCTG GGAGAAGTTT GTTCCACAG ATTGTCCCCC
801 GGCCTTCTTC CCGCTGGCCG CCATCTGCTG CAGACTGGAG CCTGAGAGCA
851 GACCAGCATT CTCGAAATTG GAGGACTCCT TTGAGGCCCT CTCCTGTAC
901 CTGGGGGAGC TGGGCATCCC GCTGCCTGCA GAGCTGGAGG AGTTGGACCA
951 CACTGTGAGC ATGCAGTACG GCCTGACCCG GGACTCACCT CCCTAGCCCT
1001 GGCCCAGCCC CCTGCAGGGG GGTGTTCTAC AGCCAGCATT GCCCTCTGT
1051 GCCCCATTCC TGCTGTGAGC AGGGCCGTCC GGGCTTCTG TGGATTGGCG
1101 GAATGTTTAG AAGCAGAACA AACCATTCTT ATTACCTCCC CAGGAGGCAA
1151 GTGGGCGCAG CACCAGGGAA ATGTATCTCC ACAGGTTCTG GGGCTAGTT
1201 ACTGTCTGTA AATCCAATAC TTGCCTGAAA GCTGTGAAGA AGAAAAAAC
1251 CCCTGGCCTT TGGGCCAGGA GGAATCTGTT ACTCGAATCC ACCCAGGAAC
1301 TCCCTGGCAG TGGATTGTGG GAGGCTCTTG CTTACACTAA TCAGCGTGAC
1351 CTGGACCTGC TGGGCAGGAT CCCAGGGTGA ACCTGCCTGT GAACTCTGAA
1401 GTCAC TAGTC CAGCTGGGTG CAGGAGGACT TCAAGTGTGT GGACGAAAGA
1451 AAGACTGATG GCTCAAAGGG TGTGAAAAAG TCAGTGATGC TCCCCCTTC
1501 TACTCCAGAT CCTGTCTTC CTGGAGCAAG GTTGAGGGAG TAGGTTTGA
1551 AGAGTCCCTT AATATGTGGT GGAACAGGCC AGGAGTTAGA GAAAGGGCTG
1601 GCTTCTGTTT ACCTGCTCAC TGGCTCTAGC CAGCCCAGGG ACCACATCAA
1651 TGTGAGAGGA AGCCTCCACC TCATGTTTTT AAACCTAATA CTGGAGACTG
1701 GCTGAGAACT TACGACAAC ATCCTTTCTG TCTGAAACAA ACAGTCACAA
1751 GCACAGGAAG AGGCTGGGGG ACTAGAAAGA GGCCCTGCCC TCTAGAAAGC
1801 TCAGATCTTG GCTTCTGTTA CTCATACTCG GGTGGGCTCC TTAGTCAGAT
1851 GCCTAAAACA TTTTGCTTAA AGCTCGATGG GTTCTGGAGG ACAGTGTGGC
1901 TTGTACAGG CCTAGAGTCT GAGGGAGGGG AGTGGGAGTC TCAGCAATCT
1951 CTTGGTCTTG GCTTCATGGC AACCCTGCT CACCCTTCAA CATGCCTGGT
2001 TTAGGCAGCA GCTTGGGCTG GGAAGAGGTG GTGGCAGAGT CTAAGGCTG
2051 AGATGCTGAG AGAGATAGCT CCCTGAGCTG GGCCATCTGA CTTCTACCTC
2101 CCATGTTTGC TCTCCCACT CATTAGCTCC TGGCAGCAT CCTCCTGAGC
2151 CACATGTGCA GGTACTGGAA AACCTCCATC TTGGCTCCA GAGCTCTAGG
2201 AACTCTTCAT CACAAC TAGA TTTGCCTCTT CTAAGTGTCT ATGAGCTTGC
2251 ACCATATTTA ATAAATTGGG AATGGGTTTG GGGTATTAAA AAAAAAAAAA
2301 AAAAAAAAAA AAAAAAAAAA (SEQ ID NO:1)

FIG.1A

FEATURES:

5'UTR: 1-228
Start Codon: 229
Stop Codon: 994
3'UTR: 997

Homologous proteins:

Top 10 BLAST Hits

	Score	E
CRA 1000682328847 /altid=gi 8051618 /def=ref NP_057952.1 LIM d...	485	e-136
CRA 18000005015874 /altid=gi 5031869 /def=ref NP_005560.1 LIM ...	485	e-136
CRA 88000001156379 /altid=gi 7434382 /def=pir JC5814 LIM motif...	469	e-131
CRA 88000001156378 /altid=gi 7434381 /def=pir JC5813 LIM motif...	469	e-131
CRA 18000005154371 /altid=gi 7428032 /def=pir JE0240 LIM kinas...	469	e-131
CRA 18000005126937 /altid=gi 6754550 /def=ref NP_034848.1 LIM ...	469	e-131
CRA 18000005127186 /altid=gi 2804562 /def=dbj BAA24491.1 (AB00...	469	e-131
CRA 18000005127185 /altid=gi 2804553 /def=dbj BAA24489.1 (AB00...	469	e-131
CRA 18000005004416 /altid=gi 2143830 /def=pir I78847 LIM motif...	468	e-131
CRA 18000005004415 /altid=gi 1708825 /def=sp P53670 LIK2_RAT LI...	468	e-131

BLAST dbEST hits:

	Score	E
gi 10950740 /dataset=dbest /taxon=96...	1049	0.0
gi 10156485 /dataset=dbest /taxon=96...	975	0.0
gi 5421647 /dataset=dbest /taxon=9606 ...	952	0.0
gi 10895718 /dataset=dbest /taxon=96...	757	0.0
gi 13043102 /dataset=dbest /taxon=960...	714	0.0
gi 519615 /dataset=dbest /taxon=9606 /...	531	e-149
gi 11002869 /dataset=dbest /taxon=96...	511	e-143

EXPRESSION INFORMATION FOR MODULATORY USE:

library source:

From BLAST dbEST hits:

gi|10950740 teratocarcinoma
gi|10156485 ovary
gi|5421647 testis
gi|10895718 nervous_normal
gi|13043102 bladder
gi|519615 infant brain
gi|11002869 thyroid gland

From tissue screening panels:

Fetal whole brain

FIG.1B

1 MVQDCQRNLA RLLLPVKVMR SLDHPNVLFK IGVLYKDKKL NLLTEYIEGG
51 TLKDFLRSMQ PFPWQQKVRK AKGIASGMDK TVVVADEGLS RLIVEERKRA
101 PMEKATTKKR TLRKNDKRR YTVVGNPYWM APEMLNGKSY DETVDIFSFG
151 IVLCEIIGQV YADPDCLPRT LDFGLNVKLF WEKFPVTPDCP PAFFPLAAIC
201 CRLEPESRPA FSKLEDSFEA LSLYLGEGLI PLPAELEELD HTVSMQYGLT
251 RDSPP (SEQ ID NO:2)

FEATURES:

Functional domains and key regions:

[1] PDOC00004 PS00004 CAMP PHOSPHO SITE

cAMP- and cGMP-dependent protein kinase phosphorylation site

Number of matches: 2

1 108-111 KKRT

2 119-122 KRYT

[2] PDOC00005 PS00005 PKC PHOSPHO SITE
Protein kinase C phosphorylation site

Number of matches: 4

1 51-53 TLK

2 106-108 TTK

3 107-109 TKK

4 111-113 TLR

[3] PDOC00006 PS00006 CK2 PHOSPHO SITE
Casein kinase II phosphorylation site

Number of matches: 4

1 51-54 TLKD

2 76-79 SGMD

3 139-142 SYDE

4 212-215 SKLE

[4] PDOC00008 PS00008 MYRISTYL
N-myristoylation site

Number of matches: 4

1 73-78 GIASGM

FIG.2A

2 77-82 GMDKTV

3 150-155 GIVLCE

4 158-163 GQVYAD

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	142	162	0.872	Putative
2	184	204	0.652	Putative

BLAST Alignment to Top Hit:

>CRA|1000682328847 /altid=gi|8051618 /def=ref|NP_057952.1| LIM
domain kinase 2 isoform 2b [Homo sapiens] /org=Homo
sapiens /taxon=9606 /dataset=nraa /length=617
Length = 617

Score = 485 bits (1235), Expect = e-136

Identities = 241/265 (90%), Positives = 241/265 (90%), Gaps = 22/265 (8%)

Query: 13 LLPVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDFPWPQQKVRFAK 72
L VKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDFPWPQQKVRFAK
Sbjct: 353 LTEVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDFPWPQQKVRFAK 412

Query: 73 GIASGM-----DKTVVWADFGLSRLIVEERKRAPMEKATTKKR 110
GIASGM DKTVVWADFGLSRLIVEERKRAPMEKATTKKR
Sbjct: 413 GIASGMAYLHSMCIHRDLNSHCLIKDKTVVWADFGLSRLIVEERKRAPMEKATTKKR 472

Query: 111 TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT 170
TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT
Sbjct: 473 TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT 532

Query: 171 LDFGLNVKLFWEKFVPTDCPPAFFPLAATCCRLEPESRPAFSKLEDSFEALSLYLGEGLGI 230
LDFGLNVKLFWEKFVPTDCPPAFFPLAATCCRLEPESRPAFSKLEDSFEALSLYLGEGLGI
Sbjct: 533 LDFGLNVKLFWEKFVPTDCPPAFFPLAATCCRLEPESRPAFSKLEDSFEALSLYLGEGLGI 592

Query: 231 PLPAELEELDHTVSMQYGLTRDSPP 255
PLPAELEELDHTVSMQYGLTRDSPP
Sbjct: 593 PLPAELEELDHTVSMQYGLTRDSPP 617 (SEQ ID NO:4)

Hmmer search results (Pfam):

Model	Description	Score	E-value	N
PF00069	Eukaryotic protein kinase domain	100.1	1.1e-26	2
CE00031	CE00031 VEGFR	4.9	0.14	1
CE00204	CE00204 FIBROBLAST_GROWTH_RECEPTOR	4.7	1	1
CE00359	E00359 bone_morphogenetic_protein_receptor	1.8	7.9	1
CE00022	CE00022 MAGUK_subfamily_d	1.5	2.5	1
CE00287	CE00287 PTK_Eph_orphan_receptor	-48.4	3.8e-05	1
CE00292	CE00292 PTK_membrane_span	-61.8	2.1e-05	1

FIG.2B

CE00291	CE00291	PTK fgf_receptor	-113.0	0.027	1
CE00286	E00286	PTK EGF_receptor	-125.1	0.0021	1
CE00290	CE00290	PTK Trk_family	-151.3	6.5e-05	1
CE00288	CE00288	PTK_Insulin_receptor	-210.4	0.014	1

Parsed for domains:

Model	Domain	seq-f	seq-t	hmm-f	hmm-t	score	E-value
PF00069	1/2	16	79 ..	41	105 ..	52.1	2.3e-13
CE00022	1/1	124	153 ..	187	216 ..	1.5	2.5
PF00069	2/2	81	156 ..	129	182 ..	48.0	3.1e-12
CE00031	1/1	129	156 ..	1114	1141 ..	4.9	0.14
CE00204	1/1	129	156 ..	705	732 ..	4.7	1
CE00359	1/1	79	157 ..	287	356 ..	1.8	7.9
CE00290	1/1	9	218 ..	1	282 []	-151.3	6.5e-05
CE00287	1/1	1	218 [.	1	260 []	-48.4	3.8e-05
CE00291	1/1	1	218 [.	1	285 []	-113.0	0.027
CE00292	1/1	1	218 [.	1	288 []	-61.8	2.1e-05
CE00288	1/1	1	218 [.	1	269 []	-210.4	0.014
CE00286	1/1	6	218 ..	1	263 []	-125.1	0.0021

FIG.2C

1 TCATCCTTGC GCAGGGGCCA TGCTAACCTT CTGTGTCTCA GTCCAATTTT
51 AATGTATGTG CTGCTGAAGC GAGAGTACCA GAGGTTTTTT TGATGGCAGT
101 GACTTGAAGT TATTTAAAAG ATAAGGAGGA GCCAGTGAGG GAGAGGGGTG
151 CTGTAAAGAT AACTAAAAGT GCACTTCTTC TAAGAAGTAA GATGGAATGG
201 GATCCAGAAC AGGGGTGTCA TACCGAGTAG CCCAGCCTTT GTTCCGTGGA
251 CACTGGGGAG TCTAACCAG AGCTGAGATA GCTTGCAGTG TGGATGAGCC
301 AGCTGAGTAC AGCAGATAGG GAAAAGAAGC CAAAAATCTG AAGTAGGGCT
351 GGGGTGAAGG ACAGGGAAGG GCTAGAGAGA CATTTGGAAA GTGAAACCAG
401 GTGGATATGA GAGGAGAGAG TAGAGGGTCT TGATTTCTGG TCTTTCATGC
451 TTAACCCAAA GCAGGTACTA AAGTATGTGT TGATTGAATG TCTTTGGGTT
501 TCTCAAGACT GGAGAAAGCA GGGCAAGCTC TGGAGGGTAT GGCAATAACA
551 AGTTATCTTG AATATCCTCA TGGTGAAAG TCCTGATCCT GTTTGAATTT
601 TGGAAATAGA AATCATTGAG AGCCAAGAGA TTGAATTGTT GAGTAAGTGG
651 GTGGTCAGGT TACAGACTTA ATTTTGGGTT AAAAAGTAAA AACAAGAAAC
701 AAGGTGTGGC TCTAAAATAA TGAGATGTGC TGGGGGTGGG GCATGGCAGC
751 TCATAAAGT ACCCTGAAAG CTCTTACATG TAAGAGTTCC AAAAATATTT
801 CCAAACTTG GAAGATTCAT TTGGATGTTT GTGTTTATTA AAATCTCTCA
851 CTAATTCATT GTCTTGTTCA CTGTCCGTAA CCCAACCTGG GATTGGTTTG
901 AGTGAGTCTC TCAGACTTTC TGCCTTGGAG TTTGTGAGAG AGATGGCATA
951 CTCTGTGACC ACTGTCACCC TAAAACCAA AAGGCCCTC TTGACAAGGA
1001 GTCTGAGGAT TTTAGACCCA GGAAGAATGA GTGATGGGCA TATATATATC
1051 CTATTACTGA GGCATGAGAA GAGTGGAATG GGTGGGTGTA GGTGGTGTTC
1101 TAAGGCCTCT TGCCAGCTTG TTTAACTCTT CTCTGGGGAA CGAGGGGGAC
1151 AACTGTGTAC ATTGCTGCT CCAGAATGAT GTTGAGCAAT CTTGAAGTGC
1201 CAGGAGCTGT GCTTTGTCTA TTCATGGCCC CTGTGCCTGT GAAACAGGGT
1251 TCGGTGACTG TCACTGTGCC TGTGGCAGTC TGTAAGTTACC CAGAGAGAAC
1301 AAAGCTGCAT ACACAGAGCG CACAAGGGAG TCTTGTAACA ACCTTGCTCT
1351 GCTTCTAGG GCTGAGTCAG GTACCACAGC TTGATCTCAG CTGTCCTCTT
1401 TATTTCAAGA AGTTGACATC TGAGCCATAC CAGGAGTATT GTATTTTGT
1451 TGAGGCCTCT CTTTTTGGAG GAACATGGAC CGACTCTGTG CTTTTGTCTA
1501 TGCTGGTCTC TGAGCTCACA CAACCCTTCA CCCTCCTTTC TCAGCCAGTG
1551 ATAGGTAAGT CTTCCCTATC TTGCAAGGCT CAGCTCAAGT GTCAGCTTCC
1601 TCTACAAAGA CTTTCCTGGT TCCCCTCATT GGAGTGAACA AGAGTTGACA
1651 TGGTAGAATG GAAAGAGCAG AAGCTTTAGA ATGAGCCAGA CCTGAGTATG
1701 AATGCTAGAT CCACCACTTA GCTAGTCAAC CCTGCCCCCT GCCTCAAGTT
1751 TTAATTTTCC TATCCATTAA GTGAATATAA TAATACCTGT GTCACAGGAT
1801 TATTTTGAGA ATTAATGAG ATTAGGTCTA TGAAAGCACC TAGCAGAGTT
1851 CTTGGCATAT AGGAGGCATT CATTAAATAT TTGTTCTTCC CTTTTATAC
1901 CCATTACTTT TCTTTTCTG AACTAAAATA ATACTTGGTT CTATCTCTGA
1951 AATAACATCC AAGTAAAAA TCAACAACAT GAAAGAGCAG TTCTTTTCCA
2001 GTGGATTTGC TTCTTAAGGA GCAGAGATTA TGTAATCTAA CAGCCTCCAA
2051 CATACAAAGA GCTTTGTATC TAGAACAGGG GTCCCCAGCC CCTGGACCGC
2101 CAACTGGTAC GGGTCTGTAG CCTGTTAGGA ACCAGGCTGC ACAGCAGGAG
2151 GTGAGCGGCG GGCCAGTGAG CATTGCTGCC TGAGCTCTGC CTCCTGTCAG
2201 ATCAGTGGTG GCATTAGATT CTCATAGGAG TGTGAACCCT ATTGTGAAT
2251 GCACATGCAA GGGATCTGGG TTGCATGCTC CTTATGAGAA TCTCACTAAT
2301 GGCTGATGAT CTGAGTTGGA ACAGTTTGAT ACCAAAACCA TCCCCCGCC
2351 CCCCAACCCC CAGCCTAGGG TCCGTGGAAA AATTGGCCCC TGGTGCCAAA
2401 AAGGTTGAGG ACTGCTGATC TAGAGGACCA ATTTATTCAA TGTTGGTTGA
2451 GTAAATGAGC TCTTGGATTA GGTGATGGAA AAATCTGAAA AAACAGGGCT

FIG.3-1

2501 TTTGAGGAAT AGGAAAAGGC AGTAACATGT TTAACCCAGA GAGAAGTTTC
2551 TGGCTGTTGG CTGGAATAG TCATAGGAAG GGCTGACACT GAAAAGAAGG
2601 AGATTGTGTT CGTTTCTTCT TCTCAGAGCT ATAAGCAAAG GCTGAAAGTT
2651 CTAGAAAAAG GCAAGTTTTG TTTCAGTAGA AAAAAGGATA ATCAGAACCA
2701 TTTTGTAGAAA ATGGAATGAG ACTACTTTTG AGGCCATGAG TTCCTTGTC
2751 CTGGAGAGAT GAGCAGAGGT TGGACAAGTG CTTACCAGAG ATCTTGTTGA
2801 GGCAGAACT GTGCATCTAG CAGAGCATTG GCCTAACCTT TCAAAATGAG
2851 ATGCTGTAA CTCAGTCTTA TTCTACATGG TAGGAATCCT GTCCCTTTGC
2901 CTCCTGCTAC TTTGGGCTC TCAACCTCTT GGTGTTGTGT GCAGGTGAAG
2951 ATGCTGGAG GTGTCCAGGC TGTGGGGACC ACATTGCTCC AAGCCAGATA
3001 TGGTACAGGA CTGTCAACGA AACCTGGCAC GGCTCTTGCT TCCGGTAGGT
3051 GGGCCTATCC TCCATCTTT ACCAGTGTAC TATGGGCCAA GCACTATTTT
3101 ATGTTCTGAT GGAACACACA GAAACAAGCT TCTGAGTTGA GAATTTCAAT
3151 CTTAGGGTGG GGAAGGAAT GTACCAAGGA AGAGCTCATG ACCAAACCTC
3201 AAGTGTGGCC CCCCTGAACC CAGGTAAAT TGAAGAGCC ATAAATGGGC
3251 CAGCTGGAGG CAGGGTGGGG GGATGAGAGG AGCCCTTTCC AGGGTTGTCC
3301 CATATCCCTC ACTTTATGGG TGAGGAACT GAGGCCCAGG AAGAGTGACT
3351 TTCTGTGGC TGCACTACAG ATTATGCAGG TACTTCAAGA GTTGTGTTGA
3401 TTCTATTTT ATTTTATTTT ATTTTATTTT ATTTTATTTT ATTTTATGAG
3451 AGGGATTCTT GCTGTTGCCC AGGCTGGAGT GCAGTGGTGC AATCTCGGCT
3501 CACTGCAATC TCTGCCTGCT GGGTTCAAGT GATTTTTCTG CCTTAGCTTC
3551 CTGAGTAGCT GAGATGACAG GCACCTGCCA CCATGCGCAG CTAATTTTTG
3601 TATTTTAGTG GAGACGGGGG TTTCAACATG TTGGTCAGGC TGGTCTTGAA
3651 CTCCTGACCT CAAATGATGC ACCACCTCG ACCTCCCAA GTGCTGGAAT
3701 TACAGGCGTG AACCACTGTG CCCAGCCAAG AGTTGTTTTT AGTGTGGTTG
3751 GCAGAGCCAG CTCTTCTTC ACCACAGGAT GCCTCCCTAG GTTCTACTT
3801 TTTGTTACTA GCTTTTATTA TAGCTATATT ATTATTATTA TTATTATTAT
3851 TATTATTATT ATTATTGAGA CAGAGTCTCG CTCTGTCGCC CAGGCTGGTG
3901 TACAGTGGTG CGATCCCGGG CCACTGCAA CCTCTGCCTC CCGAGTTCAA
3951 GCAGTTCTCC TGCTCAGCC CCCCGAGTAG GTGGGACTAC AGGCGCTGCT
4001 CACCACACCC GGCTAATTTT TGTATTTTGA GTAGAGACGG GGTTCACCT
4051 TGTGACCAG GCTGGTCTGG AGCTCTGAC CTCAGGTAAG TGCTAGAATC
4101 ACAGGCGTGA ACCACTGCGC CCAGCCAAGA GTTGTTTTTA GTGTGGTTGG
4151 CAGAGCCAGC TCTTCTCAC CACAGGTTGC CTCCCTAGGT TCCTACTTTT
4201 TGTTACTAGC TTTATTATAG CTACATTATT ATTATTATTG TTATTATTAT
4251 TGAGACAGAG TCTCGCTCTG TCGCCAGGC TGGTGACAG TGATGTGATC
4301 TTGGCTCACT GCAACCTCTG CCCCCGAGT TCAAGCAATT CTCCTGCTTC
4351 AGCCCCCTA GTAGGTGGGA CTCCAGGCAC CTGCCACCAC GCCCAGCTAA
4401 TTTTGTATT TTTAGTAGAG GCGGGGTTTC ACCTTGTTGG CCAGGCTGGT
4451 CTCAACTCC TGACCTCAGG TGATCCGCTT GCCTCGGCTT CCCAAATGT
4501 TGGGATTACA GGCATGAGCC ACCGCGCCTT GCCTATAGCT ACATTATTTT
4551 TGAGGCAGC TCAGTTTCTT AAAAATTATA CAGACTTCAA ATCAGATTTG
4601 TTCCTGCTGT CTGAGGCTCA GTTCTTCAT CTGGAAATG GATGGTAATA
4651 ATCTTGTTGA GATTGAATGA AATAATATAT GCAGTGTATC CAGTACATGG
4701 TAGACACCCA GTGAATGGTT ATTCTTCCT CCCATCGGAT TGAATTTCTC
4751 AAGGGTGGGA ACTTGCTTTT ATATTCTTCA CAACGTAAAA TAGTTGAAAT
4801 TTGTTGGTGG AAAGAAGAGC AGTCCACTCC AGAGGCTGGA TGGGCATGCC
4851 TGGCCCCCAA GGTCTGAAGT GGTAGGGCTG TGCCTATATC CTGAGAATGA
4901 GATAGACTAG GCAGGCACCT TGTGCTGTAG ATTCCAGCTC CTGCACATAG
4951 CTCTTGTTGT AAAACATCCC TGTGCTTATA CCAAGTAATT GAGTTGACCT

FIG.3-2

5001 TTAACACTT GCCTCTTCCC TGGGAACCAT ATAGGGGATT GGCCTGGAGA
5051 CGTCTGGCCT CTGGAAGAGT TGGAAAGCAG CCATCATTAT TATCCTTTCC
5101 TTTCAGCTAT AACTCAGAGC TCTCAAGTCT TTTCTGTGGA TCTTATTGCC
5151 TTGGTTCTTG CCCCTTTTAC TCCCAGGGAA GTTGATTCTG TCTTTTCTGT
5201 TCCATTTAGT ATGACAGGAG CAGAGAATGT CAGAGCTGTA AGGGACCTTA
5251 TAGTTAAAGC CTTTGGCTGG TCCTTTCATT TTATAGCTGG GACTAATAAG
5301 TAACGTCAAA ACCCAATGAG TTCACAGATT GGTCTCGCC TTGGCATGTA
5351 ACCCATATGT TCATATTCTT GCTGTTTTCC TATGTGTATG AATATTTTCT
5401 ATCCAAAATA AGCAGGACAG GGTAGAGCAA GTTAATCTTT GGAATTTCTG
5451 GATTCTCTTA GAGCTAAAAA ACTTCAGAAC TAGAAGAAAC CACCCACTAT
5501 ATGGTATAAC CCATTTCATAT CACAGATGAG GCCTGAAACC AAAAAGACTT
5551 GCTCAGGCCA TGGATGACAA GAGCTGGCCC TAGCACTGAA CTCTTGGGTC
5601 ATTTGTAGGT CTAGTCAGAT GCTAGCTTGT TAGCTCTGTG CGTGCGTGTG
5651 TGTGTGTGTG TGTGTGTGTG TGTGTGAGAT AGAGACAGAA AGATAACATA
5701 TGTACACAAA TACATAAAGA GGAAGTAGAC ACGTTAGCAT GGTAGATAAG
5751 AGTACAGGCA GGCCAGGCGT GGTGGCTCAC GCCTGTAATC CCAGCACTTT
5801 GGGAGGCCAA GGCAGGTGGA TCACCTGAGG TCAGGAATTC GAGACCAGCC
5851 TGACCAACAT GGTGAAACCC CATCTCTACT AAATACAGAA AAAAATTAGC
5901 TTGGCATGGT GGCACATGCC TGTAATCCCA GCTACTTGGG AAGCTGAAGC
5951 AGGAGAATCG CTTGAATCCG GGAAGCAGAA GTTGCACTGA GCCGAGATTG
6001 TGCCATTACA GTCTAGCCTG GGCAACAAGA GGGAACTCC ATCGCAAAAA
6051 AACAACCACC ACCAAGAGTA CAGGCTATGG AATGAGACTA TGGTTTTAAA
6101 TCCTGGCTTT GCAATTTATT AACTAGCCTT AAGTGACTTC CCTGAGCTTC
6151 AGGCACCAAT CTGTAAATG AGGATAAGAA TATTACTCAT GCCACATGGT
6201 TGTTAGGGAG GATTAATGT GATAACCTAT ATAAAGTGGC TAGCATAGCA
6251 TCTGACATAT AGAAAACCTCT TAATAGGGCC GGACGTGGTG GCTTATGCCT
6301 GTAATCCTAG CACTCTGGGA GGCCGAGGCA GAAGGATCGC TTGAGCCCAT
6351 GAGCCAGGA GTTTGAGACC AGCCTGGCCA ACATGGCAAA ACTCCACCTC
6401 TACAAAAAAT AAAAAATAT TAGCCAGGCG TGATGGCACA CACCTGTAGT
6451 CCCAGCTACT TGGGAAGCTG AGGAGCGATG ATTACCTGAG CCCAGGGATA
6501 TCAAGGCTGT AGTGAGCTGT GATCATGCCA CTGTACTCCA TCCAGCTGGG
6551 GGACAGAGTG AAACCCCTGT CTCAAAACAA AACAAATGAA AAAAAAACC
6601 CTTAATAATC AGTAACTGTC ACTTTATATT ATGTTGTGAG TGTGTGTCTA
6651 TATACACCTA TATGTATACA TTTCTCTTAT TACACATTCA TTGGTGATCT
6701 GATGTGGAGC CCCAGGGATT AAGGGCAACT TTGAACCTACC CTGACACAAT
6751 CAAGCCAAAT ATCATTCCCG TGGAGGAAGT AGAGTATCTA GGTTCGTCT
6801 CCTAGTTGCA GCTTTACCTT GAGGACAGAG ACTCTAATCC AGCTGTGCTG
6851 AAGGAGCACA TCTCCTGACT TCTGAGCTTT CCCCTGGTAA ATTCAAACCTG
6901 GATGTCACGG CGCCCTCAGA TAGAGCCTGG TAATTGGCC TGGGGAGAGT
6951 GACTGTCTTT TGGATCTAAT TTGACTTTTG CCCAGTTGG AGGAAAATCT
7001 TCAGGGCTAG GAAGGATTGT ATTTGTCTGA CCCAGAGAT AACCTGGGTT
7051 TTGAGGAACA TGGGGCATCA ACCTGAATGG TCTTGTAAGA TCTCTCCAC
7101 GCCAGCTTGC CAGTGTTTCT CTGATGAATT TAGAGTACCT GAGTAGTGCA
7151 GGCCTGCTGG GAGGAGGACT CTCCCTCTGT GCTACTCAGA GAAATTCATT
7201 CTTCAAGGCC CCCTTCCAGC CTTGCTCTTA CCCAGCTGGG CTACAGTTAC
7251 AATAAAGGAA ATGACTTTTTT TTCTCCCTT CCCCAGTAC CTTTGTTC
7301 CTAGTCACAG GGTGGGGCTG GATATTGAAT GGAGAAATTG CTGGGGTCCA
7351 TCCTAAACTC CTCCCTCAT CTCTCCCTTA CATTACCCCA TTCTTCTGTC
7401 TGCAGCCACA TCCATAATCC TGCTCTGTT AGCCTCCGA CAGACCCTCA
7451 GGTGCCCAGG ACAACAGGAA GCTACTTAAA GCTGGAACCT CAGACTGTGC

FIG.3-3

7501 AATGGAGGCC AGTGACAAAA CTGAAAGTAG CTCTGTCAGT AATTGTGCTG
7551 GTGCGATTAG GCAGCTGGCC AGAATCTTTT GGATCTCCTG GACATATGGC
7601 TGA TAGTCC TCCCAAGCCT TCCCAACAGG CCTCTTTTTT TTCCTTTTTT
7651 TCTTTCTTT TTTTCTTTT TTTCTTTCTT TCTTTTTTTT TTTTTTTAG
7701 GCTAGTGAAG TGA AATTGTG GGAGTGAAA AGGAACAAAG AAATCGGTAA
7751 CTGGTAGTGA TCAATTACTT GTAAACACTA TTGTA CTGG ACCAGCCCAG
7801 TAGGCCTTTT TTA AACTCT GAGTTACCTC TCTTCTCTT CCTTGAGCAG
7851 TGCCATTAAT TCTGTATCTG GGGCAATCCT TTCTGATGTT CTCTGGACCT
7901 GGCTCTCTCT CCTTAGGAGA GGCCAGGAGA GTAGCCAGAG AGCATGTCAT
7951 TTGTAGCTGA GGTAAAGTG TGGAGCTATC AATGGTGACC TGGCCTCTTG
8001 GCATGTTAGC AAGCCAGAGG ACCTTGACAA CTTTTTTGAT GATTGTCCGT
8051 TCACCCTGAT CAAAGGTGTT TGGCTTAGGA GGAGGGAAGA AAAGCTACCC
8101 CTATTAGTCT TGATGGCCCC AGCGTGGGTC TCTATTGCTT GACCTGGTTC
8151 CTAGCAGCAT TATCAGAAGG AAAATCCACC GCTCTTAAGG CTCCTGGGAA
8201 CTTTCAGGAC TTCCTTCTC AGGATTGCAA ACATAAGACT ATTTGAGCTT
8251 TCACTTTTGA AAAGCGGTTA CTAATACCTA TACTCTGGGA AAGGGCTAAT
8301 GCAGATAGAA GACTGTGGTC ACTGCATCAG GCAACAGACC ATTTCCGCTA
8351 AATTTAGTGA CTCCAGGAAG GCCAGTGAAG AAATAACACA CGTAGCAACC
8401 AGAGACTGTG TTGTAATATG TTGGCTGACA GCAGGGTACT TTCTGTGATG
8451 CTGAAAGCCA CATTCATTTT CTCTCCCCTC ATCCCCTATC AAGCAAGCCT
8501 GGTAGAATCA TAATTACAGT AATAGGTACC ACTTATTGAG TACTCTGTGC
8551 CAGACACCCT CCTGAGCATA CGACATGCAT AGCACATTTA ATCCTTACAA
8601 TGACTTAATA AAATGTAGTA CTAGTCTTAC TACTTTCGAG AATAGGAAA
8651 TGGAGGTAC TTGTTAAAG TCACAGAGCT AATAGGTAGC ATAGCTGAGA
8701 TTTGAACTCA GGCATTCTTA CTCCTTGCTT GCAAGAGTCT CTTGGCATTG
8751 TTGAATGCAA GCATATTTCT TAACCTCACT GAGGCTCAGT TTCCTCTTAT
8801 ATAATATGGG GTAAAGAGCC CTCACCCTGC CTGCCACACA CTGGTAGTGT
8851 CAGATAACAT TGAAGGTGT TAGTTTAAAG GCTTCATGGA CTCTATAATG
8901 TCAACAAAAG TGCTGTTAAC TTTCTTCTGG GTCTCAGGCT CCTGATGTAG
8951 AGTCAGTGGA GCAACCCTGC CATCTGCTGT TATGCTGTTG ATGTTGCTGC
9001 CACACTTACT AACCTAAACC TTTGATTCTG GCTGTGGCCT TCTCCAGAAG
9051 GTGTTTACTC ATTTGTCCAG TTTATCTTTT AGGAAACAGC CAGCCCGTAG
9101 ATCATTAAAG CTGGCTATTG GACAGGGGGC TGGGGCCTGC CTGACAGAGG
9151 AAGGAAGGGC AGACATCTGG TTCTTCTCTT GCCCTACAA GAGACTCCAG
9201 CCTGACCACA GAGTGGTACT CCTAGGATGT AGCAGCAGCA TATGAGCTTG
9251 AATGTGCCTT AATCCTGCTC TTTACTTTGA GAAGAGAGAA CTAAGGACCC
9301 ACAGATGTTT CACAGCTTCT ATAGGAGGCA GAGGTAGAAA AATGGAGAGA
9351 GATGAGGCCA GAGATAGATA ACTGATATTA ATTAACGTT GTATTAAGAA
9401 CCTCACTTAG ATTATCTGAT TCAATCTTCA TAATAACCCT GCAACCCCA
9451 CCTTTTTTTG AGAACAGGT CTTGCTCTGT TGTCCAGGCT ACAGTGCCT
9501 GGTACAATCA TAGTTCCTG CAGTGTCAAC CTCCTGAGCT CAAGCAATCC
9551 TCCCACCTCA GCCTTGCAAG CAGCTTGGAC TACAGGCGTG CCACCACACC
9601 TTGCCATTTT TTTTATTTT AAGTAGAAAC AAGGTCTTAT TAATACTATG
9651 TTGCCCAGGC TGGTCTTGAA CTCCAGCGAT CCTCCTGCC CAGCCTCCCA
9701 AAGTGCTTGG GATTACGGAA GTAAGCCACT GTGCCTGGCC AGTGCAACCC
9751 CCATTTTATA CTAAACAGG AAGGCCCAGA AAGGTTTGA GTAACCTGTC
9801 CAGGGTCACA CAGATGATAT TTGAACTCAG GTCTCCCTGG CTCCCAAGAG
9851 AGTCTGCTTT CCACTAGGAC TCCCAGGAGA AAAAAAAAAA AAAAAACAGT
9901 AGACTTGGAG ACAGAAAATC TGATTTGAGT CTTAGTTGAG CTAGGCTAAC
9951 TGTGTAAC TG GCAAGTT CCTTAGCCCC TGTGAGCCTC AGTTTCTTAT

FIG. 3-4

10001 CTGTAAAATG TCATAAAAGA AATCCATCTC ATGGAGTAGT TGTGATGATC
10051 AAGGACTCTG AAAACATTAG AATGGTTTAA TGTGAAGGAT TAGCAGCAGC
10101 ACATGGCAAC ATTGTGCATC TTATATTAAC TATCCAAATA TATCAAGCGT
10151 CATTTGCTAT ATATAAAAGT CATCAAATTA GGCAGTGTGG GGGATACGGA
10201 GTTGGCATAC TAGCCTGGCC TCTTAATTAA TTCATTAATT AGCTTATTTA
10251 TTTTGGAGAT AGGTCTTGCT CTATTGCCCA GGCTGGAGTG CAGTGGCATG
10301 ATGATAGCTT ACTATAGCCT CAATCTCCCA GGCTTAAACA ATCCTCCTGA
10351 GTAGCTGGGA CTACAGGCAC AACTACCAT GCCCAGCTAA TTTTTTTTTA
10401 ATTTTTGTGA GAGACAGGGT CTTGCTCTGT TGCCAGGCT GGTCTCAAAC
10451 TCCTGGGCTC GAGATCCTCC CACCTGGGCC TCACAAAGTG TTGGGATTAC
10501 AGGTATGAGC CACGGCACCT GGCCTGGTCT CTTAACTGGT TCCCTAAGAC
10551 AGCTGGAAAT AGAGAATGTC ATGGAGCATT CCTAACCATG GGCTCCAGCC
10601 TGGCTTTCAT TCTGTTTCTC CCCTGAAACA ACATTCCTTT AGTAATATTC
10651 CGAATAACAG CTTTCATCAGT CTGTCTACCG ACCACTCTTC AGGCTTCATC
10701 TTATATGACC TCCCAAACCTG CACTAAGGGT TGTATTAGAG AAAAGTGGAT
10751 AAAGTTCGGA GTCAGGCTGC TTGAGCTTAA ATGCCAGCTT CACTTACCAG
10801 CCACCTGACC ATGAGTCAGC TGCTTAACCA TTCTTTGCCA CAGTTTCCTT
10851 GTCTATGAAA AGGGAAATGG CTCCCACCTC AAAAAGTTGT TAACATTAAA
10901 TTCAATCATG TATTCAAAGT CCTGAGCAGA ATGTCTGGCC ATGACTGGGA
10951 CTTAACAGAT GTTAGCATTT ATTATTAGTA TCTGTCAAGT TTGAAATGTT
11001 CTCTTCCCTT GGCTTTCATG ACATTCCACA CTCTCCTGGT TTTCTCTTAC
11051 CTCTCTGGTA ATACCTGTTT GCTTATCCTT CTTTGTCCAG CTCTGGGATG
11101 TTACCATTCC TTCAGGCGTG CTGTTTTCTC CTTAGGCAGT CTTACACACA
11151 CTCATGACTT CCTTCCATTG TCCTCCACAC ACTGATGACC CTAATAACAG
11201 TATCTCCAGC CTAACCTTTT CCACTGAGTT CTAGACCCAT ATGTTGTAAT
11251 ATCAACCTGG CTTGTCCATT TGAATGTCTT CCAGGCACTT CAGACTCTCT
11301 TCTCTAGACT TTGCTGGACT TTCACTCTTC CCCCTAAAC TGGCTCCTCT
11351 TCCACTGAAA CATGTATGTC ATTGAGAGGC ACCACCATCC ACCCAGTGCC
11401 TAAGCCAGAA ACCTAGGAAT CCTTGATACC TGTCTCTCT CATCCTGCAT
11451 ATCCAAGCCT ATCAGTTTTA TCTCTAAATT ATATTTTGGT AGGTTTACTT
11501 CTTTCTTTT CTCCCACCAC CACCCTGCTC CAAGCTACCA TCATCTCACC
11551 TGGATGTCTG CAATAGCCTC ATCTCCACA GCCACTCTGC ACCCCCTAAT
11601 CTGTTCTCTA TAGAGCAGTT GGAAGGAGTG ATTTTTGTTG TTTGTTTTGT
11651 TTTGTTTTAG ACAGAGTCTC ACTCTGTTCC CCAAGGCTGG AGTGCAGTGG
11701 CACAATTTG GCTCACTGCA ACTCTGCCT CCCGGTTTA AGCAATTCTC
11751 CTGCCTCAGC CTCCAAGTA GCTGGGATTA AGGCACCGGC CCCCATACCC
11801 AGCTAATTTT TATATTTTTA GTAGAGATGG GGTTTTGCCA TGTGGCCAA
11851 GCTAGTCTCG AACTCCTGAC CTCAAGTGAT CCACCTGCCT CGGCCTCCCA
11901 AAGTGCTGGG ATTACAGGTG TGAGCCACTG CACCTGGCTG GAAGGAGTGA
11951 TCTTAAAAAA AAAAAAACA AAAAAAAT TGACTGTGTC ACTCTGTGTT
12001 GTCTCTCCTA CCTTGATAC TTCCACAAT TCCAGTGTT CTTGGATAAA
12051 GACCAAAATC CTTAACTTGG CCAGGCGCGG TGGCTCACAC CTATCATCTC
12101 AGCACTTTGG GAGGCCGAGG CAGGCAGATC ATGAAGTCAA GAGATTGAGA
12151 CCATCCTGGC CAACATGGTG AAACCCATC TCTACTAAAA ATACAAAAAT
12201 TAGCTGGTCG TGGTGGCGTG TGCTGTAGT CCCAGCTACT TGGGAGGCTG
12251 AGGCAGGAGA ATCACTTGAA CCTGGGAGGC AGAGGTTGCA GTGAGCCAG
12301 ATCACGCCAC TGCACTCCAG CCTGGTGACA GAGTAAGACT CCATCTCAAA
12351 AAAAAAAAAA AAAAAAAAAA TTCCTTAATT TGGCTACAG TAGAGCCCTC
12401 CGTAATGTGG CCTCTCTCCA CATCTCCACA ACCTCCTGCT CCTGCACCT
12451 CAGCCTCACC TCTCTCTGG ACAGGCCCTC CTTCTGACAA GGGCTTTGTT

FIG.3-5

12501 CATTCTGCTC CCTCTGCCTA GAATGCCCC TTA CTCTGTT CACTTAACTC
12551 CTGCTTATCG TTTAGATCTT TACCTGGATG GCTCAGAGAA ATATAGAAGT
12601 AATTCCTCAC CCTGAAAAAT AGGTAGGTC CCTGTTTTAT GTTTTCATAG
12651 ACCTTTCCTT TGAGGCTTTT TTTAAAAAAG TAGTTTTAAT CTCACATTTA
12701 TTCATGTGAT CATCTCCTTA ATGATATCTT AAGACCTCTA ATAGAACAAT
12751 TTGGTCATGG ACTGTGGGGT TTTTGCCCTT CATTGTGTCA GCACTGAGCA
12801 TATTGTTGGC ATAGGAGGGA TATTGTTGA ATGAATTGCT AGAGGTGGCC
12851 AAGAGATATG ATGTAAGTCA GGCTTTTCCC TGCCCTTCCC CTTCCTTCC
12901 CCCACATCCT TCCTATAGCA GCCACCGTGG CTGCAGTTAC TGTAAATGGC
12951 AAGACGGAAT CAGTTCGGGA CATTGGGTTG TTTTAGAAAA TTGCCTGCAA
13001 GTGTCAGGGT GATAAGTTAA AGCTTTGTCT TTTGCCCTCA GAGGAGCTAT
13051 CCCATAGTGA GTAGAAGCCA GAGAAGCTGA CCCCAGGAGT CCTTCTTTCC
13101 AGCAGCAGGT CTTGAGCTGC ACTTCTCTGT AGCTACAATC CAGGCAGGAA
13151 CAAGCCCTAG GTACCTCCGG AGAGGAGGGC AAGAGAGGAA GAATGAGTTC
13201 AGCTACTCTA GCCACCAAAC TGATTATGAA TTGCCCTGAA ATCTGAAAAA
13251 TTTCAATTCC AATCGTAAGT TTGTTTTGTT TCATTTTGT TTCTTAAATT
13301 GTATATTTGA AAGATGGCAT TAACTAAAGA TATATATTCA ATATAGAGTG
13351 GAAAAAATGG AATACTTGCA TAGTATCTTT TACTTATAGG TGATTTATGA
13401 TGGGGAGTGG GGTGGATAGG TTGGCAGTTC CCCCAGAAG TTGGAATGA
13451 AGTTTGTCTT CTGTGAGTTG AACTAATTAG ATCCACAAGT AATGAAGCA
13501 GTATTGTGTT GTAGTTAAGA GCACACTCTA GAACCAGATT GCTTAGTTTC
13551 AAATCCTGGT TCTGCCTTTT ATTATCTGTG TACTTTGGGC AAGTTACTTG
13601 CCCTTTGTGT GCTTCATTTT TCTCATCTAG AAAATGGAGA GGCCAGGCGT
13651 AGTGGCTCAT GCCTATAATC CCAGCACTTT GGGAGGCCGA GGCGGGCAGA
13701 TCACCTGAGG TGAGAAGTTC AAGACCAGCC TGGCCAACAT GGTGAAACCC
13751 TGTCTCTACA AAAATACAAA AATTAGCCAG GCATGATGGC GGGTGCCTGT
13801 AATCCAGCT ACCCAGGAGC CTGAGGCGGG AGAAACACTT GAACCTGGAA
13851 GGCAGAGGTT GTAGTGAGCC AGGATTGCAC CACTGCACTC CAGCCTGGGT
13901 GACAAGAGCT AGACTCAGTC TAAAAAATA AAAAAAATC AAACCTGGAGA
13951 TACAGGCTGG GTGCAGGGCT TACACTTATA ATATCAGCAC TTTGGGAGGC
14001 CTAGGCGGGA GGATTGCTTG AACTCAGGAG TTTCAAGATC AGTCTGGGTA
14051 ACAGAGCAAG ACCTCATCCC CACAAAAAAT CAAAAATTTA GCCAGGCATG
14101 GTGGCTCATG CCTGTGGTCC CAGCTACTCA GGAGGCTGAG GCGAGAGGAT
14151 TGCTTGAGCC CAGGAGGTTG AGGCTGCAGT GAACCATGAC TGCACCACTA
14201 CATGCCAGCC TGGATGACAG AGCAAGACCC TATCTCAAAA AAAAAAATAA
14251 AAAGAAACGA GCCAGGCGCG TTTGCTCAGC CCAGTAATCC CAGCACTTTG
14301 GGAGGCCAAG GCAGGTGGAT CACTTGAGGT CAGGAGATCG AGACTAGCCT
14351 GGCCAACATG GTGAAACCCC ATCTCAACTG AAAATACAAA AATTAGCCAG
14401 GCATGGTGGC ATGCTCCTGT AGTCCCAGCT ACTCACTTGG AGGCTGAGGC
14451 ACGAGAATCG CTTGAACCCA GGAGGCGGAG GTTGCACTGG GCCAACATCA
14501 TGCTACTGCA CTCCAGCCTG GGAGACAGAG CGAGACTCTG TCTCAATAAA
14551 TAAATAAACA TAAATAAATA TAAATAAATA TAAATAAATA TAAAAAATA
14601 TGGAGGCCAG CAGGCACGGT GGCTCACGCA TGTAAATCCA GCACTTTGGG
14651 AGGCCGAGGG GGGCGGATCA CAAGTCAGG AGATCGAGAC CATCCTGGCT
14701 AACACAGTGA AACCGCTCT CTAATAAATA TACAAAAAT TAGCCAGGCA
14751 TGGTGGCAGG CACCTGTAGT CCCTGCTACT CAGGAGGCTG AGGCAGGAGA
14801 ATGGCGTGAA CCCGGGAGGC GGAGCTTGCA GTGAGCTGAG ATCGCGCCAC
14851 TGCAGTCCAG CCTGGGCGAC AGAGCAAGAC TCTGTCTCAA AAAAAAATAA
14901 AAAAATGGAG GTTGGGCGCG GTGGCTCGCG CCTGTAATCC CAGCACTTTG
14951 GGAGGTCGAG GCGGGCGGAT CACCTGAGGT CAGGAGTTCC AGACCAGCCT

FIG.3-6

15001 GGCCAACATG GTGAAACCTT GTCTCTACTA AAATTACAAA AATTAGCCAG
15051 GCACGATGGC AGGCACCTGT AATCCCAGCT ACTTAGGAGA CTAAGGCAGG
15101 AGAATAGCTT GAACCTGGGA GATGGAGGTT GCAGTGTGCT GAGATCGCGC
15151 CACTGCCCTC CAGTAGAGTG AGATTCCGTC TCAAAAAAAA AAAAAAAGAA
15201 GAAATGGAGA TACAACTTA CTACCTACCT CCTTACAACC TACCCTCACA
15251 GTATTACTGT GAATAAAAGT GTGTGTAGCA CTGGGAACAC TATTCACAGA
15301 GCACTCATGA ATGTTTGTTC TTTGTTATTA GTTACTAGAG AGGCAATGT
15351 CTGCCAGGGC TGAATAATAT GTGTGAATTG GTGATTGTCG CACATATCTA
15401 AAGAAGTAGT TATTTTTTTC AATTAAACT TAGTTTAAAA ACCAATATAA
15451 GGCCGAGCGC AGTGGCTCAC ACCTGTAATC CCAGCACTTT GGGAGGCCGA
15501 GGTGGGCAGA TCATTTGAGG TCAGGAGTTC GAGACTAGCC TGGCCAACAT
15551 GGTGAAACCC TGTCTCTGCT AAAAAAAAAA AAAAAGTACA AAAATTAGCC
15601 AGGCATGATG GCAGGTCCCT GTAATCCCAG CTAATTGGGA GGCCGAGGCA
15651 GGAGAATTGC TTGAACCCAG GAGGTGGAGG TTGTAGTGAG CCGAGTTTGT
15701 GCCACTGCAC TTCAGCCTGG GTGACAGAGG GAGACTGTCT CTCAAAAAAA
15751 AAAAAAAAAA ACCAAAACCA ATATAATAAA TAAGTGGCCA GCAATGAAAC
15801 AGAAAGTGAA AAGTTAGTGA AGCAAACTA GTACTGTATT CAGATAAAGA
15851 TGCTGAATCT AGATTTGGTC ACCAGAATAG GGTCTTTTGT GGCAACCTGG
15901 GCTAGTTTGG CTGACTCACC ACTGCCAGGA TGAATTTCTT TTCAGTGGCT
15951 ACTCATTTCC CTTTATTTTA AGTCCATGCT CACAGAGCAA CTTTCTGATG
16001 CCTAATTCAG CTTCTGGGA TACTTAATAA CAGGAAGGGT CTGGAAGTAG
16051 TACCTGTATA GGGGATATGA GTGTTCTGAT TTTAATAGTC AATTCATAAG
16101 TGTACAGAGG GTTTGATAAA TGGTTAGGTC AGAACCATCA CAGAATGTCT
16151 ACACCTCTTT GGACATTAGG AAGGTCAAAA ACCTGAAAGG CCAAAAGCTA
16201 GGCTAGATT AGGGTCATT ACCAAGAAAA CATCAGCCTT GAAGAGTTCT
16251 CTGGGTGGTC CACCAGTCAA CCTTCCTTTG ATCACACCTC CTTCTCGTT
16301 GCTTCTTTAA GCATTGACCT GTAATGGGTA TGGAATTTTT TGCTCACCTA
16351 ACTCCTTCCT TTTACAGAGG AAGAAGTTGA AGCCAGAGA GATTTAATGG
16401 CTTGCCTAAG ATCACACGCA GATTTTCTGT TAACCAGGGT GATTTTTCAG
16451 GTGTTCCCTG CCAGACGAGG GCTTTTTTCC TTGAATTGCC TAGAGATTTC
16501 TTGAGATATC CGAAGCATT TTCCAGTGC AGCCTGGAGA AGGATGTCCC
16551 TGCAACACA GCATTTGTTA CTCAATGTTA GACATTCAAT TTTCTAATTA
16601 GTATCATGGA GCAACAGTGG ATGATTATCT ATAAGGGGTT GCAATTCAT
16651 GCTTATGTGC TTACAGCCA TATAGACAAA TATCAGCTGT TAAATGACA
16701 AGGCAGTAGA GATGTGGCCC CAGGACAAAG GCATACTCTG CTGTTAGTGA
16751 AACTAGTTG GCCAGCAAAT TTCACATGGG CATATACAGG GCCAATGTGA
16801 GACTTTAGGC ATTTATACCC ATTCAGAGAG CCAAAGTGGC AACTAAAGAT
16851 CAGCATTCTC TTTGGCATT CAGCTTTGCG TTCTGTAAA AATCACTGCT
16901 TGCTTAAATA CCTCTGATAG CTCTTCACTG CCTGTAGGCA ACTCTTTAGC
16951 CTAGCAGACT TGGTCTTTAG TGCTCTGCCC CTAATCTCTT CCACATTCT
17001 GGCCTCCTGT CTAATTGCTG CCCATATGTG CCATGCACTA GAGCTTACAG
17051 ACCTGCTCAG CGTTATATGA GCATACCATA CTCTTTATGC CTCAGTGCAT
17101 TTGCACATGT TGTTCCTTCA GGCCAGAATG CCTGTTACTG CCTGGCAATC
17151 AGCCTATTAG AGTCTGCCAA TACCATCCA TCTTCTGTGG AGGAGCCCCC
17201 CGCCAAATCC ACCCATACCT CTCCCCACCA ATCAGAGACT TCTTCTCTCT
17251 TTGTTATTCT CTTCTGTTAT CTCTTCATAC CTCAGTTATA TCCATTTTCAG
17301 TATTTGTTTA CACATCTAGC ATCACTCTTA GAGTGTGAAA TTCTCCAAGT
17351 GTGGAGCCGT ATCTAGTTTG TCTTTGTATC CCAGAGCTTA GCAAAGTGCC
17401 TAGAATGTAG TGGGTGCTCA GAGTGTGTC TGGGTGAATG ATGATTTTGT
17451 TGAACGACTC TTTGGACACT TGAATAAAGT CCATCCAGTA TGCACCATTA

FIG.3-7

17501 CCATCTCTTC GCTCTACAAT ATTCTTTTAG GCAAGAGCTT ATCTTTTGAG
17551 GTGATAAGAT AAGCTCAAAC TTATGTAGAC TAAGACCTCA GTCTGTAAAT
17601 GTCATCCCTA AGTCTTAAAC CATCAAAACC AGGGCCTCAA GGAATGGCAT
17651 GCCTTCTGCA ACTGTAGCAA CCTGCTGTGC TTATTTTGCC GTGTTTTCA
17701 TTTTCCCCC AAAAGCTAGA GTCCCTTCTC CCATGGGCAG TGCTGGAAGT
17751 GTGCTAACAA ATTCTTTCTC CATACTGCTT ACGATTACAA AAAAAACCT
17801 CAGCATCTCA TGCCAGACTT GAGTTAAGGT TGTTTTCTTT TGTGTCTCAG
17851 CTGTATTCTG GTCATGACTT CCTGATGATG CCCTATAGAG ATTTTGTCTGA
17901 GATCAGAGGG TGCTCCACTG CCATCAGTAG CACTGACTCT TGCAGAAGCA
17951 CCGTTTCTGA AGTTGGCTAA TGTATCCCT CACGTTTGTT TGTTTGAAAT
18001 TTGTTTTAGT TCCAGAGATA GCACTTTCAT GGAATGACGC TATCTTCTAG
18051 AATCACTTTT TTTTTTTTTT TGAGTTGGAG TCTCGCTGTG TCGCCAGGCT
18101 GGAGTGCAGT GGCACAATCT CAGCTCACTG CAATCTCCAC CTTCGGGGTT
18151 CAAGTGATTC CCCTGCCTCA GCCTCCCGAG GAGCTGTTAC TACAGGCGCA
18201 CACCCCACT CCTGGCTAAT TTTATGTGTT TTAGTAGAGA CGGGGTTTCA
18251 CCGTGTGGC CAGGATGGTC TCGATCTCCT GACTTTGTGA TCTGCCTGCT
18301 TCAGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGTCACC GCGCCTGGCC
18351 TAGAATCACC TTTTATACC ATAACGTGAG CACCACTGCC GCGTCACCAA
18401 GGAAAGAGAG AGGCAGCTAC TGTGGGGTTA CAAATGGGTG AGAGTGGCAC
18451 CAGGAAGGTG AAAGTCTCTA CTTAGCCAAG GCTTAACAAA ATGTCAATCA
18501 CCAAACATTT ATTTATTAAG CTACGTTTCA GATAAGAAGA TGAACAAGCT
18551 ATCTGTACAT TCATTTTCTC GTTTGTAACA AGGTAATGAT AGTGATCTAT
18601 CCTGCCTGCC TCTGAGGGTT ATTGTGAGAA TAAATGAAA TCAAGTGGAA
18651 AAGCACTTAG GAAAAAGAAA AGCATTGGTT TTCAATTGTT AGTGTGGATC
18701 AGAAACACTG GGGCTTGTTT AAAATGCAGA TTCTTAGCCC CAGTCTCAGC
18751 GATTCTGATT CTGTATATCT GAAGTGGGAC TCAGGAATCT TGATTTTCAA
18801 CAAGCTGACC AGAGGGTCCA ATGCTGCTAT TCCTTTAGTT AACTTTTCA
18851 AAATATTACT GTAAATCAAA TGGCAAGAAT AAAATAGTTA TTTGAGGCAG
18901 TTTTAGTATG TTGGACCTGG AGTCCAAAGA CTTGGGTCAA ACTCCAGCTT
18951 TGTCAGTTCC TAGACCTGTG ACCTTAAACA GCAACCTTCT CTGTGAACCT
19001 TAGTTCCCTC AGGAACGGCT CTGGTCACCT CCTGCTGTAC TCCATTGATG
19051 ACTCACCACA TAAGGCTCCC TGGGAGTCCC CCAAACCTTT GCTCTCTTAA
19101 CTCCTTTTAC AGCCTCCTAC ATCTCCTGCA GGTGCTGTCT TCTCCTCCTT
19151 TTTCCAGGCC CTGCTCTGAC ACAGCATTCA TTCTCCTCTG GGAAGGGTTC
19201 CTTCAATGTG TCTCCAAGCA CATCACACCC AGGAAGGACC CTGTGGCCAT
19251 ATCTGTCTAT CACCAGATCA AACTACGTGA AGGCAGGCAC TAGGTACTGT
19301 CAGTGCCAG CATAGGCCTG GCCCATACCA GGTGTCCACA GATGCCTAGT
19351 AAAGAAACCT ATGATTCAGG ACCCCCATGA TGAGCAACTA TAGCACTAGA
19401 ACAGTGATAA TAACTAATGT TTATAATGCA TCTTCAGTTT ACAGAGGGCT
19451 TTTGTACTCA TCATCTAGTT TAGTTCCTGC AACACCTCT TGAGGAATAT
19501 AGCACAAGCA GGACAAGGGA AGCCCAGAGA TGTTAAATAA TTTATCCAAG
19551 TTTATGCTGC TGGGAAGGGC AGCACTGAAA TTAAGAGAAA AGTTTTCTGA
19601 GCTCAAATCC CATGCCCTTT CCTCAATGTG AGCTCTAGCA AGGTATTGAG
19651 GAATCCTGCC TCTACAGTTC AGAGCCTCAA ATTGCTGGGT ATGTTGAGTT
19701 CTTGTATCTG ATTTTCTAG ATTTCTGCCC CACATTCTTA CTGTCTGGAT
19751 ATCAGGAAAG AGTTTATCAA ATGCTGTGG AAATCCAAGA TAAGGTCTCA
19801 TGATGAGTAA CCCAGTGAAA ACATGAAGTC AAGTCTAACT AGTCACTACT
19851 ATTTCACTAC TGCTGACTCC TGATGATCAG CTCCTTTTCT AAGTGCTTAC
19901 TGTCCACTTA TTCCATCATC TGCCTAGAAT TTATGTGAAG GAATCAAAGC
19951 AAAAGGATCA TAAGGCTTCC TTTTCCAGT ATGTTTTTCC TCCTTTTGA

FIG.3-8

20001 AACTGGGCC AGTTAGCTAT CTCCATTTTT ATTCATGAA TACATCCCCA
20051 GCGCCTGGTA TATAGTAGAT ATGGAACATT AACTTTTGA GATATTGCAC
20101 CCATTCTCCA GTTCTCCAA AGTTACTAAC AATGGTTCCA TCACTGTGCC
20151 AACATATTTT CTTTTTCAA TATATTGGA AATAATTCTC CCAGTCTGAA
20201 AATCTGAACA CATTTCATGT GACTTGGTAT CCTCATATGT CTTGGGCTTC
20251 CAATTCTCCA TTCCTAGTTT CAAGTTCATG AACTGTAAAA CAAAGGATTA
20301 GACTAAATCT CTAAGTTCT ATCCAGATGC CAAATTCITT TCTCTTTCCA
20351 TGATACCTAA GATAGATGCC AAATATTGTC TTTTACCTGG TGTGTGTGAA
20401 CATGACATCA CATTACAGGA GTAGCAGATA CTAAGTCTC ACTCTGTAAA
20451 AACTGACTG AGTTCCATGA GCCAGATACT GAAGTGAGCT TGTTCACATA
20501 TGTCTCATT TAATGCTCAT AACCCTGTGA AGCTGGGAAT TGCTGGGACA
20551 TTTTATTTAT TTATTTATTG AGACGGAGTC TGGCTCTGTC ACCTAGGCTG
20601 GTGTGCAATG GCATGATCTT GGCTCACC GC AACCTCCGCC TCCCGGGTTC
20651 AAGCGATTCT CTTGCCCTCAG CCTCCGAGT AGCTGGGATT ACGGGGCACA
20701 CACCACCACA TCCAGCTAAT TTTGTATTT TAGCAGAGAT GGAGTTTCTC
20751 CATGTTGGCC AGGTTGGTCA CGAACACTTG ACCTCAAGTG ATCTGCCTGC
20801 CTCAGCCTCC CAAAGTGCTG GGATTACAGG CATGAGCCAC CATGCCTGCC
20851 CGGGACCTT GTTTTAGAAG GATGACTGCT GCTATAATGT AGAAAGTGAT
20901 TTGGAAGAGG GGAGGAGTGG GGCACGAAAG ATGGTTAGTA GATGGGGGTG
20951 GTAATGCTTA CTTTTCAGTA TTTGGAGGCT TCGGAGTCCT CAAAAATTCT
21001 CTTCTTGAT TGGAGTCTC CCAGCCAATA GAGGGCTTCA CACAAACAGT
21051 TTCTTGGGT TTGAATTGTT TGACCAGAGC TTTCTTCCGA CAAAAGTTG
21101 GGGTGATTCA TTCATTACC ACACCTTGC TGAACATTCA CTTGGGGCTG
21151 CCGGTTATGA AGGCTATTGT TCTCCAGCCT GTCACAGAGC CTTTGAAGAC
21201 CTGTGCCTCA GCTGGTTCTA AGGAGTCAGT TTGTTAGCT CCGTGCCAGG
21251 TTTCCAACCT ATGAAATGTG CTGGAGATTA ACACCTCTCC TGCCATTTTA
21301 TCCCTACTAT AATTGCCAGT CAAAGGATTC CTGCAGTTGC CTCTGGCAGC
21351 CATAACTGAT GAATGTTCTG CCAGCTGCTC TGAGGACCTA GAAGAGCAGT
21401 TTTCTATCCA GGACAGTTT CCAAGGGTGG GAGGGTGAAA TATATCTCTC
21451 AGTGTGACAT TTCATCTCCC AGTGATGGGT GGCTTGGGCC CTTTGAAGTT
21501 GGCTCTGAGG AACCACACAC TTGGGTCTGA GCAGCCAGCA GCTTATCACA
21551 TCTGGTGATC AATCCTTCAA AGGTTCTCTC TGAAGTCTGA ATTTTGGAG
21601 GTCAAATGGA TTCCACCTGG GAGGGGCTTC TGCTTCAACT CAGGACATGG
21651 GGAGAAGGCT GTTCTCTTC CAGGGGGAGG CAGTTTTCAT GGCATTGAGA
21701 TGTCTCTCA CTTATTCCCC ACCCACCCAC CAAGTCCTTT GTAAGAGGAG
21751 TAGGGGGAGA GGAGAGCGCC TGCAGCCTCC TGCTCACATT CTTAGACACC
21801 GACTCACTGA GCCCGTCGCC GCTGGAACAG CAGAGCTGTG TGAATGTCA
21851 AGAGGAGTTA TGCTCATAGG CTCCCTGGCC TCAGTCTCTT TGTGGCTTGC
21901 ATATTCTTCC ATTAGTACTG TGTTTCATCAG ATGGAAATCA GAGGGTACAA
21951 TTAAAAGATA ATTTGCTAGT CCCAGACTTA ATTTGGGGCC CCCTTCTTGC
22001 CTGATTGAAT TACAGGGGAA CATAATAGAT TTTTGGTGAG AAATAGTTGT
22051 CTGTGTGGCT GGGAGAAAGA TTGCTCCAG CTCTCCAGCT GGGCAGCCCT
22101 TTCAGTATCC CGTATGTTAT TTCCCACTT CCAGCCCACC TCACCTCCTC
22151 TGTGGCCCTT GTGTGTCCCC TCGGCTAGGA TCCTGACCTC CTGCTCAAGA
22201 GTTTAAACTC AACTTGAGAC CCAAGGAAAA TAGAGAGCCC TCTGCAACCT
22251 CATAGGGGTG AAAAATGTTG ATGCTGGGAG CTATTTAGAG ACCTAACCAA
22301 GGCCAGACA GAGAGAGTGA CTTGCTAAAG GCCACATAGC TAGCCACAG
22351 TAGTTGTAAC AATAGTCTTA ATGATATTAA TGGCTAACAT TTATCAACCT
22401 TTAATGTGTC CCAGACTTTG TGCCAAGGTC TTACATGCAG TGCATTGTGC
22451 CATTCAAACC CAGACAGTCT GGCTCTGGGC CCAGGCTGAG CTTTGGTATA

FIG.3-9

22501 GCATGGTAGA ACGTTGTCTA TAATGTCTAG TCTGGGTTCA AATCCTGGCT
22551 TCACTTCTCA CATTTACAGC TGAGTGACCT CAGGCAAGTG ATTTAACCTC
22601 CCTGTACCTC AGTTGCTTTA TCTGTAAAGA GAAAAATCAC AGCACTGTGG
22651 AATAGTGGGG GTTAAAATTC ATTCATACAA GTAGTGCTGC AAGCAATGTT
22701 TAATACAGGG TGAGCACCTG TTCAGTGCTT CCTTCTTCTG GCTGCCTCTG
22751 GGGCTAGAGT GTGGTGTCTT CGTGGTATAG ATAGATAGAT ATGGCTGAGC
22801 TCTGCACAAA CACCAAGAGC TGTTCTTCAC TATTAGAGGT AGTAAACAGA
22851 GTGGTTGAGC TCTGTGGTTC TAGAACAGAG GCCGGCAAGC TATGGCCCAT
22901 TGCCTATTTT AATACGGCCT GTGATTGATT GATTTTTTTT TTCTTTTTGA
22951 GACAGAGTTT CACTCTTGTT GCCCAGGCTG GAATGCAATG GCACGAACTC
23001 AGCTACCGC AACCTCTGCC TCCTGGGTTT AAGCGATTCT CCTGTCTCAG
23051 CCTCTCGAGT AGCTGGGATT ACAGGCATGT GCCACCACGC CTGGCTAATT
23101 TTTGTATTTT TAGTAGAGAC AGGGTTTCTC CATGTTGGTC AGGCTAGTCT
23151 CGAACTTCCA ACCTCAGGTG ATCTGCCCCG CTCAGCCTTC CAAAGTGCTG
23201 GGATTACAGG CGTGAGCCAC CATGACTGGC CTGATTGACT GATTTTTTTA
23251 GTAGAGATAG GGTCTTGGTT TGTTACCCAG GCTGGTCTCA AACTTCTGGC
23301 TTCAAGCAGT CCTCCCTCCT TGGCCTCTCG AATGCTGGGA TTATAGGCAT
23351 GAGCCACTAT GCCTGGCCTA TATGACCTGT GATTTTTAAT GGTTAGGGGA
23401 AAAAAAGCAA AAGAATGCTT TGTGACATGT GGAAATTACA TGAAACTCAA
23451 ATATCAGTGT CCCAGCCTGG GCAACAAAGT GAGACCCTGT CTCTACAAAA
23501 AATAAAAAAA AATAAGCCAG GGCCGGGCGC AGTGGCTCAC ACCTATAATC
23551 TCAGCACTTT GGGAGGCCGA GGCAAGTGGG TCACCTGAGG TCAGGAGTTC
23601 AAGACCAGCC TGACCAATAT GGTGAAACCC TGTCTGTACT AAAACACAA
23651 AAATTAGCCG AGCATGGTGG CATGCGCCTG TAGTCCCAGC TACTTGGGAG
23701 GCTGAGACAA GAGAATTGCT TGAACCTGGG AGGCGGAGGT TGCAGTGAGC
23751 CAAGATCGCG AACTACACT GCAGCCTGGG CAACAGAGCG AGACTCCGAC
23801 ACACGCACGC ACGCACACAC ACACACACAC ACACACACAC ACGCTGGGTA
23851 TGGTGGCCAG CACGTGTGGT CCCAGGATGC ACTGGAGGCT TAGGTAGGAG
23901 GATCACTTGA GCTTAGGTGG TTGAGACTAC AATGAACCAT GTTTATACCA
23951 CTGCACCTTA GCCAGGGCAA CAGTGTGAGA CTGAATCTCA AAAGAAAAAA
24001 AAAAAAAGA AAAAAATCTT TCCATAAGTA AATATCTGTT GGAACATAGC
24051 CATGTCCCTT AGTTTATGTT TTATATATGG CTGCTTTTGC CCTATAATGA
24101 CACAATTGAG TGGCCACGAC AGTCTGTATG GCCTGCAGAG CCTAAGATAT
24151 TTGCTCTCTG GCCCTTTACA GAAAAAGTGC CTTGACCTGT GCTCTAGAGC
24201 CATATGTACC AGGTTTGAAA CTCAGCCTCA CAGCTGGGTG TGATGGCAGG
24251 CATCTGTAGT CCCAGCTACT CTGGAGGCTG AGGTGAGAGG ATCACTTGAG
24301 TCCAGAAGGT CGAGGTCAAG ATTGTAGTGA GCCATGATGG CATCACCSCA
24351 CTCCAGCCTG AGTGACAGAG AGAGACCCTG ACTCAAAAAA AAAAAACAA
24401 AAAAAAATA CACCCTCACC ACTTATCAGC TATTTGTCTT GAGAATAGTG
24451 ACATAACCCC TCAGAACCTA TTTCTAATC TGTTAAATGA GGCTGATGAC
24501 GTTTCCTCCT TTTACTGGCA ATTTAAACAT GATGGATAAT AAATGCTAAG
24551 CACTTAACAC AGGGCCTAGA AGATATTAAC TGCTCAATAA ATGGTAGCTT
24601 CTTAACAGTA TTCAAACCCA TGTGCTCTTA TCACATGCAT TGTGTCCCT
24651 GTGTCCAGTT GGTGGAATGG GAAAAGGCTC CTTGTAACC CCATCTACCA
24701 TCTTTATCAG ACTTTCCTGC CATGGTTCAC AGTAAGAGAT AGAAGCTGCA
24751 CGGTGACTTC TGGCTCTTTA CAATGGTGAG CGGTGTGTGC CTGGTAAGGG
24801 AGAGCTGATG TCACTGCCCC AAATCCAGTA GTGAGATCTG AGTGTCTGG
24851 TTTCTCCAG CAGCCTTGCT TTTTCTTTA CAATCCTGCA GGCAGGGAGA
24901 CAAGGGCTTT CTACATGGTA GGCTCTGGTT TGGTCATCGT CACAAGTGGG
24951 GGCTGTTCAG GTGGGCTCCC ATTCCAGATA CCTAGGCTTA TCAATCCCTT

FIG.3-10

25001 TTGGCACCCC AGGCCTTTTT CTCCCTCATG CCCCATTTTT CAGTTTGAAA
25051 AGCATGGTTA TCACAGGACA AGTAGAAGAA GCTCCACTGT CCACTGAGGC
25101 CAATGGATGG TGTCTGTCAT GTGAACACTC AGTGAATAGT GAGTGAATGA
25151 GAGTAACCTG GGCTCCATCC TATTTGCAGA GAGCTTTGGA AAAGATTTTT
25201 CTCCTTAAAG AGCCAGAATG AAGCCTGGTA GTGGGAGAGC TCCAGCTCTA
25251 GAGTCACATG AGCCTACATT TAAATTCCAG CCCTGCCACT GACTCCCTTT
25301 TTGACCTTGA GTGAGTTACC TAATCTCTCT GTACCTCACT TTTCTTGTCT
25351 GTAGAGTGGG AATAATTCCT GTCTCAGAGA AATAAAAGAG TGCATATAGT
25401 GTTTGCCACA TGGAGACACA TCAGGTGTAG GTTAATACTC TGGGCCTTGT
25451 TTCCTTATTT GCAACACAGC CCTGCCCTGG AGTGGGAAGT GCACCTCCCA
25501 TTGGTCAGCT CTTGAGGCTG TCCCAGGAC AGGCAGAGGG AGGGAATGAA
25551 TGGGAGCCCT AGTGCCAGGA CAGAACAGAT GGCAGCTCAG AGCTAGGATG
25601 GCTCTCTGGA CCTGTCTCTC CTACCAGAGG TCCCCCGTC TGGTGTGGCT
25651 CTTCTGGAC CTGGCATCCT CTGCTTTTTT TTTTTTCCA CCTCCAAGCA
25701 GAATTACTGT CCTGTAGGCA GCTCCTCTGC TTGAGGACAT CTGGGGCCAG
25751 ATATGTTTAC ACTCTATCCT GCCTTGCCCT TCCCTGAGCT CAGGATGGAC
25801 GCTCAATTGG TCCCAGTTAT TGTCTGCAGC GCCTGCCTGC AGCCTCGATC
25851 CAGCCAGCT CCACCCCTTG CCTGCAAGGT CTGTTTCTTA ACAGCTGCTC
25901 CAACCACACA CCTCGGTTCT GCGGGAGCCC CTCCTCTTCC TCCTCCCTC
25951 CCTCATTCAG GGGTGGGACT GAAGAAGAAG GCTAACTTGA CAGCAGCGCT
26001 TCTTCTTAG CTAGTCACCG GCCCTGCTC AAGAATGCCA GTGTGTGTGT
26051 AGCCTCCACA GAGAGGTCGT TTTCTCGGAG TCCAGAGGGG CCGCTGAGC
26101 TTCTGAGAAC TAGGGAGGAG CCATCCCAGC CATGAGCCCC TGTGGGAATC
26151 TGCTGGGGGC CAAGTGGCCT GGAGTCCTCA GGCTCCCGCA GCTGCTCCGG
26201 AGGGAGAGGT GAGCTCAGGG CAGCCTGCCT GCAGCCAGAG GTGCCGGGAG
26251 CCCCGGGCTT GTCATGGTGG CCATCTACAG CCGGCCTGAG GCAGTCACAG
26301 ACGGATTTGC AGCTGAGCCT GTCTATCTGG TGTGGGAAGA AGATGGGGAG
26351 TTAATTGTCA GTCCGGGCTT ACTTCACCTC CAGAGACCTG TTTGGGTGAG
26401 TTGGTCTCCG AGTTCCCCTC TCCATCTCTC CTGGCCCTG GTCTGAGAG
26451 GAGGGTGGTC TCCCTAAATC TCCTTCTCAC TTAGTCCTTT ACCATCGGTT
26501 CTGCCGGGCA GAAGCCAGCG GAGGTTATAC CCAAGGAGAA TCGCCTTGT
26551 GAGGTACCCC CATTATGTCC TGAAGTGGT GAGGGGAGGG ATATACCCAG
26601 AAGGAACCTT TTAGGGAGCT CCAGCTCCCC TTCTATCCCA GACAAACCTG
26651 AAGGAGCCTC CAAAAGATGC CACTGACCTG CCCATTGTAG ATGTTACTGC
26701 TTCCGGGGGG AATAGCCCAA ATAGAGTGCT GTTTCAGCT CTCACATGTC
26751 TTACCTGCGG GCCATGCTGC CTGCCAGGA ATTTGTCCCA ACAAGCAGGA
26801 TGGGCAGGTT TTGCCAAACT GTGGAACTG GCAAGTCCTG GGTGTGGGTA
26851 GCCTGGTACA CAGTAGGCAC CTTATAAAGC TTTGTTCTCT TAATGGCAGG
26901 CACATTTGCC TCTGGCCTTG AAGGGCTTCT GAGCTCCCAG GTGAATGTAG
26951 TTGCTGGGGA AAGACCTGGG CGAGTGCTTC TAAGACTGGA GCAATGGGCT
27001 TTAGAGTGTT CCTGAGCTGC TGGGCCAGCC CCCACACCTC CTCAGTCCCT
27051 AGGCCTAAGT ACCTCCACGA GCCTCTCTCT GTGGGGCTTC TCAGAGGGAG
27101 ATGTGGAAC TCTACCTCTA ACCTGGCTTT CTTTGCTCAT TGCCCCACTC
27151 CACCTCCCAT AGAAACTCCC CAGGGGGTTT CTGGCCCTCT GGGTCCCTTC
27201 TGAATGGAGC CATTCCAGGC TAGGGTGGGG TTTGTTTTCA TTCTTTGGGA
27251 GCAGCCTGTT GTTCCAAAAA GGCTGCCTCC CCCTACCAG TGGTCTGGT
27301 CGACTTTTCC CTTCTGGCTT CTCTAAGCTA GGTCCAGTGC CCAGATCTTG
27351 CTGCCGGGAT ACTAGTCAGG TGGCCAGGCC CTGGGCAGAA AAGCAGTGTA
27401 CCATGTGGTT TTGTGGAATG ACCGGACCCT GGTAGATTGC TGGGAAGTGT
27451 CTGGACAGGG GGAAGGGGGA AGGGAAGTGG TCCTCAATGC TGACTCTACC

FIG.3-11

27501 AAGCGCCCTG CTAGACACTT TATCCTTTAA TCTCTCAACA GCCTAAAGAG
27551 ATTATATATC CCCATTTTAC AGATGAGGCA ACCAGTTTCA ACAGAGTTAA
27601 CATATGGAGC CTCACTGGGC AGCTTTTTCT GTCTTCCTGA CTTTCTCTCA
27651 TCCTTCAGGG GGCTGCAGGT TTGTTTTCTT CTCCTAGTGG AGAGGAAATT
27701 CTCAGGTTTG TTTTCCTCTC CTAGCAGAGA GTAAAAAAG GGATAGTTTG
27751 CCTGACTTGT TGAAGGTGTG GCTGAGATTG TTTTCTAAAG AGCCAATGGA
27801 AATTGATCTT GAGTTTAGGA GAAAGCTTTT ACATGTGGAA TTAAGATGCC
27851 AAGTGTTGAA GTAGCCACAT TTCAGGTCCT CATTAAATTC TCTTAATCCT
27901 GGAAGGCAG CTTAGGAGAA GGGTTGTTCC TTTAGGAGCC AGGAACTATA
27951 CCCCTTTTAC CCTTGAGAG GCAGGGAAGC CAGGGAGGAC ACAACTTCTC
28001 AGGAAGAGGA GAAGCTAGAG CAGATAGTGA ACTCTCAACC TGAACCTTTA
28051 AGGGCCAGAC CACTAATGCC ACCCAAGTCC ACCTGCCGTT TGTCTTGTTT
28101 TGTCCCAGGC TTTCTGGAGA ACCTGATCTT CTGGCCCTA CCCCCAAGCT
28151 CCGTTTGCCC AGCTAGAGTC TGGGGGTAC TGAAGTCA CTCTGAGACAT
28201 TCTTCCCTTC CCCAATAAG AGGCCACATT CCTGAAGTCA CTCTGAAGA
28251 GATAGCTGCC ACACAGGGCT CTTTCCCCC AGGGAGGGAC CACCCAGACC
28301 CTCTGCTCTC CCAGGTATCC GTTACCACAT CACTACCTGG TCAGAAAGCT
28351 GTTCTGCCA TTAGCCCTC CCTCTTTTAT TATAGGATAT CCTCAAGGGC
28401 TCCTCTTTGG GCCTCAGTTT CATCCTTGGC AGAAAGTAGA CTTAGACTT
28451 CTTGGGCTCC TGAACAGGGT CTTGCTGGA TTCTGTGAAA CAAATTAAGT
28501 TCTTGACCCT AGGCTCTGG GGGAGTACAA AGTCTATGGG AGTCTGGGG
28551 CTGTGGTTGC AAGGAAAGTG ACGCAACCAG ATTCCATGGG GACATGATCA
28601 GGCCTGACAT GTGAGGGAGG AAGAGGGAGC AAGGGAATGA AGAATAACAAC
28651 TTCTGTGTCC CATAACCCC TGCCTGACAG GCCATACATA CTCAGCAGAG
28701 AATGCACTGT CTTTCTACC AACTAGCGT GAGGAGTGAG CTGCAATTAC
28751 CACTGTGCTT CCAAGTAAGA AAATACCTCA AATTGGAATT TACAAAAGAG
28801 GTAAATTAGG GAGTGGCTTT TGTCGGACAT CTTTAAAGCA TTTTCTTTT
28851 TATAGAATTT CACTTAATGT CCAATACTGA TTTAATGAGC TTGGGTTTAC
28901 ACATTATCTC TTGAAGAAAA CAAATGAACC TTTGTGTTCC AAAGCAATCC
28951 ATGTTTAAAG GGAAGAAATT ATGCATAACT CTGCCAGCT TCACAGTAAC
29001 CTTTGGCAGG TGCCTTAGGT CCTCTGGGAC TCTTTTCCTT ATCTGAAAAA
29051 TGAAGGACTT GGATCAGGTG AATGGTTCCT AGCTCTGCAA CTTATGTGGC
29101 TCCTCAGAGG CACACAAGCT CTTTTCCTT ATTTGCCAAA TAATGGAGGC
29151 CCTGTCTTTA ACTGCAGTAC AACTACACAA AATACTTGAA ACTACAGTCT
29201 TCCTGGTTTT TGGTTGGAAC TGAATCAGTG CACTCTAGCA ACACTTATTT
29251 CTTGCTGTTT GTAGGCTTCA TTATGTGTTT GGTTAATTTT TTAACAAC
29301 AATAACATAT TCCATAATAA TTACAGCTTA ATTGGCAGAC TGTTTCAGTC
29351 TATAGGATCT GCAGGAAGGA GGAGTAATAA AGGGATTTTT GACTGAGCTC
29401 TTATGGAACA GAGTCTCTCT AGGCCCTGT CATATCTGCC CTTCTGGGCC
29451 CTGGGGAAAA GTTGGCATCC CCAGTTGTGG TGCTCTCCAG GTGCCCTCAG
29501 GCTGTGGTGG AGGGAGCTTC CCATTCTCTC CTTAGCCCA CTCAATTCAG
29551 AGGCTAGGGG CTGAAAGAAG CTTCTCTACA ACTGGCTGTT CACTGGGAGG
29601 TTAAGGGATG ACCATCCAGC CAGGCCTTCC TCAGGACATG GGAGGGCTTA
29651 TGCTTTAACA TGTGTAAATC CACTGCAATA ATGACTGGTT CTTTACCCC
29701 ATAAGGTTGA GAATTTACCT GTAAACATTT TTGTCTGAAG AATTGGATG
29751 TAAGTGAGGG CTGGGCTCT ATCTTATCTC ACTTGGCTTC TCTCAGCACA
29801 GCACCTTGCC TGCTTGTTCT TACACATCCT AGATGCACAG TAACATTTT
29851 CTAATTATTA GAAATCTATT AGAATCAATT GATTTAGCT GGGCTTGGTG
29901 GCTCCTTCCT GTAATCCAG CACTTTGGGA GGCTAAGGCT GGAGGATCAC
29951 CTGAGTCCAG GAGTTTAAGA CCAGCTGGG CAACATAGGG AGACCTGTG

FIG. 3-12

30001 TCTACAAAA ATAAAAAATT AGCCAGGCAT GGTGGTGTGC ACCTGTAGTC
30051 CCAGCTACTC AGGAGGCTGA GGCAGGAGGA TCTCTTGAGC CTGGGAGGTC
30101 AGACTACAGT GAGCAATGAT TGTGCCACTG CACTCCAGCC TGGGTGACAG
30151 AGTAAGACTC TGTCTCTTAA AAAAAAAAAA AAAAAAGTTG ATTTCTATTT
30201 GGATAGATAA ATAATTCATT TTAGGACCTT TCTTTTTCAC TTACAGAAAT
30251 CTGTTTCATT CTGGGCTGAG AAGCAGGTCC ATATTGCTAG GCATAGGAGA
30301 AAAAGGGGTC TGTCTGCATT TGCCCTTGGT GGTCTCAAAT TGGGGAGGGA
30351 AAGAAATGAA CACTTACTGG CTACCTTCTG TGAGCCAGGC ATCATGCAAG
30401 ACATCTGTAC ATAATTTAAT TCTCATAACC CCATAAGATA TTATTAGCAA
30451 TGTACAAGTG AGGAACTGA GGCTCAGAGT CATGAAGTAA CTGGCCTTGG
30501 GTGACACAGA TGGTAAATGG CAGAGAAGGA ATATGGATCC AGGTCTTGAA
30551 AGAGAAAATC TCAACTGATT ATCTTTTTTA AAAAACTCAT ATGTTCTCTG
30601 CTGACTCAAA AGGTCTCTGT GTGGATCTGG GTTGACCCAC TGAAC TGACC
30651 ATCAGGGTTC CATGCACTTT GTATCTGCCC AAGCCCTCAG AACCCCTCAG
30701 TAATGTTTTG GAAGATGAGT TTTGGAGGTT GTCCTTAGGC ATAGCCTCAG
30751 CGTATGTAGG CCTCTAGGTG ATCTCCCTA ACCTGAGGAT TTCAGCTCAA
30801 TTCCTCTGG CTCCTCAGGA CAGTGGGATG ACTGGTTCAG ACCTCAGCTT
30851 TACCACCTCC CAGCTGGGTA CTCTTCTACC TACAGCCAGG GCAGATTTTG
30901 ACTTTCACTT GAACTTCCA AAAATTGAAA GGTAGAAAAA CAGCCTTGGC
30951 TTTGGGAAGA ACGTATGATG TCCATGGCCT CTAAGCATCT GAGGTGGGAC
31001 ATGTTGAGT AGCACCTTAC AGTTCCAAAG TGTGTTCTGG GTTCTTTGTT
31051 TAAAAGAACA GAGACTGCTG GGAATTGAA CACTGTGAAG TATATGAAGG
31101 AGGAGAATTG TGCTATTTAA CATTGAGTAC TTGGGCTAAA GGAGAAGCAT
31151 CACGAAGTGT TAACACTCAA AGGGTCTTGA GCTGTCAGGG CTCCAGCTTC
31201 CTTATTTTCA CAGGTGAGAA TCCTGAGGCT CAGCTGTTGA GATGTGCTGT
31251 CTCCTCCCGG TGACATAGTA CAGTGGATGT GGCTTTGCAG CCAAGCACAC
31301 ATAGCTTCAC ATTCCAGCTC CATCAATTAT GTATTGGGCA GCTTTGCAGA
31351 ATGATTTGAC TTAACTCTG CTTTTCAGTC TTCTGTAAAA CAGGGATAAT
31401 CCTGCTACCG TAGGGTTGTC AGGATTAGAG ATAATATAAA TAAGGTACCT
31451 CATATAGGAC CTGGATTATG GCTGGCATTG AATAAATAGT AGCTGTTAAT
31501 TGATAGCTAA GCTAGAACTC TGAAGTCTAC CATGGCAACT TCTTAAGTGG
31551 TCTGAGAACC CAGTTGTGTT CTGTGGCAA ACACAGCTTA GGGATCCATA
31601 CCCAGCCCTC CTGTCAGCTG TTCACCTTCC AGTTCCTCAG AGACATGTGT
31651 GGCAGTGACT TTGGCCACAT AGCTGGCTGT GCCCTTTAAA GGCATTCCCTT
31701 GACACAGATA TGTGGACTGG TGACGTTGCT CTCCAGCCAG GTGTTCTTCC
31751 CAGCAGGCTG GCCTGGCTGT CTCCTGCATG CCTGTACTTG TTTGTCTCCC
31801 TGCTCCCTCT CCTGGCCTG GCCAGAGCTA CTTGCAGCAA AAAAAAGCAG
31851 GATATTGGCA ATGGAAAGGA GGGTGTGTTT TGGTGCTCCC ATGCCCTGCG
31901 GCGCACATAC CATTGCAAGG GCGTAACAGA GCCCAGGCCT GCATTTGGGT
31951 GCAAATAAGT CTGCACACAG AAGAAAAGAA GGACCTGGTG ACCAGGAGCC
32001 ATGGAACCCT TGTGCTCCCC TACCTGGGCT ACTGGTCTT GCCACTCCTA
32051 CCATTTTCAG TTTGGAATA TTTGTTAAGG CTTTGCTCTT CCAGGTCCCTT
32101 TGCTTGGTGC TGAGTCTACC AAGAGTAAGT GGGATGCTGT TTTTGTCTCT
32151 AGGGAGCTAA CAGTCTAGTG AAGAAGAAAG ATGGTTGCCC AGGAACCTCT
32201 AAGTCAGAAG GCAGGAGGCA AGAAGGAAGC CCCTGCTCCT ACTGCCAGCC
32251 CTCTGTTGGG CACCCCATAG TTCTTCAGAA CCACATTTAA TCCTCACTGC
32301 AGGCCAGGCA TAGTGGCTCA CACCTGTAAT CGCAGCACTT CGGGAGGCCA
32351 AGGCGGGCAG ATCACTTGAG GTCGGGAGTT CGAGACCAGC CTCACCAACA
32401 TGGGGAACC CCGTCTCTAC TAAAAATAGA AAAATTAGCC GGGTGTGGTG
32451 GCATGCGCCA GTAATCCAG CTAATCCAGG GGCTGAGGTG GGAAATCAC

FIG.3-13

32501 TTGAACTCGG GAAGCAGAGG TTGCAGTGAG CCGAGATTGT GCCACTGCAC
32551 TCCAGCCTGG GCGATAAGAG CAAAATTCCA TCTCAAAAAA AAAAAGAAAA
32601 AAGAAAAAAT CCTCACTGCT ACCTTGAAAG TAGGTGATGA CATTGCCATT
32651 TCACAAATGA GAAGTGAAGG GGCTAGCCCA AGATCACTTA GGTGGTAAAT
32701 GGTGGTGCTA AGATTAGAAC CTCAGATCAT CTAGGGAAAA ACACAGATAT
32751 GCACAGAGTT AAGGGGACCC AGGGTATTGT TTGTCCTCTT GTTTCACAGG
32801 TGGGGAAACA ACCCAGAGAG GGAAAGGGGC TTGTCCAAGG CAATTTAGCA
32851 CCCAAGAACT TGAACCCATA TCTCTCTCCT CCTCATTTAG AGCTCATCCC
32901 ACATGTATCT TATATTGAGA GGAGTGTGAG CCACATACCA AGAACAGTCT
32951 TCCCCTCTGC CTCCAACCTC ACTGTGCAGT TTTGAGACAC TTCACAGCCA
33001 TACTCTTCAT GCCATACCCA GCCCTTAAGA CCCTGAAGTT CCCCTTCCAT
33051 AAGACAAGTA GGAAAAGCTA TAGGGTAAAA ATAGCCATCA GTGTTTGTG
33101 AGCACCCAGG AGGAATTGGG CACTCCAGAA AGATAAAGGG ATTCTCAGGG
33151 ACTTGCTTCT CTAGACTTCC CTAGCTCAGC TGCTTCAACT CATTCTGCC
33201 CCTCTTCTCT ACCTCCCGCA GTGCTCAGAA GTAGTAGAAC TCACTGTGGC
33251 CTCTCACCTT GCATTGTGA GTTTTATTTA GACTTTCTCT TCCTCAACTC
33301 TTCATAAGCT CATGAAAGGT GAAGTAGGGT GCCCTGTGTA TTTATCTTTT
33351 ATATCTGCAG TGCTTAGCAA GTTATAATAA TGCCTTGCC TGGCAAAAGG
33401 CTTTCTCTCA TACATTAGCT TATTTCTCT TCACATTGGC TCTTTGTAGT
33451 AATAGGATGC TATTAGTTAT TTTCAATGAG AGAAAGCTAC TAAGAGAAGT
33501 TGTCAGCTA GTGACAGTAA GTGGCTGATA AAGTGAGCTG CCATTACATT
33551 GTCATCATCT TTAATAGAAG TTAACACATA CTGAGTTTCT ACTATATTGG
33601 GTCTTTTTTT TTTTTTTTTT TTTTTTTTTT GAGACGGAAT CTTGCTCTGT
33651 TGTCAGGCT GGAACGCAGT GGTGCAATTT TGGGTCACCA CAACCTCCGC
33701 TTCCAGGTT CAAGCGATTC TCCTGCCTCA GCCTCCTGAG TAGCTGGGAC
33751 TACCAGTGCA CGCCACCACG CCCGGCTAAT TTTTGTATT TTAGTAGAGA
33801 CAGGGTTTCA CCATGTTGGC CAGGCTGGTC TTGAACTCCT GACCTTGTA
33851 TCTGCCCGCC TCAGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGCCACC
33901 GCGCCCTGCC TATATTAGGA CTTTTATATA AGCTATCTCT AGCTAGCTAG
33951 CTAGCTAGCT ATAATGTTTT TTGAGACAGA GTCTGACTCT GTCACCCAGG
34001 CTGGAGTGCA GTGGCGTGAT CTCGACTCAC TGCAACCTCC ACCTCCTGGG
34051 TTCCAGTGAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG ATTATAGGTG
34101 CATGCCACCA CGCCAGCTA ATTTTTTGTA TTTTATAGTAG ACCAGGTTTC
34151 ACCATGTTGG CCAGGCTGGT CTCGAACCTC TGACTTCAAG TGATCCACCC
34201 GCCTCGGCCT CCCAAAGTGC TGGGATTATA AGCATAAGCC ACTGTGCCCA
34251 GCTGCTCTCT ATATTTTTAA TACATATTAT TTCCATTAA TTTACAGCA
34301 GTTCATTTTA TAGATGAGGA AACTAGGCCA GAGAAGTAAA ATATCTTGCC
34351 CAAGATGATG TAACTAGTAA GTGGCAGGAT CAAGATTCAA ACCAAGCAAT
34401 GTTCAAACCT CTTGGAAGCA AGAATGTGGC CACTGTGGAA GGTGCAAGGC
34451 CTTGACAACA AGAATAGGGA AAAGAAGGAA CTAGAAGGAA AGAGATGGCA
34501 TGGGCTCAGC AGGCCAGGGA GCTCTTAGCT GTGTGTGTTG GGAAGCTCAG
34551 AAGGGAGGAA GAGGTTGTCT GTGCAGGTAA GTCCTGAGAA CACACCAGAC
34601 TTTTGAGAGG TGAGCTTCA TAGCCAGGTC ATTAGGGGAG AAGGGAGCTA
34651 TAGATTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTAG AGACGGGGTC
34701 TTAATATGTT GCCCAGGCTG GTCTTGAAC CCTGGGCTCA AGTGATCCTC
34751 CCACCTCAGC CTCCCAAAGT GCTGGGATTA GAGGCATCAG CCACCCCGCC
34801 CAGCGAGCTA TGGATCTAAC ATGTACATCT TACACAGTGC TAATAGAATG
34851 TTGGGTTTCT TCCCAATAT TTTATTTTGA AAAAAAATTC AAATATATAG
34901 AAAAGTTGAA AAATGTAGTT CAAAGAACAC CTACATACCT TTCACATAGA
34951 TTCATGATTT GTTAATGTGA TGCCACTTTG TATATATCTC TCTCCCTCCT

FIG.3-14

35001 ATCTGTATAC TTTTATTTAT TTATTTTTGC TGAACATTT CAGAGTAACT
35051 TAAAGGCATC TTGATTTTAC CCTTGAACAG TTCAATATGT TTCTGCTAAG
35101 AATTCTCCTA TATAAGTCAG ATATCATTAC ATCTAAGAAA ATTCACGGCA
35151 ATTTTACAAT ATAATATTAT AGTCCAAATC CATATTTCCT CAGTTGTTCC
35201 AAAAAATGTT CATGGCTGTT TCCTTTTTTA ATCTAAATTT GAATCCAAGT
35251 TTGAGGCATT GTATTTGGTT GCTGTGTCTC TAGGGTTTTT AAAATCTGTG
35301 CCTTTTCTTC TCCCCATGAC TTTTAGAAG AGTCAAGACC GGTTATTCTT
35351 ATAGAATAAC CCACATTCTA GATTTGCCTG ATTAGTTTTT TTATACTTAA
35401 CGTATTTTTG GCAAGAACAT TACATTGGTA ACGCTGTTGG TGATGGGTCA
35451 GTTTTGAAGA GTGGAGATGA TTAAACTGCT TTTGTTTATT GAAGTATCTG
35501 TCAAGACCAG AGATCCTTAA CTGGTGCCAT AAATAGGTTT CAGAGAATCC
35551 TTTATATATA CACCCTGTCC CCCACCTAAA TTATATACAC ATCTTCTTTA
35601 TATATTCAAT TTTCTAGGGG AGGCTTCTTG GCTTTTATCA AATTCTCAGA
35651 GGGCCCAAG ACCCAAAGAG GTTATGAAAC ACTAGTCTGT CCACTGAGGC
35701 AGGCAACACA GAGCTGGTTT CTGGGGCCTT GTTCAGTCTG AACCAGCTTC
35751 CCTTGGGGAG ATAGCACAAG GCTGTAACCT TGCCCCATCT TGGCTTTGGA
35801 TCAAAGAGGA CTGTCCATTT TGTTGTCATA CCTAGGAACC AGGGACAGCT
35851 TATGTGGCCT GGTTCAGGG ATCCAGGAGA ATTCAGTTC TTGTCTTGCC
35901 TTTAGGTGT TCAGAAATGCC AGGATTCCT CACCAACTGG TACTATGAGA
35951 AGGATGGGAA GCTCTACTGC CCCAAGGACT ACTGGGGGAA GTTTGGGGAG
36001 TTCTGTATG GGTGCTCCCT GCTGATGACA GGGCCTTTTA TGGTGAGTGA
36051 ATCCCTTCAT ATCTGCCCT CTTGGTCTTC AGAGTCCATT GACAGTGCTT
36101 CCAGTTCCT GTGGCCTGTT AATCTTTTAG TCTTCCATC AGCCAGGGCA
36151 TCTCCCTTTA TTTATTCAAT CATTCAACTA GCAGGTATCA ATTGAGCACC
36201 TACTAAGTGA AAGGTAAGAT CCTTCCCTCA AAGACTTAAT AGTTGAACGT
36251 TGGGAGTGGG AGGAGAGGCA GGCAGAGAGG AGACACAATA TAGTTGGATA
36301 AGGACCTCCA AGGAGAGTGT TACAGGCTGA GAGGAGGATA TACTTAGGTT
36351 GTCTTTAGGG AATCAGAAAA GGAGACTCTG GAATAGGCTG GCAGAGAGAG
36401 GGGCTACCTC CTATACCTGC TCTGGACAAA CGACTTTAAG CATAGTGACA
36451 GATTTGCCAA CCCTGTATTG GAAGAACTGA TCTTTTTTAG TGGGGATGAT
36501 TACTTCTGGG GATTTCTTCT CATAACTGAG ACCAAAACAG TTTTGTGAG
36551 TCTCAGAAAT GACAGGAGGT ACCAATCTGA CACTTCCTTT GGAAGCTCTA
36601 GGGCAGAGAG TGAAAGAGTG GATTTTGACG GGGGCCTTGC TTGGAGGTCA
36651 TTCACCCACC CCGTGCCTCA CTCCAGCAAC AGTGATAACT CACTTCCTTC
36701 CTCCCTTTGT ACACCTTCT CCCCACCTGC TCACAGGTGG CTGGGGAGTT
36751 CAAGTACCAC CCAGAGTGCT TTGCCTGTAT GAGCTGCAAG GTGATCATTG
36801 AGGATGGGGA TGCATATGCA CTGGTGCAAG ATGCCACCTT CACTGGTAA
36851 GATAGTGGTC CTTTGTCTAT CCTCTCCCAT ATAAGAGTGG CTGGCGGGGA
36901 GGGACAGTGG CAGGGTGAGT TGGGCAGAAG GAGTGTTAGG GTAGTCAGAG
36951 CATTGGATTG TTACCACAGC AGTGCTCTTA ACCAGCTCTT TAACCTGTAA
37001 GCAGAAATGAT TTACACATGT CTCTACCCTT TTTCTTACC AACCTTGAAA
37051 ATGTCTTCAC TCTGCCCTGC AATCCTCCCA GTGGGAGGCA CTCTTCAAGG
37101 ACGATCCCAG AACATTAAAG TCAAAGACCC CTTAGAGCTC ACCCTGTCCA
37151 ACCACCTTGG TTGATAAAAG AAGTCAGCCT GGGGCCATG GAATAGAATA
37201 GTACAAGGGC AAGGTTCTCA TTGTGAGTCA AAGGTAGAGT GAAGAGAACC
37251 CAGACCATCT CACCCCAACC CAGGCCAGTG TTTTCCAAA TATACCACTT
37301 GCTGCAGATC TAGCTCAGCA CCCCAGTCC CAGCCCACCC TGAGAACCCA
37351 GGCTCCTCAT TCTGAGCAGC CAGCTAGAAT CATGACAAAG AGGGTGGTAG
37401 TGAGACTATG GGTACTGTTG CTTAAAGCCA CATGGTGCAG TGGTTGCTGG
37451 GGGGCTTCTG TGTGGGACTC TAGCATCTTA TTCCCCCTG TGCCCTCTCC

FIG.3-15

37501 CCAGTGGGAA GTGCCACAAT GAGGTGGTGC TGGCACCCAT GTTTGAGAGA
37551 CTCTCCACAG AGTCTGTTCA GGAGCAGCTG CCCTACTCTG TCACGCTCAT
37601 CTCCATGCCG GCCACCACTG AAGGCAGGCG GGGCTTCTCC GTGTCCGTGG
37651 AGAGTGCCTG CTCCAACACTG GCCACCACTG TGCAAGTGAA AGAGTAAGTA
37701 TTTTGAGAAC CCTTCAGCAG GGGTTCTTGA GCAGAGTCTG TAAATGGGCC
37751 TCAGAGGGCT TAGACCTCCA AAGTCTCATG CAGAACTCCC TTTATTCTCA
37801 TCTCATATCT TTCTCCTGGA CCCCACTATG CTGTAACCGT ACCTGGGCCT
37851 TGGCACTTAC TGTTCTCTCT GCCCAGGCTA CTTCTACCC GATACTTAAG
37901 GCAAGAATCA CTCACCTTTC AGGTGTGAGG TTTCAGGTCA TGTTTGCTCT
37951 TTGAAATCAT CTGGCTTGAT TATGTGTATT AGTTGTTTAT CTTCTATCCC
38001 CTCCACTAGA ATGTAAATTC CAGAAGAAAC TTGCTGTCTT ATTCAGTGCT
38051 GCATGCCCAG GGCTTGGAAG AGTACCTGGC ATATAGTAGG AGTTGATTGA
38101 TTATTATTTT GTCAGTCGAG AGAATGAATG GAGAAAATGT GGTCATGGC
38151 CCAAAAGAAG TTAAGACCCT ATCCTAGATT CAGGCCAGAG ACCAGATGGA
38201 GAAAGAGTCT GTGTCTATCT AATACCAGTA ATGTCGTACC TCTGGCCGCT
38251 TACCATGTAA ATATTGATTG TGTATCTACC ATGTGTTGGA CACTAGGCTA
38301 GTGCTTGAC AGCAGGTGAA AGATACTAGA GTTTGGGAAG TCAGGAGGAG
38351 CTAAGGTCTG TTCTACAACC TTATTAGATG AAGAGGAGAG GGAATTGTGT
38401 TCAGGGCAGA GGGAGAAGCA TTTCTCCAAA AGTAGGAGTC TTAATCATGT
38451 CTGATGTAGG TTGAGTGTGG CCAGAAAAGG GGCTGTTAAG TATAGAGGGC
38501 CTGGATTATG AAAATCCAGC AGATCCATTG AGAGTTTAAG CAGCAAGGTG
38551 TTGTGACCAA GTTAACATTT TAGAAGGATC ACTGGTATGG AGGTTGGATT
38601 GGAGAGGGGA AAGCCTAAAG GTATAGAGAC TAGTTAGGAA GCTATTGTAG
38651 GCTGGGCATG GTGGTTCATG CCTGTAATCT CAGCACTTTG GGAGGCTGAG
38701 GTGGGAGGAT TGCTTGAGGC CAGGAGTTGA AGACCAACCT GGCCAACATA
38751 GCAAGACCCC GTCTCTGTTT TTCTTAATTA AAAGAAAAGT CCAGACGTAG
38801 ACATAGTGGC TCACGCCTGT AATGCCAGCA CTTTGGGAGG CCAAGGTGGG
38851 CAGATTGCTT GAGGTCAAGA GTTTGGGATT AGGCCAGGCG CAGTGGCTCA
38901 CGCCTGTAAT CCCAGCACTT TGGGAGGCCG AGGTGGGCGG ATCACAAGGT
38951 CAGGAGATCA AGACCATCCT GGCTAACACA ATGAAACCCC GTCTCTACTA
39001 AAAGTACAAA AATTAGCCGG GCATGGTGGC GGACGCCTGT AGTCCCAGCT
39051 ACTCGGAGG CTGAGGCAGG AGAATGGCGT GAACCTAGGA GGCAGGCTT
39101 GCTGTGAGCA GAGATCACGC CACTGCACTC CAGCCTGAGC GACAGAGCGA
39151 GACTCCATCT CAAAAAATAA AAAGAGTTTG GGATTAGCCT GGCCAACATG
39201 GCAAAACCCC ATCTCTACAA AAAGTACAAA AAAATTAGCT GGGTATGGTG
39251 GTGCGCGCCT GTAATCCAG TTAATCAGGA GGCTGAGGCA TGAGAATTGC
39301 TTGAGCCTGG GAGGTGGAGG TTGCAGTGAG CCCAGATCAT GCCACTGCAC
39351 TCCAGCCTGG ATGACAGAGT AAGATGCCAT CTCAAATAAA AATTAAAAAC
39401 AAAGTTTAAA AAAAAAATAG AAGCTATTAC CGTGATCCAG GTAAGAGATG
39451 TGAATAACTA CAATGATGGA AAGAAGGCAG AGTTCTTAGA GATGGGAGTA
39501 GGAGAGATGA GGGAACTCCA GATTGGGAAG ATGATGTTCA AGTTTCTGGC
39551 TTAGGCCACA GGGTGAGTGG CAATTCCCTT CACTGAGATG GGGCATCCTG
39601 GAAAAGGTGT TGCCTTTCTG TGTGGGTATC CTGGGCCCT TAGGGGCCAC
39651 TGGTGGCCTG GGCCTGGTA AACCTTCCCT GCACAAGCAG AATTGGTCAA
39701 GCAGGTTTTT AGGACATCTT TACCCTGCCT CAACTCTTGT CTGGCCAGG
39751 GTCAACCGGA TGCACATCAG TCCCAACAAT CGAAACGCCA TCCACCTGG
39801 GGACCGCATC CTGGAGATCA ATGGGACCCC CGTCCGCACA CTTGAGTGG
39851 AGGAGGTAGA GTGTGTGTCT AATCTGTCTT GTGAGGGTGG GACATGGAAC
39901 AGATCCTCTG GGAATCAGG CTGTAGCCTT TACCTTTTCC TACCCCCAGC
39951 CCATCTCTTT GTCTTAGCAT TGAGCCTGTG ACCACTGGTG ACCTATTCA

FIG.3-16

40001 GCGTAACAGG TTCCCAGGGT AGCAGGGATG GTTGATGGAC GGGAGAGCTG
40051 ACAGGATGCC AGGCAGAGGG CACTGTGAGG CCACTGGCAG CTAAAGGCCA
40101 CCATTAGACA AGTTGAGCAC TGGCCACACT GTGCCTGAGT CATCTGGGTT
40151 GGCCATGGGT GGCCTGGGAT GGGGCAGCCT GTGGGAGCTT TATACTGCTC
40201 TTGGCCACAG GTGGAGGATG CAATTAGCCA GACGAGCCAG ACACTTCAGC
40251 TGTTGATTGA ACATGACCCC GTCTCCCAAC GCCTGGACCA GCTGCGGCTG
40301 GAGGCCCGGC TCGCTCCTCA CATGCAGAAT GCCGGACACC CCCACGCCCT
40351 CAGCACCCCTG GACACCAAGG AGAATCTGGA GGGGACACTG AGGAGACGTT
40401 CCCTAAGGTG CCACCTCCCA CCCTGGCTCT GTTCTGTCCT ATGTCTGTCT
40451 CTCGGATGAA GCTGAGCTGG CTTTCAGAAG CCTGCAGAGT TAGGAAAGGA
40501 ACCAGCTGGC CAGGGACAGA CTATGAGGAT TGTGCTGACC CAGCTGCCCC
40551 TGTGGGGATC ACAGTTTACA GCCAGAGCCT GTGCGGACCC AGCTGTCTGC
40601 CAGGTTTCCT TAGAAACCTG AGAGTCAGTC TCTGTCCACT GAACTCCTAA
40651 GCTGGACAGG AGGCAGTGAT GCTAAACCCT GAAGGGCAAC ATGCGCTATG
40701 GAGAAAGCAT GGAGCTCAGA GCCTGGAGTA CGGGCACAGA TAGGATTGAA
40751 TAAATTGTGT AGAAAGACTT TGAACAACAT AAAGCAAAAG ATGAATGAAC
40801 GTTTTTTTTA GACTTGAGGG ACCAACAACC CCCAAACCCC AGATTCTGCC
40851 AGGTCCATGG GGAAGGAGAA GTTGCTTGA GTGGAAGCCC CAAGTAGGGA
40901 GACTTACAGA AAAGAAGTCA AGAGCACTGG CTCCAGGCA GAAATACTGA
40951 TACCCTACTG GGGCTTCAGG CTGAGCTCCT CCCTTCACAA ATCACTTCAT
41001 CTCTCTGAGC CTGTTTCTGC ATCTGTGACA TAAGATGGTA AGATAAAGGT
41051 GGCTGTCTCA CCAATTATGT AAGGATTAAG TGTGGAAAAG GACATAAAGT
41101 TGTATAGTGC TGCCATAGGG ACAGTGTTCA GTAAACGTGA CACATTCTTA
41151 GTATCACTAA GAATCAGGTT CTTGGCCAGG CACCGTGGCT CATGCCTGTA
41201 ATCCCAACAC TCTGGGAGGC CTAGGTCGGA GGATGGCTTG AACACAGGAG
41251 TTTGAGACCA GCCTGAGCAA CATAGTGAGA CACTGTCTCT ACAAAAAAAA
41301 AATAATAATA ATAATTGTTT TTAATTAGAT GGGCAGGGCA CTGTGGCTCA
41351 CACCTGTAAT CCCAGCACTT TGGGAGGCCA AGGCCGGAGG ATTGCTTGAG
41401 GCCAGGAGTT CAGGAGCAGC CTGGGCCACA TTCTGTCTC TACAAAGAAT
41451 AAAAAAGTTA ACTGGGCATG GTGGCACATG CCTGTAATCC CAGCTACTCA
41501 AGAGGCTGAG GAGGAGGATT GCCTGAGCCC AGGAGTTCAA GACTGCAGTG
41551 AGCCTTGATC ACACCACTGT ACTACAGCTT GGGCAACAGA GTGAGACCTT
41601 GTCTCCAAAA AAAAAAGTTT GTTTTTTTTT ATCCACTCTC CTCACCAAAC
41651 AACTGAGTA AGTTAGAGCC CTCTCAGCTG GCATGTGTTG GAAACAGTGC
41701 CCTCTCATT AAGTGCTGCC CTCACTCCCA TTGCCTCTTG GCCTTGGTCA
41751 GTATGATGAA ATTAGTGGGA GGCAGGGCAA CAGAGGGCAG GGAAGAGCTA
41801 GAAATCCATG GCCTGGAAAA GGGAAAGATT GGGAGTGGCC AGGTATCTGT
41851 AGAGCCACCA TGCAGAGGAG GGGGGCAGCT AGCCTTGTGT GCTCTGGTGG
41901 GCATGGTCAG CAGGAGGCAG AGCAAAAAGGA CAAGGGTAAG TAAACCTGTA
41951 GGTGCGGACA AGCCAAGAGC CATCCAGCGT CAGTCTCTC TGGGTAGCCC
42001 AAGTAAAGCA GGAGCATACC CCAGAGAGAA AGTTCGCAGG GCTGTTACC
42051 TGCAGTGCTG TGGACTTCAA CCTTCTTGTT CCTTCTTCAG TAAGTAAAA
42101 TAACAGTCAT TGACCATGAC TATTATCGAC CGCTTTTGAA AATGTAACA
42151 TAGTGACTTT ATTGCTGTAA AAATCATACG TGTTTATCAT CTAAAAATTC
42201 AGGAAACATG GACAGGTACA AAGATGTGCA AAATATCATC CAAAATCCCA
42251 TTTGCTGGCC AGGCACGGTG GCTCACGCCT GTAATCCCAG CACATTGGGA
42301 GGCCGAGGCG GGCAAAATCAC TTGAGGTCAG GAGTTTGAGA CCAGCCTGGC
42351 CAACATGGTG AAACCCTATC TCTACTAAAA ATACAATAAT TAGGCTGGGC
42401 GCAGTGGCTC ACGCCTATAA TCCAGCACT TTGGGAGGCC GAGGTGGGCG
42451 AATCACAAGG TCAGGAGTTT GAGACTAGCC TGCCAATAT GGTGAAACCC

FIG.3-17

42501 CATCTCTACT AAAAATACAA AAATTAGGGC CGGGTGTGGT GGCTCACGCC
42551 TGTAATCCCA GCACTTAGGG AGGCCGAGAC AGATGGATCG CGAGATCAGG
42601 AGTTCGAGAC CAACCTAGCC AACATGGTGA AACCCCATCT CTAATAAAAA
42651 AATACAAAAA TTATTGCGTT GTGGTGGCAC ACGCCTGTAA TCCCAGCTAC
42701 TTGGGAGGCT GAGGCAGGAG AATCTCTTGA ACCTGGGAGG CAGAGGTTGC
42751 AGTGAGTGGA GATCCCGCCG TTGCACTCCA GCCTGGGCGA CAGAGTGAGA
42801 CTCCATCAAA AAAAAAAAAA AAAAAAAAAA AAATTAGCCG GGCGTGGTGG
42851 CGTGACCTA TACTCCAGC TACTTGGGAG GCTGAGGCAG GAGAATCGCT
42901 TGAACCTGGA AGGCGGAGGT CGCAGTGAGC CGAGATCGTG CCATTGCACT
42951 TCAGCCTGGG CGACAGAGCG AGACTCTGTC TAAAAATAA TAATAATAAC
43001 AATAACTAGC CGGGCCTGGT GGCACATGCC TGTAAGTCCA GTTACTCAGG
43051 AGGCGGAGGC ATGAGACTCA GGTGAAGTAG GGAGACAGAG GTTGACAGTGA
43101 GCCAAGATCA CACCACTGCA CTCCAGCCTG GTTGACAGAG CGAGACTCTG
43151 TCTCAAAAAA AAAAAAATCC CATTTGCTCA TTTTTTGGAT ACTAGTATAA
43201 CTATCACTCT AAACCACTTA GTACTTAAAT CAAGCAGATA TGGGAGATGG
43251 TGAATTACCA TCTACAGTGT TGTCATATAT GTCACATACT GAGCATTATC
43301 AGCTAGTAGA ATCTAGTTAA TTGTTCTATG TGTGATGTAT GCAGAGTTCC
43351 CATTTTGAAT GTGTTTTTAC TATGCTTAAA TAAATGACTG ATGTCAGCAA
43401 CCCCCAAATG ATACATCTGA TGAAGAGCC CCTGTTCCCC AATAATAACA
43451 TCTAAACTAT AGACATTGGA ATGAACAGGT GCCCCTAAGT TTCCTCCCTC
43501 CAGGGTTTCT TGGCCGGTCT CTGAGGACTA CACATCCCTA CTCCCCTCTT
43551 TCCTCATCTT CAGGCGCAGT AACAGTATCT CCAAGTCCCC TGGCCCCAGC
43601 TCCCCAAAGG AGCCCCCTGCT GTTCAGCCGT GACATCAGCC CCTCAGAATC
43651 CCTTCGTTGT TCCAGCAGCT ATTCACAGCA GATCTTCCGG CCTGTGACC
43701 TAATCCATGG GGAGGTCCTG GGAAGGGCT TCTTTGGGCA GGCATATCAG
43751 GTGAGCGCAG GCAACAATTG CTTTGCTCTT CTGCCCCCAG TCCTCTGTCT
43801 ACTGTCTTTC GGGGATTICT CATCACTTGG CCCCACCCA CACCATGCAG
43851 GATGCCAGGC CTCCTTCTCT GCTTTGGGTG TTGGTGTGAG AGGTATCCTT
43901 CACCCCCACC CAGGCCACCT AAGGTCAATG TTGCTGTTAC AGTGAGCTTG
43951 TGGACCTGGA GATCCAGGTT GGGTTGAGCT GTGCCTGTGG CCTCCTGCC
44001 TCCAGTCAGT GGGTGTGTTG TAGGTGCCTG CAGACCTCAG TACCGGGCAT
44051 GCTACAAGGA GCACACAGGG GAATGGCTCC TGCTCCCTG GTGAACAGTC
44101 TCAGGGACTA ACCTCTCTCT TTCTCTCCTC CTCCTCCTCT TCTGCTGAGA
44151 ACTGGGAGGG GGGGTGAGGT AAGACGTGTG TCTCAGCTTG GGGGCAGCAG
44201 GGCTGGAGAG CTCACCCCG ATCCACCCAG CTCCTGGTG CATGTCTTTG
44251 GCACTGACCT TCCTGCCCC AGACTTCTGT TCACTCAGGA GACTCACTTC
44301 TATGCCAAAT GACCAGAGCC CCTGCTTGGC TTGGCAGCAT CCCCTCCTGC
44351 CTTCTTCCCC ACTTCCCTTT TCTGGTTCT TGCTGTCTCT CTGTGCATGC
44401 CCAGCTCTCC AGGAAAGAGG GTTTGCTTCC GTGTGAGTCC CATGTTGCTC
44451 CACGCTGCAT CTTCCACACA TGAATCTGT CATTCTGACC CGGCTCAGTG
44501 TGCCCTCCAA GGGATGGGAT GGCCAGCTGC ATAGATTTTC TCAAACAGTT
44551 CTCCAGAACT TCCTCTGGTC TCAGCACCAT TAACAGTCAC CCTCCCTGTA
44601 GGTGACACAC AAAGCCACGG GCAAAGTGAT GGTGATGAAA GAGTTAATTC
44651 GATGTGATGA GGAGACCCAG AAAACTTTTC TGAAGAGGT AAGAAGATGG
44701 AGGGGGCCCC GGAGGTTGGT GTCACCATG GAAGAGAGAA GACCTTACAA
44751 ATAATGGCTT CAAGAGAAAA TACAGTTTGG AATTACTGTC TTAAGACTA
44801 AGCAGAAAAAG AGCCCTAGAG GAATATCCCA CTCCTCTAA ATTACAGCGT
44851 AATTATTTGT TCAATGAACA CTTACTAAAA GCAACACAAA CAGGGTACAA
44901 GGGATGCAGT AACAAAAGAT ACAGGGTTCA GAAGAGCTCT CAGGTTATGA
44951 GGATGATGGA CATGAAAAA CTCCAATTTA GTACAACTCA ATGTTATAAT

FIG.3-18

45001 CCTCACCTGA ACGCCCTGCT AAGGGAGCCT GGAGGGGAGC TCCCTGAGCA
45051 CTCACACTCC TTGGGCATTT ACAGTTTTCA CTACCCCTCC CAAGTTACTT
45101 CATGGAGTAA CTTAAGTTGG GGACACCTGT GGTCTGGGTA TTGCCCTCCA
45151 AGCCACTTGG CCACTCCAC CCCAGTTCTC CCAATGCAGT TCCAAGGGTA
45201 AGGCCTATGA AGCCATCTCC ATCTATATGG TGGTGGTCTT CCCTCATCCT
45251 GATCTTAGTG CCCTGTCATA TCACAAGATA GGAGGTAGGA GATACAGGTG
45301 GTAACACTTG TCAAGCTGAT TCCTTGGAGG GAAGAGGTAA GGAAGACAGT
45351 GAGAAGTTAA CCACCAGCTT TCCTTGGCTT CCCCCACCCC CAGGTGAAAG
45401 TGATGCGCAG CCTGGACCAC CCCAATGTGC TCAAGTTCAT TGGTGTGCTG
45451 TACAAGGATA AGAAGCTGAA CCTGCTGACA GAGTACATTG AGGGGGGCAC
45501 ACTGAAGGAC TTTCTGCGCA GTATGGTGAG CACACCACCC CATAGTCTCC
45551 AGGAGCCTTG GTGGGTTGTC AGACACCTAT GCTATCACTA CCCTAGGAGC
45601 TTAAAGGGCA GAGGGGCCCT GCTTTGCCTC CAAAGGACCA TGCTGGGTGG
45651 GACTGAGCAT ACATAGGGAG GCTTCACTGG GAGACCACAT TGACCCATGG
45701 GGCCTGGACC ACGAGTGGGA CAGGGCTCAA CAGCCTCTGA AAATCATTCC
45751 CCATTCTGCA GGATCCGTTT CCCTGGCAGC AGAAGGTCAG GTTTGCCAAA
45801 GGAATCGCCT CCGGAATGGT GAGTCCCACC AACAAACCTG CCAGCAGGGC
45851 GAGAGTAGGG AGAGGTGTGA GAATTGTGGG CTTCACTGGA AGGTAGAGAC
45901 CCCTTCCTAT GCAACTTGTG TGGGCTGGGT CAGCAGCTAT TCATTGAGTT
45951 TGTCTGTGTC ACTGAAACTG ACCCCAGCCA ACTGTTCTCA GTTCACAGCC
46001 CTGTTTTCAA AGAATTACAC ATCTCTAAAG GCAAACAGGG CACGGACAAG
46051 GCAAACCTGA GAGGCAAACT GTAGCCTGAG ATGGCCTGGG CTGGCCATCA
46101 CAGGTATTCA GGTGCTGAGG GCCCTTAGAC CAACTAGAGC ACCTCACTGC
46151 CTAGGAAATC AATGAAGGGG AAATGAGTTC TAGCGGAGCC CTGAAGGATC
46201 AGAATTGGAT AAAGTTCTTA TTGGCAGAGA GGCACCAGGA TTGAAGTGAC
46251 AGGAGCAAAG ACCTGGGAGG AAAGAGGAGA AAATCATCTA TTTCACTGG
46301 AAACAAATGA TTCCAAGCAT AGAAATAATA ACAGCTGACA AGTACTGAGT
46351 GCCCTCTATA TGCTAGGCAC TGGGCTGAGG GATTAACATG CATGTGCATG
46401 TTTATTCTCT ATGACAACCT TGGTTTCCAG ATAAGCTGGA CTGGAAAGGG
46451 ACAGAGCTGG GATCCTGGGC TAATCAGTCT GGTGCGCAAG CCTGAGACTT
46501 TAGCCACTGC CCTTCACATG GGGGTCCATG AAAATAGTAG TAGTCTGGAA
46551 CAGTTTGGGG GTACATCAAG GTCGCTGTGT TTTAAGCTAT GGAGTCTGGA
46601 CTATAGGAGA CAAATGTAAA AGAGTTTTTT GGTGACTGG CTTTTGGTT
46651 TTTTTGTTG TTTGTTGTT TGTTGTTG TTTGTTGTT TTTCTGTT
46701 TCTGGGGCTT GAATCAGGAA GGAGGTTTTT TTGTTGTTGT TGTTTGGAGA
46751 AAGGATATTG CTCTGTTGCC CAGACTGGAG TGCAGTGGCA CGATCATGGC
46801 TCACTACAGC TTCGACCTCC TGGGCTCAAG CAATCCTCCT GCCTTAGCCT
46851 CCCAAGTAGC TGGACTACAG GTGTGTACCA CCACACCTAA TTTTTGAAT
46901 TTTTTTTCT TTTTTTTTT TTTTTTTTT GGTAGAGACA GGTCTCACT
46951 TTGTTGCCCA GGCCTGAATC TCAAACCTCT GGGCTCAAGC ATTCCTCCTG
47001 CCTCGCCCTC CCAAAGTGTT GGGATTACAG TTGTGAGCCA CCATGCCCGG
47051 CAGGAAAAGA TTTTAAAGCA AGAAAGCTTA AGAGCTGTGG TTTTCCAAA
47101 ATGAGTCTGG GCTGGCACAG TGGCTCATGC CTGTAATCCC AGCACTTTTT
47151 TGGGAGGCCG AGGTGAGTGG ATCACTTGAG GTCAGGAGTT TGAGACCAGC
47201 CTGGCCAACT GGTGAAACCC CTGTTTCTAC TAAAGAAAAA AATGCAAAAA
47251 TTAGCTGGGC GTGGTGGTGC ACGCCTGTAG TCCCAGCTAC TCAGGAGGCC
47301 GAGGCAGGAG AATAGCTTGA ACCTGGGAGG CAGAAGTTGC AGTGAGCCAA
47351 GATCACACCA CTGCATTCCA GCCTGGGTGA CAGAGTGAGA CTTATCTCA
47401 AAAAAAAAAA AAAAGAGAGA CTGATATGGT TAGTACATTG GGGTGGAAATG
47451 CGGAGGGTCC AGGGAATGGA GCCCTGCATA GGGGGCTAAT GAAACATTTT

FIG.3-19

47501 AGATTCTGA ATTAAGGTAG TGGCTGTGGG GACAGGAGCC TGGGAGGCAG
47551 GGTGGAGTCA GAATGGAGAG ACTGGTTGGC AATGAGGGAA CAGGAGGAGG
47601 AGGAGGAGGA GTTACGAGTG GCTTGAGGTG TCACTTACCA GACATTTGGG
47651 GGATGGGGGA TAGCCGTGAT TGTGAGCAA CTGGTTTGGG AAGAGCTAGC
47701 ATTGATCCCT GCTGTTCTGT GCTAGCAGAA CCTATCAGCA TCTTCTGGGC
47751 AGGAAACTGG CTCCATGAGA CTGGCTTAGG GAGAGGCTGC TAGTCACCTA
47801 ATCTGCAGAG AAGGGGCAGC TGGAGCTGTG GGACAGAAGA GGCATCCATG
47851 TAGCTGGTGG GGGTGTCTCA GCTTGTGAAG AGGAGATGGC TTTGAGCAGG
47901 GCTGACACTG AAAAGGCTGG AAGAAAAAAA CAGACACACA AGAGTCTCAG
47951 GATCAGGTAG CATAGGAAAG TTGTGGACAG TCTTTGAGGA GCACTCCCTC
48001 AGGCAGGCAG GCAGGCAGGT CATGAGCTAT AGCGATTGAG GAAGAGCTCC
48051 CTGGGTGTGT GAGCAGCTCC AGGAGCCTAA GGGATGAAAG TAGTATTGCA
48101 GGGGGCTGGA GAGCAAGGAG TGGCTCCTC TACATTTGCA AGGAAGGAG
48151 AAAGGAAGTT GCTCCTGAGA GTGGTAAGAG TCAGTGGTGG AGGCCTGGAG
48201 AGGAGACATA ACAAACAAAT TTGTTGACAA ACATTTTGGT AGGAAGGGGG
48251 AGAGCTTAAA GTTTAGACAG TGGGAAGGT GGAGTCTTAG AGGAGGTGAA
48301 TGTCTGAAAG ACAGAGCTAG CTGGAGCAAG AAGTCACTTC TCTGTTGCAG
48351 GCAGGAAGGA TCCAAAGTGG CTAAGCCAG AGATTGGGAG AGTGGGAGG
48401 AGGAGCAGC CTGGATCTAA GTAAATGGG TAGAGGTGGA GGGGGTGTG
48451 CAACGGCCAG GGTCTTCTGA AGTTGGGGAC ATTAGGAGAG AGCTGTGAGG
48501 GCTTTGGCCA GCCACTGTGC TAGTGATTGG TGAACCAAAG GATGGGCAGG
48551 AGATGGCAGC AGGGAAGCAG AGGAAGTCCA GGCTTCCTGT TGGTATTGGG
48601 ACAAGGGAGA GGCCATAGGA GGCCCTGGCC CTGTTGTCCA GGTGGGTTCT
48651 TGAAGCTGGG TGGCATGGC CTGGTAGGAG AGCATCTATG GCGCCCAATT
48701 CCAGATTGAG GGTCTAGTTG ATTTGCTGGC CCTGTAGCCT CAGCTCATGC
48751 TTCTGTTCCA GGCCTATTG CACTCTATGT GCATCATCCA CCGGGATCTG
48801 AACTCGCACA ACTGCCTCAT CAAGTTGGTA TGTCCTACTG CTCTGGGCT
48851 GGCCCTCAGG GTCCTATCCT TCCTGGCTTC CTTGTCACAA AGGAGGCTGA
48901 CTTGTCCCCT CTGGCTAGAG GGCAGAGGTG TTGCCTAGGA GCTCCTATCT
48951 TTCCCTTCCT GCTTCTTCCA ATGCCCTTCT CTGTCCTCTG GGAGCTCCGA
49001 GACACACACA GACATAATTT CACCTTCTCT CATTAGCAAC CTTTGAAATA
49051 ATTTGATTAG AAGGGACTTC AGAAGTTTGT TGACTATATG TAGAAAACCC
49101 TGTCAATTTA CCTGCTTTTG CCCCATAGTA GTCTTGTAAG ACAGTTCATT
49151 GCTGACCCCA TTTTACAGTG GTGGCACCTG AAGCCTCAGC CTGAGGCCAC
49201 CGAGCTAGTA AATTTACAGG GACCAGTTTG AGACCAGCAT TCCTCCCACT
49251 GCCCCTCAGC TGTGGTGGTT ACAATGTTGT TTGTCTTACT GACTTGCTAT
49301 CTGGCTTCCT GGGTGTCTAC CGGCTGGCCC TGGCTCTGCC CTCTAGACCC
49351 ACACCACGCA ATCTTCATTG CTTTCCCACTA TGACTGCCCT GTAGCTATTC
49401 AAAGAGCTTG TCTCCCCCAA GTCTCCCCAT CTAAGCCTC CACCTTGCTC
49451 TTTTCTGTCT TATCCTGGTT CTAGCCACTG CCTGAAATCA TTTTAGGAAT
49501 AAGACAGGAC AGGGAAAAAC AAAAGCAACC CCCTGTCCCA CCTCTGAGTT
49551 CCACTCTCCA AGTCCCTGAG CCTCACCTCC AGGGCTCCAG TGGCTCTGCC
49601 ATGAACCCAC TGTGGGCTGG GAGTCTGCTG TGCACAGATA CCAGACCCTC
49651 AGAAACACAA ATGCCAAGTG TGTCTGTTTT TTTGTTTTGT TTTGTTTTGT
49701 TTTTAGATG GAGTCTCATT CTGTTTCCCA GGCTGGAGTG CAGTGGTGCA
49751 ATCTTGGCTT ACTGCAGCCT CTACCTCCCG GGTCTAGTG ATTGTTCTGC
49801 TTCAGCCTCC CAGTAGCTAG GACTACAGGC GTGTGCCACC ACGCCAGCT
49851 AATTTTTTTT TTTTTTTTTT TGTATTTTGA GTAGAGACAG GGTTTTGCCA
49901 TGTGGCCAG GCTGGTCTTG AACTCCTGAC CTCAGGTGAT TCACCCGCTT
49951 TGGCCTCCCA AAGTCTGGG ATTACAGGTG GAAGCCACCG TGCTGGCTCT

FIG.3-20

50001 GAGTGTGTCT ATTTGATAGA GCTTTCTGCT CTGATTCTCC CTTGCTATAC
50051 ACCTTTTCTC CCCTTCTCAG TGGCTTCTCT TGCCTATGCT TCCTCCCCAG
50101 GGCCAGGTTT GAGAACATCC CCATGAAGTC CTGACCTGTC TTTTATCCTA
50151 CCAGGACAAG ACTGTGGTGG TGGCAGACTT TGGGCTGTCA CGGCTCATAG
50201 TGGGAAGAGAG GAAAAGGGCC CCCATGGAGA AGGCCACCAC CAAGAAACGC
50251 ACCTTGCGCA AGAACGACCG CAAGAAGCGC TACACGGTGG TGGGAAACCC
50301 CTA CTGGATG GCCCTGAGA TGCTGAACGG TGAGTCCTGA AGCCCTGGAG
50351 GGGACACCCG CAGAGGGAGG ACAGATGCTG CCCTTGCATC AGAGCCCTGG
50401 GAATTCAGG GGAGGCCTGT GAAGCGTAGG ACCGGATACC CAGAGCTGAG
50451 GATATTTTTC CTTTGCCAGG TGGGGCTCA CGATTTAGCT CCTGAGCTCA
50501 GGGGGCTGGG AACTGATCAG TGTCCTATCA TGGGGGATAA GGTGAGTTCT
50551 GACTGTGGCA TTTGTGCCTC AGGGATCGCT AAGAGCTCAG GCTATTGTCC
50601 CAGCTTTAGC CTTCTCTCTC CATGGTGAGA ACTGAAGTGT GGTGCCCTCT
50651 GGTGGATAAT GCTCAAACCA ACCAGAGATG CTGGTTGGGA TTCTTGAAAT
50701 CAGGGTTGTG AGGCCTCAGA AATGGTCTGA ATACAATCCA TTTTGGAGTC
50751 TGAGGCCAG AGAAGTTCAG TGAATTGCCT AGGAGCATAC AGCTGCCTAA
50801 TGGCAGAGGC TAGATGAACC CTAGTCTGGT TCTTTCCAC TTTAACGTGC
50851 AGTTTCATCC TAGGCAGTGT TATGTTATAA GGGCTCTCCA AGGCAGTTCA
50901 CCTACGGCTG AGGAAGGACT ATTTTCAGGT GGTGTCTGCG CAGGACAGCC
50951 TGTGGGGTGT CCTACAGAA CCTGTTCTAG CCCTAGTTCT TAGCTGTGGC
51001 TTAGATTGAC CCTAGACCCA GTGCAGAGCA GGTAAAGGGAT GTAAACTTAA
51051 CAGTGTGCTC TCCTGTGTTT CCCAAGGAAA GAGCTATGAT GAGACGGTGG
51101 ATATCTTCTC CTTTGGGATC GTTCTCTGTG AGGTGAGCTC TGGCACCAAG
51151 GCCATGCCCG AGGCAGCAGG CCTAGCAGCT CTGCCTTCCC TCGGAAGCTGG
51201 GGCATCTCCT CCTAGGGATG ACTAGCTTGA CTAATAATCA CATGGGTGTA
51251 GGGTTTTATG GTTTATAACG CATCTGCACA TCTTTGCCAC GTTCGTGTTT
51301 CATTGGTCTT AAGAGAAGGA CTGGCAGGGT TTTTTGTTT TAGATGGAGC
51351 CTCACCTCGT TGCCAGGCT GGAGTGCAGT GGCACAATCT GGGCTCACTG
51401 CAACCTCTGC CTTCTGGGTT CAAGTGATTC TCCTGCCTCA GCCTCCCAAG
51451 TAGCTGGGAC TACCGGCACA CACCACCATG CCCGGCTAAT TTTTGTATTT
51501 TTAGTAGAGA CAGGGTTTCA CCATGTTGGC CAGGCTGGTC TTGAACCTCG
51551 GACCTCAGGT GATCCGCCCTG CCTCAGCCTC TAAAAGTGCT GGAATTAATA
51601 GGCGTGAGCT ACCTCGCCCG GCCAGGTTTT TTTTTTTTTT TTTTAGTTG
51651 AGGAACTGA GGCTTGAAG AGGGCAGTGG CTTGCACATG GTCGATAAGG
51701 GGCAGATGAG ACTCAGAATT CCAGAAGGAA GGGCAAGAGA CTGTTTATGT
51751 GGCTGTCTAG CTAGCTCTTG GGCCAAATGT AGCCCTTCTC AGTTCCTTC
51801 AAGTAGAAGT AGCCACTCTA GGAAGTGCA GCCCTGTGCC AGGTACCACG
51851 TGGACAGAGT GAGGAATCTT GGAAAGATTC CTACCTTTAG GAGTTTAGTC
51901 AGGTGACAGC ATATCTCAGC GACTCAAACA CACACACATT CAAAGCCTTC
51951 TGTAATTCCT ACAAAGTTGT GAGGGGTAGA GGAGAGGAGA GACAAGGGAT
52001 GGTTAGGATA ATGAAGGAAT GTTTTGTTTT TGTTTTTGTT TTTGAGATGG
52051 AGTTTCACTC TGTCACCCAG GCTGGAGTGC AGAGGTGCAA TCTTGCTCA
52101 CTGCAGCCTC CGCTCCCAG GTTCAAGCAA TCCTCTGCC TCAGCCTCCC
52151 AAGTAGCTGG GACTACAGGT GTGCGCCACC ACGCCTGGCT AATTTTTGTA
52201 TTTTCACTAG AGACAGGGTT TCGCCATATT GGCCAGGCTG GTCTCAAATG
52251 CCTGACCTCA GGTGATACAC CCGCTTCAGC CTCCCAAAGT GCTGAGATTA
52301 CAGGCATGAG CTACCGTGCC TGGCCATGAA GGAAGATTTG TTTTAAAAAA
52351 TTGTTTTCTT TAATATTAAT TGAACACCTC GTTCAGAGC ACTGGGCTGG
52401 TGCCAGAGGG TTTCAGACAT GAATCAGATC CAGCACCTCA TAGAGCCTTA
52451 ATCTGGCACA CACACACAGC CACAAGGAGA CACAGACAAG GCAGGGTAGG

FIG.3-21

52501 ATGAGTGGAA GCTAGGAGCA GATGCTGATT TGGAACACTT GGCTTCTGCA
52551 GTGAAGCCCC TTCTTAGTCC TCTTCAGTAA CCCAGCTCTC AGTGGATACA
52601 GGTCTGGATT AGTAAGATTT GGAGAGATGA TTGGGGATTG GGGAGAGCTC
52651 TCTAACCTAT TTTACCACCT CCTCTTCTGC CATTCTTCCT GTCCACATCC
52701 CCAGCATCCC TTTCCCTTGC CAAGTATCTG TGGCCTCTGT AGTCCTTTGT
52751 AACAGCTGT CTCTTACCC TACAGATCAT TGGGCAGGTG TATGCAGATC
52801 CTGACTGCCT TCCCCGAACA CTGGACTTTG GCCTCAACGT GAAGCTTTTC
52851 TGGGAGAAGT TTGTTCCAC AGATTGTCCC CCGGCTTCT TCCGCTGGC
52901 CGCCATCTGC TGCAGACTGG AGCCTGAGAG CAGGTTGGTA TCCTGCCTTT
52951 TTCTCCCAGC TCACAGGGTC CTGGGACGTT TGCCTCTGTC TAAGGCCACC
53001 CCTGAGCCCT CTGCAAGCAC AGGGGTGAGA GAAGCCTTGA GGTCAAGAAT
53051 GTGGCTGTCA ACCCCTGAGC CATCTGACAA CACATATGTA CAGGTTGGAG
53101 AAGAGAGAGG TAAAGACATA GCAGCAAGTA ATCTGGATAG GACACAGAAA
53151 CACAGCCATT AAAAGAAAGT TAAAAGAAG GAAATTCACC CAAACCATTT
53201 GAATACAGTA AGTGATTCA TCTTCGATA TTCCCTGTC CATATCTACA
53251 CATATACTTT TTTTATAGT AAATAGTTCT GTATTTTGCC CTGCATTTCC
53301 CTTGTGTTTA CTATCCAGTC TTCCTGTTTA TCATTTTGT CGACAACATG
53351 AAATTCTATT GAGAGACTGT CTGAACATAT TGTAAATGTAG ATGTTCAAGT
53401 TTTTCCAGTT TCTCTTTACA ATAGGTATTT AACTACAGTG AGCAGTTTAA
53451 TGCAATTTAGC TAATTTCTCC TTTGAGGAAG TATTTTCAA ATTACCTTTA
53501 TTCTTCTCAG GTAATAATTT CATTATTACC AAAGTTACCC TAGGTCCTTT
53551 CAAGTGTTGT GTTAAAAAAC GAGAATCTGG CTGGGCGCGA TGGCTCACAC
53601 CTGTAATCCC AGCACTTTGG GAGGCTGAGG CTGGTGGATC ACCTGAGGTC
53651 TGGAGTTTGA GACCAGCTG GCCAACATGG TGAACCCCA TCTCTACTAA
53701 AAATACAAAA CTTAGCCAGG CATGGTGGCA GGTGCCTGTA ACCCCAGCTA
53751 CTTGGGAGGC TGAGGCAGGA GAATTGCTTG AACCAGGGG CGGAGGTTGC
53801 AGTGAGCCGA TATCACGCCA TTGCACTCCA GCCTCGGCAA CAAGAGTGAA
53851 ACTCTGTCTC AAAAATGGGG TTCTTTTCTC GCCATCAAAA ATCATGTTTC
53901 TTTTAAAAAC AAGTTCAAAC ATTACCAAAG TTTATAGCAC AGGAAATACG
53951 TCTTCTGTAA TCTCCCTTAA CCAATATATC CCTCAACATT CTCCTCACCC
54001 CCAACTCCAC CCTCCCAGGA TAACCAGTTG GGACATAATC TTTATTTAAA
54051 AATGGTTTCC GGATAGAGAA AGCGCTTCGG CGGCGGCAGC CCCGGCGCGG
54101 GCCGCAGGGG ACAAGGGGCG GGCGGATCGG CGGGGAGGGG GCGGGGCGCG
54151 ACCAGGCCAG GCCCGGGGCG TCCGCATGCT GCAGCTGCCT CTCGGGCGCC
54201 CCCGCCGCCG CCTCGCCGCG GGAGCCGGCG AGCTAACCTG AGCCAGCCGG
54251 CGGGCGTCAC GGAGGCGGCG GCACAAGGAG GGGCCCCACG CGGCACGCTG
54301 GCCCGGAGG CCGCCGTGGC GGACAGCGGC ACCGCGGGGG GCGGCGCGTT
54351 GGCGGCCCGG GCCCGGGCCC CCAGGCCAGG CAGTGGCGGC CAAGGACCAC
54401 GCATCTACTT TCAGAGCCCC CCCCggggcc GCAGGAGAGG GCCCGGGCTG
54451 GGGCGATGAT GAGGGCCAG TGAGGCGCCA AGGGAAGGTC ACCATCAAGT
54501 ATGACCCCAA GGAGCTACGG AAGCACCTCA ACCTAGAGGA GTGGATCCTG
54551 GAGCAGCTCA CGCGCCTCTA CGACTGCCAG GAAGAGGAGA TCTCAGAACT
54601 AGAGATTGAC GTGGATGAGC TCCTGGACAT GGAGAGTGAC GATGCCTGGG
54651 CTTCCAGGGT CAAGGAGCTG CTGGTTGACT GTTACAAACC CACAGAGGCC
54701 TTCTCTCTG GCCTGCTGGA CAAGATCCGG GCCATGCAGA AGCTGAGCAC
54751 ACCCAGAAG AAGTGAGGT CCCCACCCA GGCGAACGGT GGCTCCCAT
54801 GGACAATCGC TACCCCCGA CTCGTAGCA ACAGCAATAC CGGGGACCC
54851 TGCGGCCAGG CCTGGTTCCA TGAGCAGGGC TCCTCGTGCC CCTGGCCAG
54901 GGGTCTCTTC CCTGCCCCC TCAGTTTTCC ACTTTTGGAT TTTTTATTG
54951 TTATTAAACT GATGGGACTT TGTGTTTTTA TATTGACTCT GCGGCACGGG

FIG.3-22

55001 CCCTTTAATA AAGCGAGGTA GGGTACGCCT TTGGTGCAGC TCAAAAAA
55051 AAAAAAAT GATTTCAGC GGTCCACATT AGAGTTGAAA TTTTCTGGTG
55101 GGAGAATCTA TACCTTGTTT CTTTATAGGC CAAGGACCGC AGTCCTTCAG
55151 TAACACCAGT GTAAAAGCTT GAGGAGAAAT TGTGAAGCTA CACAGTATTT
55201 GTTTTCTAAT ACCTCTTGTC ATTCTAAATA TCTTTAATTT ATTA AAAAAT
55251 ATATATATAC AGTATTGAAT GCCTACTGTG TGCTAGGTAC AGTTCTAAAC
55301 ACTTGGGTTA CAGCAGCGAA CAAAATAAAG GTGCTTACCC TCATAGAACA
55351 TAGATTCTAG CATGGTATCT ACTGTATCAT ACAGTAGATA CAATAAGTAA
55401 ACTATATTGA ATATTAGAAT GTGGCAGATG CTATGGAAAA AGAGTCAAGA
55451 CAAGTAAAGA CGATTGTTCA GGGTACCAGT TGCAATTTTA AATATGGTCG
55501 TCAGAGCAGG CCTCACTGAG GTGACATGAC ATTTAAGCAT AAACATGGAG
55551 GAGGAGGAGT AAGCCTGAGC TGTCTTAGGC TTCCGGGGCA GCCAAGCCAT
55601 TTCCGTGGCA CTAGGAGCCT GGTGTTTCCG ATTCCACCTT TGATAACTGC
55651 ATTTTCTCTA AGATATGGGA GGAAGTTTT TCTCCTATTG TTTTAAAGTA
55701 TTAACCCAG CTAGTCCAGC CTTGTTATAG TGTTACCTAA TCTTTATAGC
55751 AAATATATGA GGTACCGGTA ACATTATGCC CATTTCTCAC AGAGGCACTA
55801 CTAGGTGAAG GAGTTTGCCT GACGTTATAC AACCAGGAAG TAGCTGAGCC
55851 TAGATCCCTT CCACCCACCC CATGGCCCTG CTCATGTTCC ACCTGCCTCT
55901 AATTTACCTC TTTTCTTCT AGACCAGCAT TCTCGAAATT GGAGGACTCC
55951 TTTGAGGCC TCTCCCTGTA CCTGGGGGAG CTGGGCATCC CGCTGCCTGC
56001 AGAGCTGGAG GAGTTGGACC AACTGTGAG CATGCAGTAC GGCCTGACCC
56051 GGGACTCACC TCCCTAGCCC TGGCCCAGCC CCCTGCAGGG GGGTGTCTA
56101 CAGCCAGCAT TGCCCTCTG TGCCCATTC CTGCTGTGAG CAGGGCCGTC
56151 CGGGCTTCT GTGGATTGGC GGAATGTTA GAAGCAGAAC AAGCCATTCC
56201 TATTACCTCC CCAGGAGGCA AGTGGGCGCA GCACCAGGGA AATGTATCTC
56251 CACAGGTTCT GGGGCCTAGT TACTGTCTGT AAATCCAATA CTTGCCTGAA
56301 AGCTGTGAAG AAAAAAAT CCCCTGGCCT TTGGGCCAGG AGGAATCTGT
56351 TACTCGAATC CACCCAGGAA CTCCTGGCA GTGGATTGTG GGAGGCTCTT
56401 GCTTACACTA ATCAGCGTGA CCTGGACCTG CTGGGCAGGA TCCCAGGGTG
56451 AACCTGCCGT TGAACCTGA AGTCACTAGT CCAGCTGGGT GCAGGAGGAC
56501 TTCAAGTGTG TGGACGAAAG AAAGACTGAT GGCTCAAAGG GTGTGAAAAA
56551 GTCAGTGATG CTCCCCCTT CTA CTCCAGA TCCTGTCTT CCTGGAGCAA
56601 GGTTGAGGGA GTAGGTTTTG AAGAGTCCCT TAATATGTGG TGAACAGGC
56651 CAGGAGTTAG AGAAAGGGCT GGCTTCTGTT TACCTGCTCA CTGGCTCTAG
56701 CCAGCCAGG GACCACATCA ATGTGAGAGG AAGCCTCCAC CTCATGTTTT
56751 CAACTTAAT ACTGGAGACT GGCTGAGAAC TTACGGACAA CATCCTTTCT
56801 GTCTGAAACA AACAGTCACA AGCACAGGAA GAGGCTGGGG GACTAGAAAG
56851 AGGCCCTGCC CTCTAGAAAG CTCAGATCTT GGCTTCTGTT ACTCATACTC
56901 GGGTGGGCTC CTTAGTCAGA TGCTAAAC ATTTTGCCTA AAGCTCGATG
56951 GGTTCTGGAG GACAGTGTGG CTTGTACAG GCCTAGAGTC TGAGGGAGGG
57001 GAGTGGGAGT CTCAGCAATC TCTTGGTCTT GGCTTCATGG CAACCACTGC
57051 TCACCCTTCA ACATGCCTGG TTTAGGCAGC AGCTTGGGCT GGAAGAGGT
57101 GGTGGCAGAG TCTCAAAGCT GAGATGCTGA GAGAGATAGC TCCCTGAGCT
57151 GGGCCATCTG ACTTCTACCT CCCATGTTTG CTCTCCAAC TCATTAGCTC
57201 CTGGGCAGCA TCCTCCTGAG CCACATGTGC AGGTACTGGA AAACCTCCAT
57251 CTTGGCTCCC AGAGCTCTAG GAACTCTTCA TCACAACTAG ATTTGCCTCT
57301 TCTAAGTGTG TATGAGCTTG CACCATATTT AATAAATTGG GAATGGGTTT
57351 GGGGTATTAA TGCAATGTGT GGTGGTTGTA TTGGAGCAGG GGAATTGAT
57401 AAAGGAGAGT GGTGCTGTT AATATTATCT TATCTATTGG GTGGTATGTG
57451 AAATATTGTA CATAGACCTG ATGAGTTGTG GGACCAGATG TCATCTCTGG

FIG.3-23

57501 TCAGAGTTTA CTTGCTATAT AGACTGTACT TATGTGTGAA GTTTGCAAGC
57551 TTGCTTTAGG GCTGAGCCCT GGAAGCCAG CAGCAGCACA GTTCAGCATT
57601 GTGTGGCTGG TTGTTTCCTG GCTGTCCCA GCAAGTGTAG GAGTGGTGGG
57651 CCTGAAGTGG GCCATTGATC AGACTAAATA AATTAAGCAG TTAACATAAC
57701 TGGCAATATG GAGAGTGAAA ACATGATTGG CTCAGGGACA TAAATGTAGA
57751 GGGTCTGCTA GCCACCTTCT GGCCTAGCCC ACACAACTC CCCATAGCAG
57801 AGAGTTTTCA TGCACCAAG TCTAAAACCC TCAAGCAGAC ACCCATCTGC
57851 TCTAGAGAAT ATGTACATCC CACCTGAGGC AGCCCTTCC TTGCAGCAGG
57901 TGTGACTGAC TATGACCTTT TCCTGGCCTG GCTCTCACAT GCCAGCTGAG
57951 TCATTCTTCA GGAGCCCTAC CCTTTCATCC TCTCTATATG AATACTTCCA
58001 TAGCCTGGGT ATCCTGGCTT GCTTTCCTCA GTGCTGGGTG CCACCTTTGC
58051 AATGGGAAGA AATGAATGCA AGTCACCCCA CCCCTTGTGT TTCCTTACAA
58101 GTGCTTGAGA GGAGAAGACC AGTTTCTTCT TGCTTCTGCA TGTGGGGGAT
58151 GTCGTAGAAG AGTGACCATT GGGAAGGACA ATGCTATCTG GTTAGTGGGG
58201 CCTTGGGCAC AATATAAATC TGTAACCCCA AAGGTGTTTT CTCCCAGGCA
58251 CTCTCAAAGC TTGAAGAATC CAACTTAAGG ACAGAATATG GTTCCCGAAA
58301 AAAACTGATG ATCTGGAGTA CGCATTGCTG GCAGAACCAC AGAGCAATGG
58351 CTGGGCATGG GCAGAGGTCA TCTGGGTGTT CCTGAGGCTG ATAACCTGTG
58401 GCTGAAATCC CTTGCTAAAA GTCCAGGAGA CACTCCTGTT GGTATCTTTT
58451 CTTCTGGAGT CATAGTAGTC ACCTTGACAG GAACTTCCTC AGCCAGGGC
58501 TGCTGCAGGC AGCCAGTGA CCCTTCCTCC TCTGCAGTTA TTCCCTTTT
58551 GGCTGCTGCA GCACCACCC CGTCACCCAC CACCCAACCC CTGCCGCACT
58601 CCAGCCTTTA ACAAGGGCTG TCTAGATATT CATTTTAACT ACCTCCACCT
58651 TGGAAACAAT TGCTGAAGGG GAGAGGATTT GCAATGACCA ACCACCTTGT
58701 TGGGACGCCT GCACACCTGT CTTTCCTGCT TCAACCTGAA AGATTCTGA
58751 TGATGATAAT CTGGACACAG AAGCCGGGCA CGGTGGCTCT AGCCTGTAAT
58801 CTCAGCACTT TGGGAGGCCT CAGCAGGTGG ATCACCTGAG ATCAAGAGTT
58851 TGAGAACAGC CTGACCAACA TGGTGAAACC CCGTCTCTAC TAAAAATACA
58901 AAAATTAGCC AGGTGTGGTG GCACATACCT GTAATCCCAG CTAATCTGGA
58951 GGCTGAGGCA GGAGAATCGC TTGAACCCAC AAGGCAGAGG TTGCAGTGAG
59001 GCGAGATCAT GCCATTGCAC TCCAGCCTGT GCAACAAGAG CCAAACCTCA
59051 TCTCAAAAAA AAAAA (SEQ ID NO:3)

FEATURES:

Start: 3000
Exon: 3000-3044
Intron: 3045-45393
Exon: 45394-45525
Intron: 45526-45761
Exon: 45762-45818
Intron: 45819-50154
Exon: 50155-50329
Intron: 50330-51076
Exon: 51077-51132
Intron: 51133-52775
Exon: 52776-52933
Intron: 52934-55922
Exon: 55923-56064
Stop: 56065

FIG.3-24

CHROMOSOME MAP POSITION:
Chromosome 22

ALLELIC VARIANTS (SNPs):

DNA Position	Major	Minor	Domain
941	A	T	Beyond ORF(5')
2612	G	A	Beyond ORF(5')
5080	G	A	Intron
6599	-	A C	Intron
6983	C	G	Intron
9885	A	-	Intron
12538	G	T	Intron
17707	T	C	Intron
18219	-	A	Intron
19670	C	T	Intron
21153	G	T	Intron
24566	C	-	Intron
26604	G	A	Intron
27255	C	G	Intron
27399	T	C	Intron
28088	G	A	Intron
28734	G	A	Intron
29246	-	T	Intron
29490	G	A	Intron
29934	T	C	Intron
34480	A	G	Intron
38812	T	C	Intron
40731	C	G	Intron
41303	T	A	Intron
41305	-	A	Intron
41457	G	C	Intron
43168	A	- T	Intron
43357	T	G	Intron
45664	T	C	Intron
47549	A	C	Intron
47908	C	A	Intron
52267	C	A	Intron
54654	T	C	Intron
54679	C	G	Intron
54693	A	C	Intron
54706	T	C	Intron
54712	T	C	Intron
54799	T	C	Intron
54819	G	A	Intron
55499	C	T	Intron
56825	C	A	Beyond ORF(3')
58871	T	A	Beyond ORF(3')

Context:

FIG.3-25

DNA

Position

941

GAGTAAGTGGGTGGTCAGGTTACAGACTTAATTTTGGGTTAAAAAGTAAAAACAAGAAAC
AAGGTGTGGCTCTAAAAATAATGAGATGTGCTGGGGTGGGGCATGGCAGCTCATAAACTG
ACCTGAAAGCTCTTACATGTAAGAGTTCAAAAATATTTCCAAAACCTTGAAGATTCAT
TTGGATGTTTGTTCATTAAAACTCTCACTAATTCATTGTCTTGCCACTGTCCGTAA
CCCAACCTGGGATTGGTTTGAGTGAGTCTCTCAGACTTTCTGCCTTGGAGTTTGTGAGAG
[A,T]

GATGGCATACTCTGTGACCACTGTCACCCTAAAACAAAAAGGCCCTCTTGACAAGGAG
TCTGAGGATTTTAGACCCAGGAAGAATGAGTGATGGGCATATATATCTTACTGAG
GCATGAGAAGAGTGGAATGGGTGGGTTGAGGTGGTGTTTAAGGCCTCTTGCCAGCTTGT
TTAACTCTTCTGGGGAACGAGGGGACAACGTGTACATTGGCTGCTCCAGAATGATG
TTGAGCAATCTGAAGTGCCAGGAGCTGTGCTTTGTCTATTGATGGCCCTGTGCTGTG

2612

TGAGTTGGAACAGTTTGATACAAAACCATCCCCCGCCCCCAACCCCAAGCTAGGGT
CCGTGGAAAAATTGGCCCTGGTGCCAAAAAGGTTGAGGACTGCTGATCTAGAGGACCAA
TTTATTCAATGTTGGTTGAGTAAATGAGCTCTTGGATTAGGTGATGAAAAATCTGAAAA
AACAGGGCTTTTGAGGAATAGGAAAAGGCAGTAACATGTTTAACCCAGAGAGAAGTTTCT
GGCTGTTGGCTGGGAATAGTCATAGGAAGGGCTGACACTGAAAAGAAGGAGATTGTGTTT
[G,A]

TTTCTTCTTCTCAGAGCTATAAGCAAAGGCTGAAAGTTCTAGAAAAAGGCAAGTTTTGTT
TCAGTAGAAAAAAGGATAATCAGAACCATTTTTAGAAAAATGGAATGAGACTACTTTTGAG
GCCATGAGTTTCTTGTCCCTGGAGAGATGAGCAGAGGTTGGACAAGTGCTTACCAGAGAT
CTTGTGGAGGCAGAACTGTGCATCTAGCAGAGCATTGGCCTAACCCCTTCAATGAGAT
GCTGTTAACTCAGTCTTATTCTACATGGTAGGAATCCTGTCCCTTGCCTCTGCTACTT

5080

ACAACGTAAAATAGTTGAAATTTGTGGTGGAAGAAGAGCAGTCCACTCCAGAGGCTGG
ATGGGCATGCCTGGCCCCAAGGTCTGAAGTGGTAGGGCTGTGCTATATCCTGAGAATG
AGATAGACTAGGCAGGCACCTTGTGCTGTAGATTCCAGCTCCTGCACATAGCTCTTGTG
TAAACATCCCTGTGCTTATACCAAGTAATTGAGTTGACCTTTAAACACTTGCCTCTTCC
CTGGGAACCATATAGGGGATTGGCTGGAGACGTCTGGCCTCTGGAAGAGTTGAAAGCA
[G,A]

CCATCATTATTATCCTTTCTTTTCTCAGCTATAACTCAGAGCTCTCAAGTCTTTTCTGTGGA
TCTTATTGCTTGGTTCTTGGCCCTTTTACTCCAGGGAAGTTGATTCTGTCTTTTCTGT
TCCATTTAGTATGACAGGAGCAGAGAATGTCAGAGCTGTAAGGGACCTTATAGTTAAAGC
CTTTGGCTGGTCTTTTCAATTTATAGCTGGGACTAATAAGTAACGTCAAAACCCAATGAG
TTCACAGATTGGGTCTCGCCTTGGCATGTAACCCATATGTTTCAATTTCTGTGTTTTCC

6599

CTGTAATCCTAGCACTCTGGGAGGCCGAGGCAGAAGGATCGCTTGAGCCCATGAGCCAG
GAGTTTGAGACCAGCCTGGCCAAACATGGCAAACTCCACCTCTACAAAAATACAAAAAT
ATTAGCCAGGCGTGATGGCACACACCTGTAGTCCCAGCTACTTGGGAAGCTGAGGAGCGA
TGATTACCTGAGCCCAGGATATCAAGGCTGTAGTGAGCTGTGATCATGCCACTGTACTC
CATCCAGCTGGGGACAGAGTGAAACCCCTGTCTCAAAACAAAACAAATGAAAAAAAAA
[-,A,C]

CCTTAATAATCAGTAACGTGCTACTTTATATTATGTTGTGAGTGTGTGTCTATATACCT
ATATGTATACATTTCTTATTACACATTCATTGGTGATCTGATGTGGAGCCCAAGGAT
TAAGGGCAACTTTGAACTACCTGACACAATCAAGCCAAATATCATTTCCGTGGAGGAAG
TAGAGTATCTAGTTCTGTCTCCTAGTTGCAGCTTTACCTTGAGGACAGAGACTCTAATC
CAGCTGTGCTGAAGGAGCACATCTCCTGACTTCTGAGCTTTCCCTGGTAAATTCAAAC

FIG.3-26

- 6983 CACATTCATTGGTGATCTGATGTGGAGCCCCAGGGATTAAGGGCAACTTTGAACTACCCCT
GACACAATCAAGCCAAATATCATTTCCCGTGGAGGAAGTAGAGTATCTAGGTTCTGTCTCC
TAGTTGCAGCTTTACCTTGAGGACAGAGACTCTAATCCAGCTGTGCTGAAGGAGCACATC
TCCTGACTTCTGAGCTTTCCCTGGTAAATTCAAACTGGATGTCACGGGCCCTCAGATA
GAGCCTGGTAATTTGCCCTGGGAGAGTGACTGTCTTTGGATCTAATTTGACTTTTGCC
[C, G]
CAGTTGGAGGAAAATCTTCAGGGCTAGGAAGGATTGTATTTGTCTGACCCAGAGATAAC
CTGGGTTTTGAGGAACATGGGGCATCAACCTGAATGGTCTTGTAAGATCTCTCCACGCC
AGCTTGCCAGTGTTTCTCTGATGAATTTAGAGTACCTGAGTAGTCAGGCCTGCTGGGAG
GAGGACTCTCCCTCTGTGCTACTCAGAGAAATTCATTCTCAAGGCCCTTCCAGCCTT
GCTCTTACCCAGCTGGGCTACAGTTACAATAAAGGAAATGACTTTTCTTCCCTTCCC
- 9885 GCGTGCCACCACACCTTGCCATTTTTTTTTATTTTAAGTAGAAACAAGGCTTTATTAAT
ACTATGTTGCCAGGCTGGTCTTGAACCTCAGCGATCCTCTGCCCCAGCCTCCCAAAGT
GCTTGGGATTACGGAAGTAAGCCACTGTGCCTGGCCAGTGAACCCCATTTTATACTAA
AACAGGAAGGCCCAGAAAGGTTTGGAGTAACTTGTCCAGGGTCACACAGATGATATTTGA
ACTCAGGTCTCCCTGGCTCCCAAGAGAGTCTGCTTTCCACTAGGACTCCAGGAGAAAAA
[A, -]
AAAAAAAAAACAGTAGACTTGGAGACAGAAAATCTGATTTGAGTCTTAGTTGAGCTAGG
CTAACTGTGTAACGTGGGCAAGTTCTTAGCCCTGTGAGCCTCAGTTTCTTATCTGTA
AAATGTCATAAAAGAAATCCATCTCATGGAGTAGTTGTGATGATCAAGGACTCTGAAAC
ATTAGAATGGTTTAAATGTGAAGGATTAGCAGCAGCACATGGCAACATTGTGCATCTTATA
TTAACTATCCAAATATATCAAGCGTCATTTGCTATATATAAAGTCATCAAAATAGGCAC
- 12538 ACTTGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCC
CAGATCACGCCACTGCACCTCCAGCCTGGTGACAGAGTAAGACTCCATCTCAAAAAAAAAA
AAAAAAAAAAAAAATTCTTAATTTGGCCTACAGTAGAGCCCTCCGTAATGTGGCTCTCT
CCACATCTCCACAACCTCTGCTCCCTGCACCTCAGCCTCACCTCTCTCTGGACAGGCC
CTCCTTCTGACAAGGGCTTTGTTCAATCTGCTCCCTCTGCCTAGAATGCCCCCTTACTCT
[G, T]
TTCACCTAACTCCTGCTTATCGTTTAGATCTTACCTGGATGGCTCAGAGAAATATAGAA
GTAATTCCTACCCCTGAAAAATAGGTTAGGTCCTGTTTTATGTTTTATAGACCTTTCC
TTTGAGGCTTTTTTTAAAAAAGTAGTTTTAATCTCACATTTATTCATGTGATCATCTCCT
TAATGATATCTTAAGACCTCTAATAGAACAATTTGGTCATGGACTGTGGGGTTTTTGCC
CTCATTGTGTCAGCACTGAGCATATTGTTGGCATAGGAGGATATTTGTTGAATGAATTG
- 17707 GTAGTGGTGCTCAGAGTGTGCTGGGTGAATGATGTATTTGTTGAACGACTCTTTGGA
CACTTGAATAAAGTCCATCCAGTATGCACCATACCATCTCTTCGCTCTACAATATTCCT
TTAGGCAAGAGCTTATCTTTTGAGGTGATAAGATAAGCTCAAACCTATGTAGACTAAGAC
CTCAGTCTGTAAATGTCATCCCTAAGTCTTAAACCATCAAACCAGGGCTCAAGGAATG
GCATGCCCTCTGCAACTGTAGCAACCTGCTGTGCTTATTTGCCGTGTTTTTCATTTTTC
[T, C]
CCCCAAAGCTAGAGTCCCTTCTCCCATGGGCAGTGCTGGAAGTGTGCTAACAAATTCCTT
CTCCATACTGCTTACGATTACAAAAAAACCCTCAGCATCTCATGCCAGACTTGAGTTAA
GGTTGTTTTCTTTTGTGTGTCAGCTGTATTCTGGTCATGACTTCTGATGATGCCCTATA
GAGATTTTCTGATGATCAGAGGTGCTCCACTGCCATCAGTAGCACTGACTCTTGCGAGAA
GCACCGTTTCTGAAGTTGGCTAATGTCATCCCTCACGTTGTTTGTGTTTGAATTTGTTTT

FIG.3-27

- 18219 TGCCATCAGTAGCACTGACTCTTGCAGAAGCACCGTTTCTGAAGTTGGCTAATGTCATCC
CTCACGTTTGTGTTTGAATTTGTTTGTAGTTCAGAGATAGCACTTTCATGGAATGAC
GCTATCTTCTAGAATCACTTTTTTTTTTTTTTGTAGTTGGAGTCTCGCTGTGTCGCCAGG
CTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAATCTCCACCTTCCGGGTCAAGTGAT
TCCCCTGCCTCAGCCTCCCGAGGAGCTGTACTACAGGCGCACACCCCCACTCCTGGCTA
[-.A]
TTTTATGTGTTTTAGTAGAGACGGGTTTCACCGTGTGGCCAGGATGGTCTCGATCTCC
TGACTTTGTGATCTGCCTGCTTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGTCAC
CGCGCCTGGCCTAGAATCACCTTTTTATACCATAACGTGAGCACCCTGCCGCGTCACCA
AGGAAAGAGAGAGGCAGCTACTGTGGGGTTACAAATGGGTAAAGAGTGGCACCAGGAAGGT
GAAAGTCTCTACTTAGCCAAGGCTTAACAAAATGTCAATCACCAAACATTTATTTATTA
- 19670 GACCCCATGATGAGCAACTATAGCACTAGAACAGTGATAATACTAATGTTTATAATGC
ATCTTCAGTTTACAGAGGGCTTTTGTACTCATCATCTAGTTTAGTTCCTGCAACAACCTC
TTGAGGAATATAGCACAAGCAGGACAAGGGAAGCCAGAGATGTTAAATAATTTATCCAA
GTTTATGCTGCTGGGAAGGGCAGCACTGAAATTAAGAAAAGTTTCTGAGCTCAAATC
CCATGCCCTTCTCAATGTGAGCTCTAGCAAGGTATTACAGGAATCCTGCCTCTACAGTT
[C,T]
AGAGCCTCAAATTGCTGGGTATGTTGAGTTCTTGATCTGATTTTTCTAGATTTCTGCCC
CACATTTCTACTGTCTGGATATCAGGAAAGAGTTTATCAAATGCCTGTGGAATCCAAGA
TAAGGTCTCATGATGAGTAACCCAGTGAAAACATGAAGTCAAGTCTAACTAGTCACTACT
ATTTCACTACTGCTGACTCCTGATGATCAGCTCCTTTTCTAAGTGCTTACTGTCCACTTA
TTCCATCATCTGCCTAGAATTTATGTGAAGGAATCAAAGCAAAGGATCATAAGGCTTCC
- 21153 GGACCTTGTTTTAGAAGGATGACTGCTGCTATAATGTAGAAAGTGATTTGGAAGAGGGG
AGGAGTGGGGCAGGAAAGATGGTTAGTAGATGGGGGTGGTAATGCTTACCTTTCAGTATT
TGGAGGCTTCGGAGTCTCAAAAATTCCTTCTTGATTGGAGTCTCCAGCCAATAGA
GGGCTTCACACAAACAGTTTCTGGGTTTTGAATTGTTTGACCAGAGCTTTCTCCGACA
AAAGGTTGGGGTGATTCATTCACTTACCACACCTTGCTGAACATTCAGTTGGGGCTGCC
[G,T]
GTTATGAAGGCTATTGTTCTCCAGCCTGTCACAGACGCTTTGAAGACCTGTGCCTCAGCT
GGTTCTAAGGAGTCAGTTTGTTCAGCTCCGTGCCAGGTTTCCAACCTATGAAATGTGCTG
GAGATTAACACCTCTCCTGCCATTTTATCCCTACTATAATTGCCAGTCAAAGGATTCCTG
CAGTTGCCTCTGGCAGCCATAACTGATGAATGTTCTGCCAGCTGCTCTGAGGACCTAGAA
GAGCAGTTTTCTATCCAGGACCAGTTTCCAAGGGTGGGAGGGTGAAATATATCCTCCAGT
- 24566 CTA CTCTGGAGGCTGAGGTGAGAGGATCACTTGAGTCCAGAAGGTCGAGGTCAAGATTGT
AGTGAGCCATGATGGCATCACCGCACTCCAGCCTGAGTGACAGAGAGAGACCTGACTCA
AAAAAAAAAAAAACAAAAAACCCTCACCATTATCAGCTATTTGTCTTGAGAA
TAGTGACATAACCCCTCAGAACCTATTTCTAATCTGTTAAATGAGGCTGATGACGTTTC
CTCCTTTTACTGGCAATTTAAACATGATGGATAATAAATGCTAAGCACTTAACACAGGGC
[C,-]
TAGAAGATATTAACGTCTAATAAATGGTAGCTTCTTAACAGTATTCAAACCATGTGCT
CTTATCACATGCATTGTTGTCCCTGTGTCCAGTTGGTGGAATGGGAAAAGGCTCCCTTGT
AACCCCATCTACCATCTTTATCAGACTTTCCTGCCATGGTTCACAGTAAGAGATAGAAGC
TGCACGGTGACTTCTGGCTCTTTACAATGGTGAGCGGTGTGTGCCTGGTAAGGGAGAGCT
GATGTCACTGCCCAAATCCAGTAGTGAGATCTGAGTGTCTGGTTTCTCCAGCAGCCT

FIG.3-28

- 26604 GATTTGCAGCTGAGCCTGTCTATCTGGTGTGGGAAGAAGATGGGGAGTTACTTGTCACTC
CCGGCTTACTTCACCTCCAGAGACCTGTTTCGGTGAGTTGGTCTCCGAGTTCCTCTCC
ATCTCTCCTGGCCCTGGTCCTGAGAGGAGGGTGGTCTCCCTAAATCTCCTTCTCACTTA
GTCTTTTACCATCGGTTCTGCCGGGCAGAAGCCAGCGGAGTTATACCAAGGAGAATCG
GCCTTGTGAGGTACCCCCATTATGTCTGGAAGTGGTGAGGGGAGGGATATACCCAGAAG
[G,A]
AACTTCTTAGGGAGCTCCAGCTCCCCCTTCTATCCAGACAAACCTGAAGGAGCCTCCAA
AGATGCCACTGACCTGCCATTGTAGATGTTACTGCTTCGGGGGGAATAGCCCAATAG
AGTGCTGTTTCCAGCTCTCACATGTCTTACCTGCCGGCCATGCTGCCTGCCAGGAATTT
GTCCCAACAAGCAGGATGGGCAGGTTTTGCCAACTGTGGAACTGGCAAGTCTGGGTG
TGGGTAGCCTGGTACACAGTAGGCACCTTATAAACGTTTGTCTCTTAATGGCAGGCACA
- 27255 TGGGGAAGACCTGGGCGAGTGCTTCTAAGACTGGAGCAATGGGCTTTAGAGTGTTCTG
AGCTGCTGGGCCAGCCCCACACCTCCTCAGTCCCTAGGCCTAAGTACCTCCACGAGCCT
CTCTCTGTGGGGCTTCTCAGAGGGAGATGTGAACTCTACCTCTAACCTGGCTTTCTTT
GCTCATTGCCCACTCCACCTCCCATAGAACTCCCCAGGGGGTTTCTGGCCCTCTGGGT
CCCTTCTGAATGGAGCCATTCCAGGCTAGGGTGGGGTTTGTTCATTCTTTGGGAGCAG
[C,G]
CTGTTGTTCCAAAAGGCTGCCTCCCCCTCACCAGTGGTCTGGTCGACTTTTCCCTTCT
GGCTTCTCTAAGCTAGGTCCAGTGCCAGATCTTGCTGCCGGGATACTAGTCAGTGCGC
AGGCCCTGGGCAGAAAAGCAGTGACCATGTGGTTTTGTGGAATGACCGGACCTGGTAG
ATTGCTGGGAAGTGCTGGACAGGGGAAGGGGAAGGGAAGTGGTCTCAATGCTGACT
CTACCAAGCGCCCTGCTAGACACTTATCCTTTAATCTCTCAACAGCCTAAAGAGATTAT
- 27399 AGATGTGGAACTCTACCTCTAACCTGGCTTTCTTTGCTCATTGCCCACTCCACCTCCC
ATAGAACTCCCCAGGGGGTTTCTGGCCCTCTGGGTCCCTTCTGAATGGAGCCATTCCAG
GCTAGGGTGGGGTTTGTTCATTCTTTGGGAGCAGCCTGTTGTTCCAAAAGGCTGCCT
CCCCCTCACCAGTGGTCTGGTCGACTTTTCCCTTCTGGCTTCTCTAAGCTAGGTCCAGT
GCCAGATCTTGCTGCCGGGATACTAGTCAGGTGGCCAGGCCCTGGGCAGAAAAGCAGTG
[T,C]
ACCATGTGGTTTTGTGGAATGACCGGACCCTGGTAGATTGCTGGGAAGTGCTGGACAGG
GGGAAGGGGAAGGGAAGTGGTCTCAATGCTGACTCTACCAAGCGCCCTGCTAGACACT
TTATCCTTTAATCTCTCAACAGCCTAAAGAGATTATATCCCCATTTTACAGATGAGGC
AACCAGTTTCAACAGAGTTAATATATGGAGCCTCACTGGGCAGCTTTTTCTGTCTTCCTG
ACTTTCTCTCATCCTTCAGGGGGCTGCAGGTTTGTTCCTTCTCTAGTGGAGAGGAAAT
- 28088 AAGAGCCAATGGAAATTGATCTTGAGTTTAGGAGAAAGCTTTTACATGTGGAATTAAGAT
GCCAAGTGTGAGTAGCCACATTTAGGTCCTCATTAATTTCTCTTAATCCTGGGAAGG
CAGCTTAGGAGAAGGGTTGTCTTTAGGAGCCAGGAACTATACCCCTTTTACCCTTGGA
GAGGCAGGGAAGCCAGGGAGGACACAACCTCTCAGGAAGAGGAGAAGCTAGAGCAGATAG
TGAACCTCAACCTGAACCTTTAAGGGCCAGACCACTAATGCCACCAAGTCCACCTGCC
[G,A]
TTTGCTTGTCTGTCCCAGGCTTTCTGGAGAACCTGATCTTCTTGCCCTACCCCCAAG
CTCCGTTTGGCCAGCTAGAGTCTGGGGGTACTGACTGACTTTTCGTAGACATTCTCCCT
TCCCCAAATAAGAGGCCACATTCTGAAGTCACTTCTGAAGAGATAGTGCACACAGGG
CTCTTTCCCCCAGGGAGGGACCCAGACCCTGCTCTCCCAGGTATCCGTTACCAC
ATCACTACCTGGTCAGAAAGCTGTTCTGCCATTAGCCCTCCCTCTTTATTATAGGAT

FIG.3-29

- 28734 AAGTAGAAGCTAGACTTCTTGGGCTCCTGAACAGGGTCCTTGCTGGATTCTGTGAAACAA
ATTAAGTTCTTGACCTAGGCCTCTGGGGAGTACAAAGTCTATGGGAGTTCTGGGGCTG
TGGTTGCAAGGAAAGTGACGCAACCAGATTCCATGGGGACATGATCAGGCGTGACATGTG
AGGGAGGAAGAGGGAGCAAGGGAATGAAGAATACAACCTCTGTGTCCCATACACCCCTGC
CTGACAGGCCATACATACTCAGCAGAGAATGCACTGTCTTCTACCACACTAGCGTGAG
[G,A]
AGTGAGCTGCAATTACCACTGTGCTTCCAAGTAAGAAAATACCTCAAATTGGAATTTACA
AAAGAGGTAAATTAGGAGTGGCTTTTGTGCGACATCTTTAAAGCATTTTCTTTTATA
GAATTTCACTTAATGTCCAATACTGATTAATGAGCTTGGGTTTACACATTATCTCTTGA
AGAAAACAAATGAACCTTTGTGTTCCAAAGCAATCCATGTTTAAAGGGAAAAAATTATGC
ATAACTCTGCCCAGCTTCACAGTAACCTTTGGCAGGTGCCTTAGGTCTCTGGGACTCTT
- 29246 AATCCATGTTTAAAGGGAAAAAATTATGCATACTCTGCCCAGCTTCACAGTAACCTTTG
GCAGGTGCCTTAGGTCCTCTGGGACTCTTTTCTTATCTGAAAAATGAAGGACTTGGATC
AGGTGAATGGTTCCAGCTCTGCAACTATGTGGCTCCTCAGAGGCACACAAGCTCTTTT
CCATTATTTGCCAAATAATGGAGGCCCTGTCTTTAACTGCAGTACAACACAAAAATAC
TTGAAACTACAGTCTTCTGGTTTTTGGTTGGAAGTGAATCAGTGCACTCTAGCAACACT
[-.T]
ATTTCTTGCTGTTCTGAGGCTTCATTATGTGTTTGGTTAATTTTTTAAACAACAATAAC
ATATTCCATAATAATTACAGCTTAATTGGCAGACTGTTTCAGTCTATAGGATCTGCAGGA
AGGAGGAGTAATAAAGGGATTTTGAAGCTCTTATGGAACAGAGTCTCTTAGGCCC
CTGTCAATCTGCCCTTCTGGGCCCTGGGGAAAAGTTGGCATCCCCAGTTGTGGTGTCT
CCAGGTGCCCTCAGGCTGTGGTGGAGGGAGCTTCCCATCTCTCTCAGCCACTCAAT
- 29490 AACTACAGTCTTCTGGTTTTTGGTTGGAAGTGAATCAGTGCACTCTAGCAACACTTATT
TCTTGCTGTTCTGAGGCTTCATTATGTGTTTGGTTAATTTTTTAAACAACAATAACATA
TTCCATAATAATTACAGCTTAATTGGCAGACTGTTTCAGTCTATAGGATCTGCAGGAAGG
AGGAGTAATAAAGGGATTTTGAAGCTCTTATGGAACAGAGTCTCTTAGGCCCTG
TCATATCTGCCCTTCTGGGCCCTGGGGAAAAGTTGGCATCCCCAGTTGTGGTGTCTCCA
[G,A]
GTGCCCTCAGGCTGTGGTGGAGGGAGCTTCCATTCTCTCTCAGCCACTCAATTCAG
AGGCTAGGGGCTGAAAGAAGCTTCTTACAAGTGGCTGTTCACTGGGAGGTTAAGGGATG
ACCATCCAGCCAGGCCCTTCTCAGGACATGGGAGGCTTATGCTTTAATCATGTGTAAATC
CACTGCAATAATGACTGGTTCTTTACCCCATAGGTTGAGAATTTACCTGTAAACATTT
TTGTCTGAAGAATTTGGATGTAAGTGAGGGCTGGGCTCTATCTTATCTCACTTGGCTTC
- 29934 GGACATGGGAGGGCTTATGCTTTAATCATGTGTAATCCACTGCAATAATGACTGGTTCTT
TTACCCCATAGGTTGAGAATTTACCTGTAAACATTTTGTCTGAAGAATTTGGATGTAA
GTGAGGGCTGGGCCTCTATCTTATCTCACTTGGCTTCTCTCAGCACAGCACCTTGCCTGC
TTGTTCTTACACATCCTAGATGCACAGTAACATTTCTTAATTATTAGAAATCTATTAGA
ATCAATTGATTTCACTGGGCTTGGTGGCTCTTCTGTAAATCCAGCACTTTGGGAGGC
[T,C]
AAGGCTGGAGGATCACCTGAGTCCAGGAGTTTAAAGACCAGCTGGGCAACATAGGGAGAC
CCTGTCTCTACAAAAAATAAAAAATTAGCCAGGCATGGTGGTGTGCACCTGTAGTCCCAG
CTACTCAGGAGGCTGAGGCAGGAGGATCTCTTGAAGCTGGGAGGTGAGCTACAGTGAGC
AATGATTGTGCCACTGCACTCCAGCCTGGGTGACAGAGTAAGACTCTGTCTCTTAAAAA
AAAAAAAAAAAAAGTTGATTTCTATTGGATAGATAAATAATTCATTTTAGGACCTTTCTT

FIG.3-30

- 34480 CTGACTTCAAGTGATCCACCCGCTCGGCCTCCCAAAGTGCTGGGATTATAAGCATAAAGC
CACTGTGCCCAGCTGCTCTATATTTTTAATACATATTATTTCCATTAAATTTTCACAGC
AGTTCATTTTATAGATGAGGAACTAGGCCAGAGAAGTAAATATCTTGCCCAAGATGAT
GTAAC TAGTAAGTGGCAGGATCAAGATTCAAACCAAGCAATGTTCAAACCTCTTGGAAGC
AAGAATGTGGCCACTGTGGAAGGTGCAAGGCC TTGACAACAAGAATAGGGAAAAGAAGGA
[A, G]
CTAGAAGGAAAGAGATGGCATGGGCTCAGCAGGCCAGGGAGCTCTTAGCTGTGTGTGTG
GGAAGCTCAGAAGGGAGGAAGAGGTTGTCTGTGCAGGTAAGTCCTGAGAACACACCAGAC
TTTTGAGAGGTGGAGCTTCATAGCCAGGTCATTAGGGGAGAAGGGAGCTATAGATTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTATAGACGGGGTCTTACTATGTTGCCAGGCTG
GTCTTGAACCTCTGGGCTCAAGTGATCTCCACCTCAGCCTCCCAAAGTGCTGGGATTA
- 38812 AAATCCAGCAGATCCATTGAGAGTTTAAGCAGCAAGGTGTTGTGACCAAGTTAACATTTT
AGAAGGATCACTGGTATGGAGTTGGATTGGAGAGGGGAAAGCCTAAAGGTATAGAGACT
AGTTAGGAAGCTATTGTAGGCTGGGCATGGTGGTTCATGCCTGTAATCTCAGCACTTTGG
GAGGCTGAGGTGGGAGGATTGCTTGAGGCCAGGAGTTGAAGACCAACCTGGCCAACATAG
CAAGACCCGCTCTGTGTTTTCTTAATTAAGAAAAGTCCAGACGTAGACATAGTGGCT
[T, C]
ACGCCTGTAATGCCAGCACTTTGGGAGGCCAAGGTGGGCAGATTGCTTGAGGTCAAGAGT
TTGGGATTAGGCCAGGCCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAG
GTGGGCGGATCACAAGGTCAGGAGATCAAGACCATCCTGGCTAACACAATGAAACCCCGT
CTCTACTAAAAGTACAAAATTAGCCGGGCATGGTGGCGGACGCCTGTAGTCCCAGCTAC
TCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTAGGAGGCGGAGCTTGCTGTGAGCAGA
- 40731 GTTCTGTCTATGTCTGTCTCTCGGATGAAGCTGAGCTGGCTTTGAGAAGCCTGCAGAGT
TAGGAAAGGAACCACTGAGGACAGACTATGAGGATTGTGCTGACCCAGCTGCCCC
TGTGGGGATCACAGTTTACAGCCAGAGCCTGTGCGGACCCAGCTGTCTGCCAGGTTTCCT
TAGAAACCTGAGAGTCAGTCTGTGCTCACTGAACTCCTAAGCTGGACAGGAGGCACTGAT
GCTAAACCTGAAGGGCAACATGGCCTATGGAGAAAGCATGGAGCTCAGAGCCTGGAGTA
[C, G]
GGGCACAGATAGGATTGAATAAATTGTGTAGAAAGACTTTGAAAACAATAAGCAAAAGA
TGAATGAACGTTTTTTTAGACTTGAGGGACCAACAACCCCCAAACCCAGATTCTGCCA
GGTCCATGGGGAAGGAGAAGTTGCCTTGAGTGGAGGCCCAAGTAGGGAGACTTACAGAA
AAGAAGTCAAGAGCACTGGCTCCAGGCAGAAATACTGATACCCTACTGGGGCTTCAGGC
TGAGCTCCTCCCTTCACAAATCACTTCATCTCTGAGCCTGTTTCTGCATCTGTGACAT
- 41303 CTCTGAGCCTGTTTTCTGCATCTGTGACATAAGATGGTAAGATAAAGGTGGCTGTCTCACC
AATTATGTAAGGATTAAATGTGGAAGGACATAAAGTTGTATAGTGCTGCCATAGGGAC
AGTGTTCAAGTAAACGTGACACATTCTTAGTATCACTAAGAATCAGGTTCTTGCCAGGCA
CCGTGGCTCATGCCTGTAATCCCAACACTCTGGGAGGCC TAGGTCGGAGGATGGCTTGAA
CACAGGAGTTTGAGACCAGCCTGAGCAACATAGTGAGACACTGTCTCTACAAAAA
[T, A]
AATAATAAATTTGTTTTAATTAGATGGGCAGGCACTGTGGCTCACACCTGTAATCCC
AGCACTTTGGGAGGCCAAGGCCGAGGATTGCTTGAGGCCAGGAGTT CAGGAGCAGCCTG
GGCCACATTCCTGTCTCTACAAAGAATAAAAAAGTTAACTGGGCATGGTGGCACATGCCT
GTAATCCCAGCTACTCAAGAGGCTGAGGAGGAGGATTGCCTGAGCCAGGAGTTCAAGAC
TGCAGTGAGCCTTGATCACACCACTGTACTACAGCTTGGGCAACAGAGTGAGACCTGTCT

FIG.3-31

- 41305 CTGAGCCTGTTTCTGCATCTGTGACATAAGATGGTAAGATAAAGGTGGCTGTCTACCAA
TTATGTAAGGATTAAATGTGGAAAAGGACATAAAGTTGTATAGTGTGCCATAGGGACAG
TGTTCAAGTAAACGTGACACATTCTAGTATCACTAAGAATCAGGTTCTTGGCCAGGCACC
GTGGCTCATGCCTGTAATCCCAACTCTGGGAGGCCTAGGTGGAGGATGGCTTGAACA
CAGGAGTTTGAGACCAGCCTGAGCAACATAGTGAGACACTGTCTCTACAAAAAAAATA
[-.A]
TAATAATAATTGTTTTAATTAGATGGGCAGGCACTGTGGCTCACACCTGTAATCCCAG
CACTTTGGGAGGCCAAGGCCGAGGATTGCTTGAGGCCAGGAGTTCAGGAGCAGCCTGGG
CCACATTCTGTCTCTACAAAGAATAAAAAAGTTAACTGGGCATGGTGGCAGATGCCTGT
AATCCCAGCTACTCAAGAGGCTGAGGAGGAGGATTGCCTGAGCCAGGAGTTCAAGACTG
CAGTGAGCCTTGATCACACCACTGTACTACAGCTTGGGCAACAGAGTGAGACCTTGCTC
- 41457 CTAAGAATCAGGTTCTTGGCCAGGCACCGTGGCTCATGCCTGTAATCCCAACTCTGGG
AGGCCTAGGTGGAGGATGGCTTGAACACAGGAGTTTGAGACCAGCCTGAGCAACATAGT
GAGACACTGTCTCTACAAAAAAAATAATAATAAATTGTTTTAATTAGATGGGCAG
GGCACTGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGCCGAGGATTGCT
TGAGGCCAGGAGTTCAGGAGCAGCCTGGGCCACATTCTGTCTCTACAAAGAATAAAAA
[G.C]
TAACTGGGCATGGTGGCAGATGCCTGTAATCCCAGCTACTCAAGAGGCTGAGGAGGAGG
ATTGCCTGAGCCAGGAGTTCAAGACTGCAGTGAGCCTTGATCACACCACTGTACTACAG
CTTGGGCAACAGAGTGAGACCTTGCTCTCAAAAAAAAAGTTTGTTTTTTTTATCCACT
CTCCTACCAAACAACTGAGTAAGTTAGAGCCCTCTCAGCTGGCATGTGTTGGAAACAG
TGCCCTCTCATTAAGTGCTGCCCTCACTCCCATTGCCTCTTGGCCTGGTTCAGTATGAT
- 43168 AGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCTGGAAGGCGGAGGTGCGAGTG
AGCCGAGATCGTGCCATTGCACTTCAGCCTGGGCAGACAGCGAGACTCTGTCTCAAAAA
TAATAATAATAACAATAACTAGCCGGGCCTGGTGGCAGATGCCTGTAGTCCAGTTACTC
AGGAGGCGGAGGCATGAGACTCAGGTGAAGTGGGAGACAGAGGTTGCAGTGAGCCAAGA
TCACACCACTGCACTCCAGCCTGGTTGACAGAGCGAGACTCTGTCTCAAAAAAAAATA
[A. - .T]
CCCATTGCTCATTTTTTGGATACTAGTATAACTATCACTCTAAACCAGTTAGTACTTAA
ATCAAGCAGATATGGGAGATGGTGAATTACCATCTACAGTGTGTCATATATGTCACATA
CTGAGCATTATCAGTAGTAGAATCTAGTTAATTGTTCTATGTGTGATGTATGCAGAGTT
CCCATTGTAATGTGTTTTACTATGCTTAAATAAATGACTGATGTCAGCAACCCCAAAA
TGATACATCTGATGTAAGAGCCCCTGTTCCCAATAATAACATCTAAACTATAGACATTG
- 43357 AGGCATGAGACTCAGGTGAAGTGGGAGACAGAGGTTGCAGTGAGCCAAGATCACACCAC
TGCACTCCAGCCTGGTTGACAGAGCGAGACTCTGTCTCAAAAAAAAATAATCCCATTG
CTCATTTTTTGGATACTAGTATAACTATCACTCTAAACCAGTTAGTACTTAAATCAAGCA
GATATGGGAGATGGTGAATTACCATCTACAGTGTGTCATATATGTCACATACTGAGCAT
TATCAGCTAGTAGAATCTAGTTAATTGTTCTATGTGTGATGTATGCAGAGTTCCCATTTT
[T.G]
AATGTGTTTTTACTATGCTTAAATAAATGACTGATGTGAGCAACCCCAAAATGATACATC
TGATGTAAGAGCCCCTGTTCCCAATAATAACATCTAAACTATAGACATTGGAATGAACA
GGTGCCCTAAGTTTCTCCCTCCAGGTTTCTTGGCCGGTCTCTGAGGACTACACATCC
CTACTCCCGTCTTCTCATCTTCAGGCGCAGTAACAGTATCTCCAAGTCCCTGGCCCC
AGCTCCCAAGGAGCCCCTGCTGTTGAGCCGTGACATCAGCCGCTCAGAATCCCTTCGT

FIG.3-32

45664 CCAGCTTTCCTTGGCTTCCCCACCCCCAGGTGAAAGTGATGCGCAGCCTGGACCACCCC
AATGTGCTCAAGTTCATTGGTGTGCTGTACAAGGATAAGAAGCTGAACCTGCTGACAGAG
TACATTGAGGGGGGCACACTGAAGGACTTCTGCGCAGTATGGTGAGCACACCACCCCAT
AGTCTCCAGGAGCCTTGGTGGGTGTGACACACCTATGCTATCACTACCCTAGGAGCTTA
AAGGGCAGAGGGGCCCTGCTTGGCTCCAAAGGACCATGCTGGGTGGGACTGAGCATACA
[T,C]
AGGGAGGCTTCACTGGGAGACCACATTGACCCATGGGGCTGGACCACGAGTGGGACAGG
GCTCAACAGCCTCTGAAAATCATTCCCCATTCTGCAGGATCCGTTCCCTGGCAGCAGAA
GGTCAGGTTTGCCAAAGGAATCGCCTCCGGAATGGTGAGTCCCACCAACAAACCTGCCAG
CAGGGCAGAGTAGGGAGAGGTGTGAGAATTGTGGGCTTCACTGGAAGGTAGAGACCCCT
TCCTATGCAACTTGTGTGGGCTGGGTGACGAGCTATTCATTGAGTTTGTGTGCTACTG

47549 AATTAGCTGGGCGTGGTGGTGCACGCCTGTAGTCCCAGCTACTCAGGAGGCCGAGGCAGG
AGAATAGCTTGAACCTGGGAGGCAGAAAGTTGCAGTGAGCCAAGATCACACCACTGCATT
CAGCCTGGGTGACAGAGTGAGACTTCATCTCAAAAAAAAAAAAAAGAGAGACTGATATG
GTTAGTACATTGGGGTGAATGCGGAGGGTCCAGGGAATGGAGCCCTGCATAGGGGGCTA
ATGAAACATTTAGATTTCTGAATTAAGGTAGTGGCTGTGGGGACAGGAGCCTGGGAGGC
[A,C]
GGGTGGAGTCAGAATGGAGAGACTGGTTGGCAATGAGGGAACAGGAGGAGGAGGAGGAGG
AGTTACGAGTGGCTTGAGGTGTCACTTACCAGACATTTGGGGGATGGGGGATAGCCGTGA
TTGTTGAGCAACTGGTTTGGGAAGAGCTAGCATTGATCCCTGCTGTTCTGTGCTAGCAGA
ACCTATCAGCATCTTCTGGGCAGGAACTGGCTCCATGAGACTGGCTTAGGGAGAGGCTG
CTAGTCACCTAATCTGCAGAGAAGGGGCAGCTGGAGCTGTGGGACAGAAGAGGCATCCAT

47908 GGAGTTACGAGTGGCTTGAGGTGTCACTTACCAGACATTTGGGGGATGGGGGATAGCCGT
GATTGTTGAGCAACTGGTTTGGGAAGAGCTAGCATTGATCCCTGCTGTTCTGTGCTAGCA
GAACCTATCAGCATCTTCTGGGCAGGAACTGGCTCCATGAGACTGGCTTAGGGAGAGGC
TGCTAGTCACCTAATCTGCAGAGAAGGGGCAGCTGGAGCTGTGGGACAGAAGAGGCATCC
ATGTAGCTGGTGGGGTGTCTCAGCTTGTGAAGAGGAGATGGCTTTGAGCAGGGCTGACA
[C,A]
TGAAAAGGCTGGAAGAAAAAACAGACACACAAGAGTCTCAGGATCAGGTAGCATAGGAA
AGTTGTGGACAGTCTTGGAGGAGCACTCCCTCAGGCAGGCAGGCAGGCAGGTGATGAGCT
ATAGCGATTAGGAAGAGCTCCCTGGGTGTGTGAGCAGCTCCAGGAGCCTAAGGGATGAA
AGTAGTATTGCAGGGGGCTGGAGAGCAAGGAGTGGCTCCTTCTACATTTGCAAGGGAAGG
AGAAAGGAAGTTGCTCCTGAGAGTGTAAGAGTCAGTGGTGGAGGCTGGAGAGGAGACA

52267 TTGTGAGGGGTAGAGGAGAGGAGAGACAAGGGATGGTTAGGATAATGAAGGAATGTTTTG
TTTTTGTGTTTTGTTTTGAGATGGAGTTTCACTCTGTCAACCAGGCTGGAGTGCAGAGGT
GCAATCTTGGCTCACTGCAGCCTCCGCCTCCAGGTTCAAGCAATCCTCCTGCCTCAGCC
TCCAAGTAGCTGGGACTACAGGTGTGCGCCACCAGCCTGGCTAATTTTTGTATTTTCA
GTAGAGACAGGGTTTCGCCATATTGGCCAGGCTGGTCTCAAATGCCTGACCTCAGGTGAT
[C,A]
CACCCGCTTCAGCCTCCCAAAGTGCTGAGATTACAGGCATGAGCTACCGTGCCTGGCCAT
GAAGGAAGATTTGTTTTAAAAAATTGTTTTCTTTAATATTAATTGAACACCTGTGTTAG
AGCACTGGGCTGGTGCCAGAGGGTTTCAGACATGAATCAGATCCAGCACCTCATAGAGCC
TTAATCTGGCACACACACAGCCACAAGGAGACACAGACAAGGCAGGGTAGGATGAGTG
GAAGCTAGGAGCAGATGCTGATTTGGAACACTTGGCTTCTGCAGTGAAGCCCTTCTTAG

FIG.3-33

- 54654 GGCCCCGGCCCCGGCCCCAGGCCAGGCAGTGGCGGCCAAGGACCACGCATCTACTTTCA
GAGCCCCCCCCGGGGCCGAGGAGAGGGCCGGGCTGGCGGATGATGAGGGCCAGTGA
GGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCACCTCAACC
TAGAGGAGTGGATCCTGGAGCAGCTCACGCGCTCTACGACTGCCAGGAAGAGGAGATCT
CAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGCCTGGGCTT
[T, C]
CAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCTTCATCTCTGGCCT
GCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGAAGAAGTGAGGGTCCCC
GACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCGACCTCGTAGCAACAG
CAATACCGGGGACCTGCGGCCAGGCCTGTTCCATGAGCAGGGCTCCTCGTGCCCTG
GCCCAGGGGTCTCTCCCTGCCCTCAGTTTTCCACTTTTGGATTTTTTATTGTTAT
- 54679 GGCAGTGGCGGCCAAGGACCACGCATCTACTTTAGAGCCCCCCCCGGGGCCGAGGAGA
GGGCCCCGGGCTGGCGGATGATGAGGGCCAGTGAGGCGCCAAGGGAAGGTCACCATCAA
GTATGACCCCAAGGAGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCT
CACGCGCTCTACGACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGA
GCTCCTGGACATGGAGAGTGACGATGCCTGGGCTCCAGGGTCAAGGAGCTGCTGTTGA
[C, G]
TGTTACAAACCCACAGAGGCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAG
AAGCTGAGCACACCCAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGTCCCAT
AGGACAATCGCTACCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCTGCGGCCAG
GCCTGTTCCATGAGCAGGGCTCCTCGTGCCCTGGCCCAGGGGTCTCTTCCCTGCCCT
CTCAGTTTTCCACTTTTGGATTTTTTATTGTTATTAACTGATGGGACTTTGTGTTTTT
- 54693 AGGACCACGCATCTACTTTAGAGCCCCCCCCGGGGCCGAGGAGAGGGCCCCGGGCTGGG
CGGATGATGAGGGCCAGTGAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGG
AGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTACGCGCTCTACG
ACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGG
AGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGTTGACTGTTACAAACCCA
[A, C]
AGAGGCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACC
CCAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTAC
CCCCGACCTCGTAGCAACAGCAATACCGGGGGACCTGCGGCCAGGCTGTTCCATGA
GCAGGGCTCCTCGTGCCCTGGCCCAGGGGTCTCTTCCCTGCCCTCAGTTTTCCACT
TTTGGATTTTTTATTGTTATTAACTGATGGGACTTTGTGTTTTTATTGACTCTGCG
- 54706 TACTTTAGAGCCCCCCCCGGGGCCGAGGAGAGGGCCCCGGGCTGGGCGGATGATGAGGG
CCCAGTGAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCA
CCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTACGCGCTCTACGACTGCCAGGAAGA
GGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGC
CTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCTTCAT
[T, C]
TCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGAAGAAGTGA
GGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCGACCTCGT
AGCAACAGCAATACCGGGGGACCTGCGGCCAGGCTGTTCCATGAGCAGGGCTCCTCG
TGCCCTGGCCCAGGGGTCTCTTCCCTGCCCTCAGTTTTCCACTTTTGGATTTTTT
ATTGTTATTAACTGATGGGACTTTGTGTTTTTATTGACTCTGCGCACGGGCCCTT

FIG.3-34

- 54712 CAGAGCCCCCCCCGGGGCCGCAGGAGAGGGCCCGGGCTGGGCGGATGATGAGGGCCAGT
GAGGCGCCAAGGAAGGTCAACATCAAGTATGACCCCAAGGAGCTACGGAAGCACCTCAA
CCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCTCTACGACTGCCAGGAAGAGGAGAT
CTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGCCCTGGGC
TTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCCTTCATCTCTGG
[T, C]
CTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGAAGAAGTGAGGGTCC
CCGACCCAGGCGAAGCGGTGGCTCCCATAGGACAATCGCTACCCCCGACCTCGTAGCAAC
AGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCC
TGGCCAGGGGTCTCTTCCCTGCCCCCTCAGTTTCCACTTTTGGATTTTTTATTGTT
ATTAAGTATGGGACTTTGTGTTTTATATTGACTCTGCGGCACGGGCCCTTAATAAA
- 54799 GTATGACCCCAAGGAGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCT
CACGCGCTCTACGACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGA
GCTCCTGGACATGGAGAGTGACGATGCCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGA
CTGTTACAAACCCACAGAGGCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCA
GAAGCTGAGCACACCCAGAAGAAGTGAGGGTCCCGACCCAGGCGAACGGTGGCTCCCA
[T, C]
AGGACAATCGCTACCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAG
GCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCTGGCCAGGGGTCTCTTCCCTGCCCC
CTCAGTTTTCCACTTTTGGATTTTTTATTGTTATTAACTGATGGGACTTTGTGTTTT
ATATTGACTCTGCGGCACGGGCCCTTAATAAAGCGAGGTAGGGTACGCCCTTGGTGCA
CTCAAAAAAAAAAAAAAAAAATGATTCCAGCGGTCCACATTAGAGTTGAAATTTCTGGT
- 54819 GGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCTCTACGACTGCC
AGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTG
ACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGG
CCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGA
AGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCC
[G, A]
ACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGG
CTCCTCGTGCCCCGGCCAGGGGTCTTCCCTGCCCCCTCAGTTTTCCACTTTTGA
TTTTTTATTGTTATTAACTGATGGGACTTTGTGTTTTATATTGACTCTCGGCACGG
GCCCTTAATAAAGCGAGGTAGGGTACGCCCTTGGTGCACTCAAAAAAAAAAAAAAAAA
TGATTTCCAGCGGTCCACATTAGAGTTGAAATTTCTGGTGGGAGATCTATACCTGTT
- 55499 TTGTTTTCTAATACCTCTTGTCATTCTAAATATCTTTAATTTATAAAAATATATAT
ACAGTATTGAATGCCACTGTGTGCTAGGTACAGTTCTAAACACTTGGGTTACAGCAGCG
AACAAAATAAAGGTGCTTACCCTCATAGAACATAGATTCTAGCATGGTATCTACTGTATC
ATACAGTAGATAACAATAAGTAACTATATTGAATATTAGAATGTGGCAGATGCTATGGAA
AAAGAGTCAAGACAAGTAAAGACGATTGTTACGGGTACCAGTTGCAATTTTAAATATGGT
[C, T]
GTCAGAGCAGGCCTCACTGAGGTGACATGACATTTAAGCATAAACATGGAGGAGGAGAG
TAAGCCTGAGCTGTCTTAGGCTTCCGGGGCAGCCAAGCCATTTCGGTGCACTAGGAGCC
TGGTGTTCGATTCCACCTTTGATAACTGCATTTCTCTAAGATATGGGAGGGAAGTTT
TTCTCCTATTGTTTTAAGTATTAACCTCAGCTAGTCCAGCCTTGTTATAGTGTTACCTA
ATCTTTATAGCAATATATGAGGTACCGGTAACATTATGCCATTTCTCACAGAGGCACT

FIG. 3-35

56825 ACTGATGGCTCAAAGGGTGTGAAAAAGTCAGTGATGCTCCCCCTTTCTACTCCAGATCCT
GTCCCTTCTGGAGCAAGGTTGAGGGAGTAGGTTTTGAAGAGTCCCTTAATATGTGGTGGA
ACAGGCCAGGAGTTAGAGAAAGGGCTGGCTTCTGTTTACCTGCTCACTGGGTCTAGCCAG
CCCAGGGACCACATCAATGTGAGAGGAAGCCTCCACCTCATGTTTTCAAACCTAATACTG
GAGACTGGCTGAGAACTTACGGACAACATCCTTTCTGTCTGAAACAAACAGTCACAAGCA
[C,A]
AGGAAGAGGCTGGGGGACTAGAAAGAGGCCCTGCCCTCTAGAAAGCTCAGATCTTGGCTT
CTGTTACTCATACTCGGGTGGGTCCTTAGTCAGATGCCATAAACATTTTGCCTAAAGCT
CGATGGGTTCTGGAGGACAGTGTGGCTTGTACAGGCCCTAGAGTCTGAGGGAGGGGAGTG
GGAGTCTCAGCAATCTCTTGGTCTTGGCTTCATGGCAACCACTGCTCACCTTCAACATG
CCTGGTTTAGGCAGCAGCTTGGGCTGGGAAGAGGTGGTGGCAGAGTCTCAAAGCTGAGAT
58871 CGTCACCCACCACCCAACCCCTGCCGCACTCCAGCCTTTAACAAGGGCTGTCTAGATATT
CATTTTAACTACCTCCACCTTGGAACAATTGCTGAAGGGGAGAGGATTTGCAATGACCA
ACCACCTTGTTGGGACGCCTGCACACCTGTCTTTCCTGCTTCAACCTGAAAGATTCTGA
TGATGATAATCTGGACACAGAAGCCGGGCACGGTGGCTTAGCCTGTAATCTCAGCACTT
TGGGAGGCCTCAGCAGGTGGATCACCTGAGATCAAGAGTTTGAGAACAGCCTGACCAACA
[T,A]
GGTGAAACCCCGTCTCTACTAAAAATACAAAATTAGCCAGGTGTGGTGGCACATACCTG
TAATCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCGCTTGAACCCACAAGGCAGAGGT
TGCAGTGAGGCGAGATCATGCCATTGCACTCCAGCCTGTGCAACAAGAGCCAAACTCCAT
CTCAAAAAAAAAA

FIG.3-36

1

ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF

FIELD OF THE INVENTION

The present invention is in the field of kinase proteins that are related to the serine/threonine kinase subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect protein phosphorylation and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Protein Kinases

Kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Uncontrolled signaling has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and psoriasis. Reversible protein phosphorylation is the main strategy for controlling activities of eukaryotic cells. It is estimated that more than 1000 of the 10,000 proteins active in a typical mammalian cell are phosphorylated. The high energy phosphate, which drives activation, is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc), cell cycle checkpoints, and environmental or nutritional stresses and is roughly analogous to turning on a molecular switch. When the switch goes on, the appropriate protein kinase activates a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.

The kinases comprise the largest known protein group, a superfamily of enzymes with widely varied functions and specificities. They are usually named after their substrate, their regulatory molecules, or some aspect of a mutant phenotype. With regard to substrates, the protein kinases may be roughly divided into two groups; those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity and phosphorylate threonine and tyrosine residues. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The N-terminal domain, which contains subdomains I-IV, generally folds into a two-lobed structure, which binds and orients the ATP (or GTP) donor molecule. The larger C terminal lobe, which contains subdomains VI A-XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Subdomain V spans the two lobes.

The kinases may be categorized into families by the different amino acid sequences (generally between 5 and 100 residues) located on either side of, or inserted into loops of, the kinase domain. These added amino acid sequences allow the regulation of each kinase as it recognizes and interacts with its target protein. The primary structure of the kinase domains is conserved and can be further subdivided into 11 subdomains. Each of the 11 subdomains contains specific residues and motifs or patterns of amino acids that

2

are characteristic of that subdomain and are highly conserved (Hardie, G. and Hanks, S. (1995) *The Protein Kinase Facts Books*, Vol 1:7-20 Academic Press, San Diego, Calif.).

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic-ADP-ribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The cyclic-AMP dependent protein kinases (PKA) are important members of the STK family. Cyclic-AMP is an intracellular mediator of hormone action in all prokaryotic and animal cells that have been studied. Such hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cyclic-AMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K. J. et al. (1994) *Harrison's Principles of Internal Medicine*, McGraw-Hill, New York, N.Y., pp. 416-431, 1887).

Calcium-calmodulin (CaM) dependent protein kinases are also members of STK family. Calmodulin is a calcium receptor that mediates many calcium regulated processes by binding to target proteins in response to the binding of calcium. The principle target protein in these processes is CaM dependent protein kinases. CaM-kinases are involved in regulation of smooth muscle contraction (MLC kinase), glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM kinase I phosphorylates a variety of substrates including the neurotransmitter related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) *EMBO Journal* 14:3679-86). CaM II kinase also phosphorylates synapsin at different sites, and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. Many of the CaM kinases are activated by phosphorylation in addition to binding to CaM. The kinase may autophosphorylate itself, or be phosphorylated by another kinase as part of a "kinase cascade".

Another ligand-activated protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) *J. Biol Chem.* 15:8675-81). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

The mitogen-activated protein kinases (MAP) are also members of the STK family. MAP kinases also regulate intracellular signaling pathways. They mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S. E. and Weinberg, R. A. (1993) *Nature* 365:781-783). MAP kinase signaling

pathways are present in mammalian cells as well as in yeast. The extracellular stimuli that activate mammalian pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1).

PRK (proliferation-related kinase) is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryotic cells (Li, B. et al. (1996) *J. Biol. Chem.* 271:19402-8). PRK is related to the polo (derived from humans polo gene) family of STKs implicated in cell division. PRK is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation. Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

The cyclin-dependent protein kinases (CDKs) are another group of STKs that control the progression of cells through the cell cycle. Cyclins are small regulatory proteins that act by binding to and activating CDKs that then trigger various phases of the cell cycle by phosphorylating and activating selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to the binding of cyclin, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue.

Protein tyrosine kinases, PTKs, specifically phosphorylate tyrosine residues on their target proteins and may be divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane protein-tyrosine kinases are receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor and other specific proteins. Growth factors (GF) associated with receptor PTKs include; epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Such receptors that function through non-receptor PTKs include those for cytokines, hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes.

Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells where their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Carbonneau H and Tonks NK (1992) *Annu. Rev. Cell. Biol.* 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

LIM Domain Kinases

The novel human protein, and encoding gene, provided by the present invention is related to the family of serine/threonine kinases in general, particularly LIM domain kinases (LIMK), and shows the highest degree of similarity to LIMK2, and the LIMK2b isoform (Genbank gi8051618) in particular (see the amino acid sequence alignment of the protein of the present invention against LIMK2b provided in

FIG. 2). LIMK proteins generally have serine/threonine kinase activity. The protein of the present invention may be a novel alternative splice form of the art-known protein provided in Genbank gi805161; however, the structure of the gene provided by the present invention is different from the art-known gene of gi8051618 and the first exon of the gene of the present invention is novel, suggesting a novel gene rather than an alternative splice form. Furthermore, the protein of the present invention lacks an LIM domain relative to gi8051618. The protein of the present invention does contain the kinase catalytic domain.

Approximately 40 LIM proteins, named for the LIM domains they contain, are known to exist in eukaryotes. LIM domains are conserved, cystein-rich structures that contain 2 zinc fingers that are thought to modulate protein-protein interactions. LIMK1 and LIMK2 are members of a LIM subfamily characterized by 2 N-terminal LIM domains and a C-terminal protein kinase domain. LIMK1 and LIMK2 mRNA expression varies greatly between different tissues. The protein kinase domains of LIMK1 and LIMK2 contain a unique sequence motif comprising Asp-Leu-Asn-Ser-His-Asn in subdomain VIB and a strongly basic insert between subdomains VII and VIII (Okano et al., *J. Biol. Chem.* 270 (52), 31321-31330 (1995)). The protein kinase domain present in LIMKs is significantly different than other kinase domains, sharing about 32% identity.

LIMK is activated by ROCK (a downstream effector of Rho) via phosphorylation. LIMK then phosphorylates cofilin, which inhibits its actin-depolymerizing activity, thereby leading to Rho-induced reorganization of the actin cytoskeleton (Maekawa et al., *Science* 285: 895-898, 1999).

The LIMK2a and LIMK2b alternative transcript forms are differentially expressed in a tissue-specific manner and are generated by variation in transcriptional initiation utilizing alternative promoters. LIMK2a contains 2 LIM domains, a PDZ domain (a domain that functions in protein-protein interactions targeting the protein to the submembranous compartment), and a kinase domain; whereas LIMK2b just has 1.5 LIM domains. Alteration of LIMK2a and LIMK2b regulation has been observed in some cancer cell lines (Osada et al., *Biochem. Biophys. Res. Commun.* 229: 582-589, 1996).

For a further review of LIMK proteins, see Nomoto et al, *Gene* 236 (2), 259-271 (1999).

Kinase proteins, particularly members of the serine/threonine kinase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of kinase proteins. The present invention advances the state of the art by providing previously unidentified human kinase proteins that have homology to members of the serine/threonine kinase subfamily.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human kinase peptides and proteins that are related to the serine/threonine kinase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity in cells and tissues that express the kinase. Experimental data as provided in FIG. 1

indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

DESCRIPTION OF THE FIGURE SHEETS

FIG. 1 provides the nucleotide sequence of a cDNA molecule that encodes the kinase protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

FIG. 2 provides the predicted amino acid sequence of the kinase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIG. 3 provides genomic sequences that span the gene encoding the kinase protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in FIG. 3, SNPs were identified at 42 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a kinase protein or part of a kinase protein and are related to the serine/threonine kinase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human kinase peptides and proteins that are related to the serine/threonine kinase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these kinase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the kinase of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known kinase proteins of the serine/threonine kinase subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The art has clearly established the commercial importance of

members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known serine/threonine kinase family or subfamily of kinase proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the kinase family of proteins and are related to the serine/threonine kinase subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the kinase peptides of the present invention, kinase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the kinase peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the kinase peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated kinase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as

provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. For example, a nucleic acid molecule encoding the kinase peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the kinase peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The kinase peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a kinase peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the kinase peptide. "Operatively linked" indicates that the kinase peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the kinase peptide.

In some uses, the fusion protein does not affect the activity of the kinase peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant kinase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A kinase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the kinase peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the kinase peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A. M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D. W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part 1, Griffin, A. M., and Griffin, H. G.,

eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWS-gapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the kinase peptides of the present invention as well as being encoded by the same genetic locus as the kinase peptide provided herein. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a kinase peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by the same genetic locus as the kinase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of

the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Paralogs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the kinase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the kinase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a kinase peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., *Science* 247:1306-1310 (1990).

Variant kinase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., *Science* 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as kinase activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., *J. Mol. Biol.* 224:899-904 (1992); de Vos et al. *Science* 255:306-312 (1992)).

The present invention further provides fragments of the kinase peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a kinase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the kinase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the kinase peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in kinase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pro-

teolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins—Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan et al. (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the kinase peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature kinase peptide is fused with another compound, such as a compound to increase the half-life of the kinase peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature kinase peptide, such as a leader or secretory sequence or a sequence for purification of the mature kinase peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a kinase-effector protein interaction or kinase-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, kinases isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant

brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. A large percentage of pharmaceutical agents are being developed that modulate the activity of kinase proteins, particularly members of the serine/threonine kinase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to kinases that are related to members of the serine/threonine kinase subfamily. Such assays involve any of the known kinase functions or activities or properties useful for diagnosis and treatment of kinase-related conditions that are specific for the subfamily of kinases that the one of the present invention belongs to, particularly in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the kinase, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the kinase protein.

The polypeptides can be used to identify compounds that modulate kinase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the kinase. Both the kinases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the kinase. These compounds can be further screened against a functional kinase to determine the effect of the compound on the kinase activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the kinase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the kinase protein and a molecule that normally interacts with the kinase protein, e.g. a substrate or a component of the signal pathway that the kinase protein normally interacts (for example, another kinase). Such assays typically include the steps of combining the kinase protein with a candidate compound under conditions that allow the kinase protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the kinase protein and the target, such as any of the associated effects of signal

transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., *Nature* 354:82-84 (1991); Houghten et al., *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant kinases or appropriate fragments containing mutations that affect kinase function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) kinase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate kinase activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the kinase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the kinase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the kinase can be assayed. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

Binding and/or activating compounds can also be screened by using chimeric kinase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized by the native kinase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the kinase is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the kinase (e.g. binding part-

ners and/or ligands). Thus, a compound is exposed to a kinase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble kinase polypeptide is also added to the mixture. If the test compound interacts with the soluble kinase polypeptide, it decreases the amount of complex formed or activity from the kinase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the kinase. Thus, the soluble polypeptide that competes with the target kinase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the kinase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ^{35}S -labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of kinase-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a kinase-binding protein and a candidate compound are incubated in the kinase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the kinase protein target molecule, or which are reactive with kinase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the kinases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of kinase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating cells or tissues that express the kinase. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. These methods of treatment include the steps of administering a modulator of

kinase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the kinase proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693/1696; and Brent WO94110300), to identify other proteins, which bind to or interact with the kinase and are involved in kinase activity. Such kinase-binding proteins are also likely to be involved in the propagation of signals by the kinase proteins or kinase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such kinase-binding proteins are likely to be kinase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a kinase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a kinase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the kinase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a kinase-modulating agent, an antisense kinase nucleic acid molecule, a kinase-specific antibody, or a kinase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The kinase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The method involves contacting a biological sample with a compound capable of interacting with the kinase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A bio-

logical sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered kinase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M. W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the kinase protein in which one or more of the kinase functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are

more or less active in substrate binding, and kinase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Accordingly, methods for treatment include the use of the kinase protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, *Antibodies*, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the kinase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or kinase/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody

to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic

proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the kinase peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptide's activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a kinase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the kinase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by

recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprise several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of

a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the kinase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the kinase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in FIG. 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60–70%, 70–80%, 80–90%, and more typically at least about 90–95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60–70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1–6.3.6. One example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 50–65°C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. As illustrated in FIG. 3, SNPs were identified at 42 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in kinase protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA includes Southern hybridizations and in situ hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a kinase protein, such as by measuring a level of a kinase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a kinase gene has been mutated. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by

virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate kinase nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the kinase gene, particularly biological and pathological processes that are mediated by the kinase in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The method typically includes assaying the ability of the compound to modulate the expression of the kinase nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired kinase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the kinase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for kinase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the kinase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of kinase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of kinase mRNA in the presence of the candidate compound is compared to the level of expression of kinase mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate kinase nucleic acid expression in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for kinase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the kinase nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the kinase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in kinase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in kinase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the kinase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the kinase gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a kinase protein.

Individuals carrying mutations in the kinase gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., *Science* 241:1077-1080 (1988); and Nakazawa et al., *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal

genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a kinase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant kinase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., *Adv. Chromatogr.* 36:127-162 (1996); and Griffin et al., *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., *Science* 230:1242 (1985)); Cotton et al., *PNAS* 85:4397 (1988); Saleeba et al., *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., *PNAS* 86:2766 (1989); Cotton et al., *Mutat. Res.* 285:125-144 (1993); and Hayashi et al., *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the kinase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control kinase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene

involved in transcription, preventing transcription and hence production of kinase protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into kinase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of kinase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired kinase nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the kinase protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in kinase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired kinase protein to treat the individual.

The invention also encompasses kits for detecting the presence of a kinase nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting kinase nucleic acid in a biological sample; means for determining the amount of kinase nucleic acid in the sample; and means for comparing the amount of kinase nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect kinase protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application W095/11995 (Chee et al.), Lockhart, D. J. et al. (1996; *Nat. Biotech.* 14: 1675-1680) and Schena, M. et al. (1996; *Proc. Natl. Acad. Sci.* 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be

preferable to use oligonucleotides that are only 7–20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementarity matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the kinase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the kinase gene of the present invention. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., *Techniques in Immunocytochemistry*, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified kinase gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extra-chromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia

viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., *Gene* 69:301-315 (1988)) and pET 11 d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada et al., *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, et al., *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan et al., *Cell* 30:933-943(1982)), pJRY88 (Schultz et al., *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow et al., *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman et al., *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*. 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the

recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as kinases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with kinases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of Vectors and Host Cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a kinase protein or peptide that can be further purified to produce desired amounts of kinase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the kinase protein or kinase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native kinase protein is useful for assaying compounds that stimulate or inhibit kinase protein function.

Host cells are also useful for identifying kinase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant kinase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native kinase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for

studying the function of a kinase protein and identifying and evaluating modulators of kinase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the kinase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence (s) can be operably linked to the transgene to direct expression of the kinase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. *PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman et al. *Science* 251:1351-1355 (1991)). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recom-

binase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. *Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect substrate binding, kinase protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo kinase protein function, including substrate interaction, the effect of specific mutant kinase proteins on kinase protein function and substrate interaction, and the effect of chimeric kinase proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more kinase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1
<211> LENGTH: 2320
<212> TYPE: DNA
<213> ORGANISM: Human

<400> SEQUENCE: 1

```

cccaggcgcg cgtaggcggt gcatcccggt cgcgcctggg gctgtggtct tccgcgcct      60
gaggcgcgcg cggcaggagc tgaggggagt tgtagggaac tgaggggagc tgctgtgtcc      120
cccgctctct cctcccatc tccgcgctcc cgggaccatg tccgcgctgg cgggtgaaga      180
tgtctgagag tgtccaggct gtggggacca cattgtccca agccagatat ggtacaggac      240

```

-continued

tgtaacgaa acctggcacg gctcttgctt ccggtgaaag tgatgcgcag cctggaccac	300
cccaatgtgc tcaagttcat tgggtgtgctg tacaaggata agaagctgaa cctgctgaca	360
gagtacattg agggggggcac actgaaggac tttctgcgca gtatggatcc gttcccctgg	420
cagcagaagg tcaggtttgc caaaggaatc gctccggaa tggacaagac tgtggtggtg	480
gcagactttg ggctgtcacg gctcatagtg gaagagagga aaaggggccc catggagaag	540
gccaccacca agaaacgcac cttgcgcaag aacgaccgca agaagcgcta cacggtggtg	600
ggaaacccct actggatggc ccctgagatg ctgaacggaa agagctatga tgagacggtg	660
gatatcttct cctttgggat cgttctctgt gagatcattg ggaggtgta tgcagatcct	720
gactgccttc cccgaacact ggactttggc ctcaactga agcttttctg ggagaagttt	780
gttcccacag attgtccccc ggcttcttc ccgctggccg ccactgctg cagactggag	840
cctgagagca gaccagcatt ctgaaattg gaggaactct ttgaggccct ctccctgtac	900
ctgggggagc tgggcatccc gctgcctgca gagctggagg agttggacca cactgtgagc	960
atgcagtacg gcctgaccgg ggaactcacct ccctagccct ggcccagccc cctgcagggg	1020
ggtgttttac agccagcatt gccctctgtg gccctattcc tgcgtgagc agggccgtcc	1080
gggcttctg tggattggcg gaatgttag aagcagaaca aaccattcct attacctccc	1140
caggaggcaa gtggggcgag caccaggga atgtatctcc acaggttctg gggcctagt	1200
actgtctgta aatccaatc ttgcctgaaa gctgtgaaga agaaaaaac ccttggcctt	1260
tggggcagga ggaatctgtt actcgaatcc acccaggaac tccctggcag tggattgtgg	1320
gaggctcttg cttaactaa tcagcgtgac ctggacctgc tgggcaggat cccagggtga	1380
acctgcctgt gaactctgaa gtcactagtc cagctgggtg caggaggact tcaagtgtgt	1440
ggacgaaga aagactgatg gctcaaaggg tgtgaaaaag tcagtgtgac tcccccttc	1500
tactccagat cctgtccttc ctggagcaag gttgaggag taggttttga agagtccctt	1560
aatatgtggt ggaacaggcc aggagttaga gaaagggtg gcttctgtt acctgtcac	1620
tggtcttagc cagcccaggg accacatcaa tgtgagagga agcctccacc tcatgttttc	1680
aaacttaata ctggagactg gctgagaact tacggacaac atcctttctg tctgaaacaa	1740
acagtacaa gcacaggaag aggctggggg actagaaga ggcctgccc tctagaaagc	1800
tcagatcttg gcttctgtta ctactactg ggtgggctcc ttagtcagat gcctaaaca	1860
ttttgcctaa agctcgatgg gttctggagg acagtgtggc ttgtcacagg cctagagtct	1920
gaggggaggg agtgggagtc tcagcaatct cttggtcttg gcttcatggc aaccactgct	1980
caccttcaa catgctggt ttaggcagca gcttgggctg ggaagaggtg gtggcagagt	2040
ctcaaaagctg agatgctgag agagatagct ccctgagctg ggccatctga cttctacctc	2100
ccatgtttgc tctcccaact cattagctcc tgggcagcat cctcctgagc cacatgtgca	2160
ggtactggaa aacctccatc ttggctccca gagctctagg aactcttcat cacaactaga	2220
tttgctctt ctaagtgtct atgagcttgc accatattta ataaattggg aatgggttgg	2280
gggtattaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	2320

<210> SEQ ID NO 2

<211> LENGTH: 255

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 2

Met Val Gln Asp Cys Gln Arg Asn Leu Ala Arg Leu Leu Leu Pro Val

-continued

1	5	10	15
Lys Val Met Arg Ser Leu Asp His Pro Asn Val Leu Lys Phe Ile Gly	20	25	30
Val Leu Tyr Lys Asp Lys Lys Leu Asn Leu Leu Thr Glu Tyr Ile Glu	35	40	45
Gly Gly Thr Leu Lys Asp Phe Leu Arg Ser Met Asp Pro Phe Pro Trp	50	55	60
Gln Gln Lys Val Arg Phe Ala Lys Gly Ile Ala Ser Gly Met Asp Lys	65	70	75
Thr Val Val Val Ala Asp Phe Gly Leu Ser Arg Leu Ile Val Glu Glu	85	90	95
Arg Lys Arg Ala Pro Met Glu Lys Ala Thr Thr Lys Lys Arg Thr Leu	100	105	110
Arg Lys Asn Asp Arg Lys Lys Arg Tyr Thr Val Val Gly Asn Pro Tyr	115	120	125
Trp Met Ala Pro Glu Met Leu Asn Gly Lys Ser Tyr Asp Glu Thr Val	130	135	140
Asp Ile Phe Ser Phe Gly Ile Val Leu Cys Glu Ile Ile Gly Gln Val	145	150	155
Tyr Ala Asp Pro Asp Cys Leu Pro Arg Thr Leu Asp Phe Gly Leu Asn	165	170	175
Val Lys Leu Phe Trp Glu Lys Phe Val Pro Thr Asp Cys Pro Pro Ala	180	185	190
Phe Phe Pro Leu Ala Ala Ile Cys Cys Arg Leu Glu Pro Glu Ser Arg	195	200	205
Pro Ala Phe Ser Lys Leu Glu Asp Ser Phe Glu Ala Leu Ser Leu Tyr	210	215	220
Leu Gly Glu Leu Gly Ile Pro Leu Pro Ala Glu Leu Glu Glu Leu Asp	225	230	235
His Thr Val Ser Met Gln Tyr Gly Leu Thr Arg Asp Ser Pro Pro	245	250	255

<210> SEQ ID NO 3
 <211> LENGTH: 59065
 <212> TYPE: DNA
 <213> ORGANISM: Human

<400> SEQUENCE: 3

tcaccccttc gcaggggcca tgctaaccctt ctgtgtctca gtccaatttt aatgtatgtg	60
ctgctgaagc gagagtacca gaggtttttt tgatggcagt gacttgaact tatttaaaag	120
ataaggagga gccagtgagg gagaggggtg ctgtaaagat aactaaaagt gcacttcttc	180
taagaagtaa gatggaatgg gatccagaac aggggtgtca taccgagtag cccagccttt	240
gttccgtgga cactggggag tctaaccag agctgagata gcttgagtg tggatgagcc	300
agctgagtag agcagatagg gaaaagaagc caaaaactg aagtagggct ggggtgaagg	360
acagggaagg gctagagaga catttggaag gtgaaccag gtggatatga gaggagagag	420
tagagggtct tgatttcggg tctttcatgc ttaaccana gcaggtacta aagtatgtgt	480
tgattgaatg tctttgggtt tctcaagact ggagaaagca gggcaagctc tggagggtat	540
ggcaataaca agttatcttg aatatcctca tggtggaag tcctgatect gtttgaattt	600
tggaaataga aatcattcag agccaagaga ttgaattgtt gagtaagtgg gtggtcaggt	660
tacagactta attttgggtt aaaaagtaaa aacaagaagc aaggtgtggc tctaaaataa	720

-continued

tgagatgtgc tgggggtggg gcatggcagc tcataaactg accctgaaag ctcttacatg	780
taagagttcc aaaaatattt ccaaaacttg gaagattcat ttggatgttt gtgttcatta	840
aaatctctca ctaattcatt gtcttgtcca ctgtccgtaa cccaacttg gattggttg	900
agtgaagtct tcagacttct tgccttgagc tttgtgagag agatggcata ctctgtgacc	960
actgtcacc ctaaaacaaa aaggcccttc ttgacaagga gtctgaggat tttagacca	1020
ggaagaatga gtgatggca tatatatatc ctattactga ggcagagaa gagtgaatg	1080
ggtgggttga ggtggtgttt taaggcctct tgccagcttg tttaactctt ctctgggaa	1140
cgagggggac aactgtgtac attggctgct ccagaatgat gttgagcaat cttgaagtgc	1200
caggagctgt gctttgtcta ttcattggcc ctgtgcctgt gaaacagggt tcggtgactg	1260
tcactgtgcc tgtggcagtc ttagttacc cagagagaac aaagctgcat acacagagcg	1320
cacaaggag tcttgaaca acctgtcct gctttctagg gctgagtcag gtaccacagc	1380
ttgatctcag ctgtcctctt tatttcaaga agttgacatc tgagccatac caggagtatt	1440
gtattttgt tgaggcctct ctttttgag gaacatggac cgactctgtg cttttgtcta	1500
tgtgtgtctc tgagctcaca caacccttca cctccttctc tcagccagtg ataggttaagt	1560
cttccctatc ttgcaaggct cagctcaagt gtcagcttcc tctacaaaga ctttctgtgt	1620
tccctcatt ggagtgaaca agagttgaca tggtagaatg gaaagagcag aagctttaga	1680
atgagccaga cctgagtatg aatgctagat ccaccactta gctagtcaac cctgccccct	1740
gcctcaagtt ttaattttcc tatccattaa gtgaatataa taatacctgt gtcacaggat	1800
tattttgaga attaaatgag attaggtcta tgaaagcacc tagcagagtt cttggcata	1860
aggaggcatt cattaatat ttgttcttcc ctttttatac ccattacttt tcttttctg	1920
aactaaaaa atacttggtt ctatctctga aataacatcc aagtgaanaa tcaacaacat	1980
gaaagagcag ttcttttcca gtgatttgc ttcttaagga gcagagatta tgtaactaa	2040
cagctccaa catacaaga gctttgtatc tagaacagg gtcccagcc cctggaccgc	2100
caactgttac ggtgtgtgag cctgttagga accaggctgc acagcaggag gtgacggcg	2160
ggccagttag cattgtgccc tgagctctgc ctctgtcag atcagtgggt gcattagatt	2220
ctcataggag tgtgaacct attgtgaact gcacatgcaa gggatctggg ttgcagtctc	2280
cttatgagaa tctcactaat ggctgatgat ctgagttgga acagtttgat accaaaacca	2340
tccccccgc cccaacccc cagcctaggg tccgtggaaa aattggcccc tgggtccaaa	2400
aagggtgag actgctgac tagaggacca atttattcaa tgttgggtga gtaaatgagc	2460
tcttggtta ggtgatgaa aaatctgaaa aaacagggtc ttgaggaat aggaaaaggc	2520
agtaacatgt ttaaccaga gagaagtttc tggctgttg ctgggaatag tcataggag	2580
ggctgacact gaaaagaagg agattgtgtt cgtttctct tctcagagct ataagcaag	2640
gctgaagtt ctagaaaaa gcaagttttg ttctagtaga aaaaaggata atcagaacca	2700
tttttagaaa atggaatgag actactttg aggccatgag ttcctgttcc ctggagagat	2760
gagcagaggt tggacaagt cttaccagag atcttgtgga ggcagaaact gtgcattctag	2820
cagagcattg gcctaaccct ttcaaatgag atgctgttaa ctacgtctta ttctacatgg	2880
taggaatcct gtccctttgc ctctgtctac ttggggctc tcaacctctt ggttttgtt	2940
gcaggtaag atgtctggag gtgtccaggc tgtggggacc acattgtctc aagccagata	3000
tggtagagga ctgtcaacga aacctggcac ggctcttctc tccgtagagt gggcctatcc	3060
tcccatctt accaggtac tatgggcaa gcactatttc atgttctgat ggaacacaca	3120

-continued

gaaacaagct tctgagttga gaatttcaat cttaggggtgg ggaaggaat gtaccaagga 3180
 agagctcatg accaaacctc aagtgtggcc cccctgaacc caggttaaat tggaagagcc 3240
 ataaatgggc cagctggagg cagggtgggg gtagtagagg agccctttcc agggttgtcc 3300
 cataccctc actttatggg tgaggaaact gaggccagg aagagtact ttcctgtggc 3360
 tgcactacag attatgcagg tacttcaaga gttgtttgta ttcttatttt attttatttt 3420
 attttatttt attttatttt attttatgag agggattctt gctgttgccc aggtgtgagt 3480
 gcagtggtgc aatctcggct cactgcaatc tctgctgct gggttcaagt gatttttctg 3540
 ccttagcttc ctgagtagct gagatgacag gcacctgcca ccctgcgcag ctaatttttg 3600
 tatttttagt gagacggggg ttccaacatg ttggtcaggc tggcttgaa ctccctgacct 3660
 caaatgatgc acccaacctc acctccnaa gtgtggaat tacaggcgtg aacctagtg 3720
 cccagccaag agttgttttt agtgtggtg gcagagccag ctcttcttc accacaggat 3780
 gcctccctag gtctctactt ttgttacta gcttttatta tagctatatt attattatta 3840
 ttattattat tattattatt attattgaga cagagtctcg ctctgtcgc caggctggtg 3900
 tacagtggg cgatccggg ctactgcaa cctctgcctc ccgagttcaa gcagttctcc 3960
 tgctcagcc ccccgagtag gtgggactac aggcgcctgc caccacccc ggctaatttt 4020
 tgtattttta gttagagcgg ggttcacct tgttgaccag gctggtctg agctcctgac 4080
 ctcaggaag tgctagaatc acaggcgtga accactgcgc ccagccaaga gttgttttta 4140
 gtgtggttg gcagagccagc tcttctcacc cacaggtgc ctccctaggt tctactttt 4200
 tgttactagc ttattatag ctacattatt attattattg ttattattat tgagacagag 4260
 tctgctctg tcgccaggc tgggtacag tgatgtgac ttggctcact gcaacctctg 4320
 ccccccaggt tcaagcaatt ctctgcttc agcccccta gtaggtggga ctccaggcac 4380
 ctgccaccac gcccgactaa ttttgtatt tttagtagag gcggggttc acctgttg 4440
 ccaggctggt ctcaaaactcc tgacctcagg tgatccgct gcctggcct cccaaaatgt 4500
 tgggattaca ggcagtagcc accgcgcct gcctatagct acattatttt ttagggcagc 4560
 tcagtttctt aaaaattata cagacttcaa atcagatttg ttcctgctg ctgaggctca 4620
 gtttcttcat ctggaatg gatggaata atcttggtga gattgaatga aataatatat 4680
 gcagtgatc cagtagatgg tagacacca gtgaatggtt attccttct cccatcggt 4740
 tggaattctc aagggtggga acttgtctt atattcttca caacgtaaa tagttgaaat 4800
 ttgttggtg aaagaagagc agtccactcc agaggctgga tgggcatgcc tggccccc 4860
 ggtctgaagt ggtagggtg tgcttatatc ctgagaatga gatagactag gcaggcacct 4920
 tgtgctgtag attccagctc ctgcacatag ctcttggtt aaaaatccc tgtgcttata 4980
 ccaagtaatt gagttgacct ttaaacactt gcctcttccc tgggaacct ataggggatt 5040
 ggctgggaga cgtctggcct ctggaagagt tggaaagcag ccatcattat tatccttcc 5100
 tttcagctat aactcagagc tctcaagtct tttctgtgga tcttattgcc ttggtcttg 5160
 ccccttttac tcccaggga gttgattctg tcttttctgt tccatttagt atgacaggag 5220
 cagagaatgt cagagctgta agggacctta tagttaagc ctttggtgg tcttttctt 5280
 ttatagctg gactaataag taacgtcaa acccaatgag ttcacagatt ggtctcgc 5340
 ttggcatgta acccatatgt tcatattctt gctgttttcc tatgtgatg aatatttct 5400
 atccaaaata agcaggacag gtagagcaa gtaaatctt ggaatttctg gattctctta 5460

-continued

gagctaaaaa acttcagaac tagaagaac caccactat atggataac ccattcatat	5520
cacagatgag gectgaacc aaaaagactt gctcaggcca tggatgacaa gagctggccc	5580
tagcactgaa ctcttgggtc attttaggt ctagtcagat gctagcttgt tagctctgtg	5640
cgtgcgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgagat agagacagaa agataacata	5700
tgtacacaaa tacataaaga ggaagtagac acgttagcat ggtagataag agtacaggca	5760
ggccaggcgt ggtggctcac gcctgtaac ccagcacttt gggaggccaa ggcaggtgga	5820
tcacctgagg tcaggaattc gagaccagcc tgaccaacat ggtgaaccc catctctact	5880
aaatacagaa aaaaattagc ttggcatggt ggcacatgcc tgtaatcca gctacttggg	5940
aagctgaagc aggagaatcg cttgaatccg ggaagcagaa gtgcagtgga gccgagattg	6000
tgccattaca gtctagcctg ggcaacaaga gggaaactcc atcgcaaaa aacaaccacc	6060
accaagagta caggctatgg aatgagacta tggttttaaa tcttggcttt gcaatttatt	6120
aactagcctt aagtgaattc cctgagcttc aggcaccaat ctgtaaatg aggataagaa	6180
tattactcat gccacatggt tgtagggag gattaaatgt gataacctat ataaagtggc	6240
tagcatagca tctgacatat agaaaactct taatagggcc ggacgtgtgt gcttatgcct	6300
gtaatcctag cactctggga ggccgaggca gaaggatcgc ttgagcccat gagcccagga	6360
gtttgagacc agcctggcca acatggcaaa actccacctc tacaanaaa acaaaaatat	6420
tagccaggcg tgatggcaca cacctgtagt cccagctact tgggaagctg agggagcgatg	6480
attacctgag cccagggata tcaaggctgt agtgagctgt gatcatgcca ctgtactcca	6540
tccagctggg ggacagagtg aaacccctgt ctcaaaacaa aacaatgaa aaaaaaaccc	6600
cttaataatc agtaactgtc actttatatt atgttgtgag tgtgtgtcta tatacaccta	6660
tatgtataca tttctcttat tacacattca ttggtgatct gatgtggagc cccagggtatt	6720
aaggggcaat ttgaactacc ctgacacaat caagccaat atcattcccg tggaggaggt	6780
agagtatcta ggttctgtct cctagtgtca gctttacctt gaggacagag actctaacc	6840
agctgtgctg aaggagcaca totcctgact tctgagcttt cccctggtaa attcaactg	6900
gatgtcacgg cgccctcaga tagagcctgg taatttgccc tggggagagt gactgtcttt	6960
tggatctaatt ttgacttttg cccagttgg aggaaaatct tcagggctag gaaggattgt	7020
atttgtctga cccagagat aacctgggtt ttgaggaaca tggggcatca acctgaatgg	7080
tcttgtaaga tctctccac gccagcttgc cagtgtttct ctgatgaatt tagagtacct	7140
gagtagtgca ggcctgctgg gagaggact ctccctctgt gctactcaga gaaattcatt	7200
cttcaaggcc ccttccagc cttgctctta cccagctggg ctacagttac aataaaggaa	7260
atgacttttc ttctccctt cccccagtac ctttgttttc ctagtacag ggtggggctg	7320
gatattgaat ggagaaattg ctgggttcca tctaaaactc ctcccctcat ctctccctta	7380
cattaccocca ttcttctgtc tgcagccaca tccataatcc tgcctctgtt agccttccga	7440
cagaccctca ggtgccagg acaacaggaa gctacttaaa gctggaacct cagactgtgc	7500
aatggaggcc agtgacaaaa ctgaagtag ctctgtcagt aattgtgctg gtgcgattag	7560
gcagctggcc agaattcttt ggtatcctg gacatatggc tgactagtcc tcccaagcct	7620
tcccaacagg cctctttttt ttcctttttt tctttttttt tttttttt tttctttctt	7680
tctttttttt ttttttttag gctagtgaag tgaaattgtg ggagtggaaa aggaacaaag	7740
aaatcggtaa ctggtagtga tcaattactt gtaaacacta ttgtacttgg accagcccag	7800
taggcctttt ttaaaactct gagttacctc tctttccttt ccttgagcag tgccattaat	7860

-continued

tctgtatctg gggcaatcct ttctgatgtt ctctggacct ggctctctct ccttaggaga 7920
ggccaggaga gtagccagag agcatgtcat ttgtagctga ggttaaagtg tggagctatc 7980
aatggtgacc tggcctcttg gcatgttagc aagccagagg accttgacaa cttttttgat 8040
gattgtccgt tcaccctgat caaagggtgtt tggcttagga ggagggaaga aaagctaccc 8100
ctattagtct tgatggcccc agcgtgggtc tctattgctt gacctgggtc ctacgagcat 8160
tatcagaagg aaaatccacc gctcttaagg ctctgggaa ctttcaggac ttcctttctc 8220
aggattgcaa acataagact atttgagctt tcacttttga aaagcggta ctaataccta 8280
tactctggga aagggttaat gcagatagaa gactgtgttc actgcatcag gcaacagacc 8340
atttcgcta aatttagtga ctccaggaag gccagtgaag aaataacaca cgtagcaacc 8400
agagactgtg ttgtaatatg ttggctgaca gcaggggtact ttctgtgatg ctgaaagcca 8460
cattcatttt ctctccctc atcccatct aagcaagcct ggtagaatca taattacagt 8520
aataggtagc acttattgag tactctgtgc cagacacct cctgagcata cgacatgcat 8580
agcacattta atccttacia tgacttaata aaatgtagta ctagtcttac ctacttcgag 8640
aatagggaat tggaggttac ttgtttaaag tcacagagct aataggtagc atagctgaga 8700
tttgaactca ggcattctta ctccctgctt gcaagagtct cttggcattc ttgaatgcaa 8760
gcatatttct taacctcact gaggtcagt ttcctcttat ataatatggg gtaaaagacc 8820
ctcaccctgc ctgccacaca ctggtagtgt cagataacat tgaagggtgt tagtttaaa 8880
gcttcattga ctctataatg tcaacaaaag tgctgttaac tttctcttgg gtctcaggct 8940
cctgatgtag agtcagtga gcaacctgc catctgctgt tatgtgttg atgttgctgc 9000
cacacttact aacctaaacc ttgattctg gctgtggcct tctccagaag gtgtttactc 9060
atttgctcag tttatctttt aggaacagc cagcccgtag atcattaagg ctggctattg 9120
gacagggggc tggggcctgc ctgacagagg aagggaaggc agacatctgg ttcttctct 9180
gcccctacaa gagactccag cctgaccaca gagtggtact cctaggatgt agcagcagca 9240
tatgagcttg aatgtgcctt aatcctgctc tttactttga gaagagagaa ctaaggaccc 9300
acagatgttt cacagcttct ataggaggca gaggtagaaa aatggagaga gatgaggcca 9360
gagatagata actgatatta attaaacgtt gtattaagaa cctcacttag attatctgat 9420
tcaatcttca taataacctt gcaaccccca cctttttttg agaacagggt cttgctctgt 9480
tgtccaggct acagtgcact ggtacaatca tagttcactg cagtgtcaac ctctgagct 9540
caagcaatcc tcccacctca gccttgcaag cagcttgac tacaggcgtg ccaccacacc 9600
ttgccatttt tttttatttt aagtagaaac aaggctctat taatactatg ttgccaggc 9660
tggcttgaa ctccagcgt cctcctgccc cagcctccca aagtgtcttg gattacggaa 9720
gtaagccact gtgcctggcc agtgcaacct ccattttata ctaaaacagg aaggccaga 9780
aagggttgga gtaactgtc cagggtcaca cagatgatat ttgaactcag gtctccctgg 9840
ctcccaagag agtctgctt ccactaggac tcccaggaga aaaaaaaaaa aaaaacagt 9900
agacttgag acagaaaatc tgatttgagt cttagttag ctaggctaac tgtgtaactg 9960
tgggcaagt ccttagcccc tgtgacctc agtttcttat ctgtaaatg tcataaaaga 10020
aatccatctc atggagtagt tgtgatgac aaggactctg aaaacattag aatggtttaa 10080
tgtgaaggat tagcagcagc acatggcaac attgtgcac ttatattaac tatccaaata 10140
tatcaagcgt catttgctat atataaaagt catcaaatta ggcactgtgg gggatacgga 10200

-continued

gttggcatac tagcctggcc tcttaattaa ttcattaatt agcttattta tttttgagat 10260
aggctcttgc ctattgccca ggctggagtg cagtggcatg atgatatctt actatagcct 10320
caatctccca ggcttaaca atcctcctga gtagctggga ctacaggcac acactaccat 10380
gccagctaa tttttttta attttttgta gagacagggt ctgtctctgt tgcccaggct 10440
ggtctcaaac tcttgggctc gagatcctcc cacctgggccc tcacaaagtg ttgggattac 10500
aggatgagc cacggcacct ggctgtgtct cttactgggt tccctaagac agctggaaat 10560
agagaatgct atggagcatt cctaaccatg ggctccagcc tggctttcat tctgtttctc 10620
ccctgaaaca acattccttt agtaaatatc cgaataacag ctctcatcagt ctgtctaccg 10680
accactcttc aggcttcctc ttatatgacc tcccaactg cactaagggt tgtattagag 10740
aaaagtggat aaagtctgga gtcaggctgc ttgagcttaa atgccagctt cacttaccag 10800
ccacctgacc atgagtcagc tgcttaacca ttctttgcca cagtttctct gtctatgaaa 10860
agggaaatgg ctcccacctc aaaaagtgtg taacattaaa ttcaatcatg tattcaaagt 10920
cctgagcaga atgtctggcc atgactggga cttaacagat gttagcattt attattagta 10980
tctgtcagtc ttgaaatgtt ctcttccctt ggctttcatg acattccaca ctctcctggt 11040
tttctcttac ctctctgcta atacctgttt gcttaccctt ctttgtccag ctctgggag 11100
ttaccattcc ttcaggcgtg ctgttttctc cttaggcagt cttacacaca ctcatgactt 11160
ccttcatttg tctccacac actgatgacc ctaaaatcag tatctccagc ctaaaacctt 11220
ccactgagtt cttagcccat atgttgtaact atcaacctgg cttgtccatt tgaatgtctt 11280
ccaggcaact cagactctct tctctagact ttgctggact ttcaactctc cccctaaaac 11340
tggtcctct tccactgaaa catgtatgct attgagaggc accaccatcc acccagtgcc 11400
taagccagaa acctaggaat ccttgatacc tgttctctct catcctgcat atccaagcct 11460
atcagtttta tctctaaatt atattttgtt aggtttactt ctttctttt ctcccaccac 11520
caccctgctc caagctacca tcactctacc tggatgtctg caatagcctc atctcccaca 11580
gccactctgc acccccta atctgtctcta tagagcagtt ggaaggagtg atttttgttg 11640
tttgttttgt ttgttttag acagagtctc actctgttcc ccaaggctgg agtgccagtg 11700
cacaatttgc gctcactgca acttctgcct cccgggttta agcaattctc ctgectcagc 11760
ctcccaagta gctgggatta aggcacccgc ccccatacc agctaatttt tatattttta 11820
gtagagatgg ggttttgcca tgttggccaa gctagtctcg aactcctgac ctcaagtgat 11880
ccacctgcct cggcctccca aagtgtggg attacagggt tgagccactg caccgtggctg 11940
gaaggagtga tcttaaaaa aaaaaaaca aaaaaaact tgactgtgtc actctgtgtt 12000
gtctctecta ccttgatac ttccacaact tccagtggt cttggataaa gaccaaaatc 12060
cttaacttgg ccaggcgctg tggctcacac ctatcatctc agcactttgg gaggccgagg 12120
caggcagatc atgaagtcaa gagattgaga ccatcctggc caacatgggt aaaccccatc 12180
tctactaaaa atacaaaat tagctgtctg tgggtggctg tgctgtagt cccagctact 12240
tggtgggctg aggcaggaga atcacttgaa cctgggaggc agaggttgca gtgagcccag 12300
atcacgccac tgcactccag cctggtgaca gagtaagact ccatctcaaa aaaaaaaa 12360
aaaaaaaaa ttcttaatt tggcctacag tagagccctc cgtaatgtgg cctctctcca 12420
catctccaca acctctgct cctgcactt cagctctcaco tctctctgg acaggccctc 12480
cttctgacaa gggctttgtt cattctgctc cctctgcta gaatgcccc ttaactctgt 12540
cacttaactc ctgcttatcg tttagatctt tacctggatg gctcagagaa atatagaagt 12600

-continued

aattcctcac cctgaaaaat aggttaggtc cctgttttat gtttccatag accttcctt 12660
tgaggctttt tttaaaaaag tagttttaat ctcacattta ttcattgat catctcctta 12720
atgatatctt aagacctcta atagaacaat ttggtcatgg actgtggggt tttgccccct 12780
cattgtgtca gcactgagca tattgttggc ataggaggga tattgttga atgaattgct 12840
agagggtggc aagagatatg atgtaagtcg ggcttttccc tgcccttccc ctcccccttc 12900
ccccatcctt tcctatagca gccaccgtgg ctgcagttac tgtaaatggc aagacggaat 12960
cagttccgga cattgggttg ttttagaaaa ttgcctgcaa gtgtcagggg gataagttaa 13020
agctttgtct tttgccctca gaggagctat cccatagtga gtagaagcca gagaagctga 13080
ccccaggagt ccttctttcc agcagcaggt cttgagctgc acttctctgt agctacaatc 13140
caggcaggaa caagccctag gtacctccgg agaggagggc aagagaggaa gaattgagttc 13200
agctactcta gccaccaaac tgattatgaa ttgccctgaa atctgaaaaa tttcaattcc 13260
aatcgttaagt ttgttttgtt tcattttgtt ttcttaaat gtatatttga aagatggcat 13320
taactaaaga tatatattca atatagagtg gaaaaaatgg aatacttgca tagtatcttt 13380
tacttatagg tgatttatga tggggagtggt ggtggatagg ttggcagttc cccaagaag 13440
ttggaatga agtttgtcct ctgtgagttg aactaattag atccacaagt aatgaaagca 13500
gtatttgttt gtagttaaga gcacactcta gaaccagatt gcttagtttc aaatcctggt 13560
tctgcctttt attatctgtg tactttgggc aagttaactg ccttttgtgt gcttcatttt 13620
tctcatctag aaaatggaga ggccaggcgt agtggctcat gctataatc ccagcacttt 13680
gggagggcga ggggggcaga tcacctgagg tgagaagttc aagaccagcc tggccaacat 13740
ggtgaaacct tgtctctaca aaaatacaaa aattagccag gcatgatggc ggggtcctgt 13800
aatccagctt acccaggagc ctgaggcggg agaaacactt gaacctggaa ggcagagggt 13860
gtagttagcc aggattgcac cactgcactc cagcctgggt gacaagagct agactcagtc 13920
taaaaaaaaa aaaaaaaac aaactggaga tacaggctgg gtgcagggtt tacactata 13980
atatcagcac tttgggagc ctaggcggga ggattgcttg aactcaggag tttcaagatc 14040
agtctgggta acagagcaag acctcatccc caaaaaaat caaaaattta gccaggcatg 14100
gtggctcatg cctgtgttcc cagctactca ggaggctgag gcgagaggat tgcttgagcc 14160
caggagggtt aggtgtcagt gaacctgac tgcaccacta catgccagcc tggatgacag 14220
agcaagacct tatctcaaaa aaaaaaaaaa aaagaaacga gccaggcgcg tttgctcacg 14280
ccagtaatcc cagcactttg ggaggccaag gcagggtgat cacttgaggt caggagatcg 14340
agactagcct ggccaacatg gtgaaacccc atctcaactg aaaatacaaa aattagccag 14400
gcatgttggc atgtcctgtt agtccdagct actcacttgg aggtgaggc acgagaatcg 14460
cttgaaacca ggaggcggag gttgcagtgg gccaacatca gtgactgca ctccagcctg 14520
ggagacagag cgagactctg tctcaataaa taaataaaca taaataaaa taaataaaa 14580
taaaataaaa taaaaaata tggaggccag caggcacggt ggctcacgca tgtaatccca 14640
gcactttggg aggcgaggg gggcgatca caaggtcagg agatcgagac catcctggct 14700
aacacagtga aaccgctct ctactaaaa tacacaaat tagccaggca tgggtgcagg 14760
cacctgtagt cctgctact caggaggctg aggcaggaga atggcgtgaa cccgggaggg 14820
ggagcttgca gtgagctgag atcgccccc tgacgtccag cctgggcgac agagcaagac 14880
tctgtctcaa aaaaaaaaaa aaaaatggag gttggcgcg gtggctcgcg cctgtaatcc 14940

-continued

cagcactttg ggaggtcgag gcgggcggat cacctgaggt caggagtcc agaccagcct 15000
 ggccaacatg gtgaacacct gtctctacta aaattacaaa aattagccag gcacgatggc 15060
 aggcacctgt aatcccagct acttaggaga ctaaggcagg agaatagctt gaacctggga 15120
 gatggaggtt gcagtgtgct gagatcgcc cactgccctc cagtagagtg agattccgtc 15180
 tcaaaaaaaaa aaaaaagaa gaaatggaga tacaacctta ctacctacct cttacaacc 15240
 taccctcaca gtattactgt gaataaaagt gtgtgtagca ctgggaacac tattcacaga 15300
 gcaactcatg atgtttgttc ttgtttatta gttactagag aggcataatgt ctgccagggc 15360
 tgaataatat gtgtgaattg gtgattgtcg cacatatcta aagaagtagt tatttttttc 15420
 aattaaaact tagtttaaaa accaatataa ggccgagcgc agtgggtcac acctgtaato 15480
 ccagcacttt gggaggccga ggtgggcaga tcatttgagg tcaggagtgc gagactagcc 15540
 tggccaacat ggtgaacccc tgtctctgct aaaaaaaaa aaaaagtaca aaaattagcc 15600
 aggcattgat gcaggtccct gtaatcccag ctacttggga ggccgaggca ggagaattgc 15660
 ttgaaccogag gaggtggagg ttgtagttag ccgagtttgt gccactgcac ttcagcctgg 15720
 gtgacagagg gagacactgt ctcaaaaaaa aaaaaaaa accaaaacca atataataaa 15780
 taagtggcca gcaatgaac agaaagtga aagttagtga agcaaaacta gtactgtatt 15840
 cagataaaga tgctgaatct agatttggtc accagaatag ggtcctttgt ggcaacctgg 15900
 gctagtttgg ctgactcacc actgccagga tgaattttct ttcagtggct actcatttc 15960
 ctttatttta agtccatgct cacagagcaa cctctctgat cctaattcag cttcctggga 16020
 tacttaataa caggaggggt ctggaagtag tacctgtata ggggatatga gtgttctgat 16080
 ttaatatgac aattcataag tgtacagagg gtttgataaa tggttaggtc agaaccatca 16140
 cagaatgtct acacctcttt ggacattagg aaggtcaaaa acctgaagg ccaaaagcta 16200
 ggctagatt aggggtcatt accaagaaaa catcagcctt gaagagttct ctgggtggtc 16260
 caccagtcaa cttcctttg atcacacctc cttcctcggt gcttctttaa gcattgaact 16320
 gtaatgggta tgggaatttt tgctcaccta actccttctt ttacagagg aagaagttga 16380
 agccagaga gatttaattg ctgacctaa atcacagca gattttctgt taaccagggt 16440
 gatttttcag gtgttccctg ccagacgagg gcttttttcc ttgaattgcc tagagatttc 16500
 ttgagatata cgaagcattt ttccagtgcc agcctggaga aggatgtccc tgtaacaca 16560
 gcatttgta ctcaatgta gacattcaat ttctaatta gtatcatgga gcaacagtgg 16620
 atgattatct ataaggggtt gcaattccat gcttatgtgc ttacagcca tatagacaaa 16680
 tatcagctgt taaaatgaca aggcagtaga gatgtggccc caggacaaa gcatactctg 16740
 ctgttagtga acactagttg gccagcaaat ttcacatggg catatacacg gccaaactgta 16800
 gactttaggc atttataccc attcagagag ccaaaactggc aactaaagat cagcattctc 16860
 tttggcattt cagctttgag ttctgttaaa aatcactgct tgcttaata cctctgtag 16920
 ctcttctact cctgtaggca actcttttag ctacagact tggcttttag tgctctgccc 16980
 ctactctctt ccaccattct ggcctcctgt ctaattgctg cccatattgt ccatgcaacta 17040
 gagcttacag acctgctcag cgttatatga gcataccata ctctttatgc ctacgtgcat 17100
 ttgcacatgt tgttccctca ggccagaatg cctgttactg cctggcaatc agcctattag 17160
 agtctgcaa taccatccca tctctgtgg agggaccccc cgccaaatcc acccatacct 17220
 ctccccacca atcagagact tctctctctt ttgtattct cttcgttatt ctcttcatac 17280
 ctacagttata tccatttcag tatttggtta cacatctagc atcactctta gagtgtgaaa 17340

-continued

ttctccaagt gtggagccgt atctagtttg tctttgtatc ccagagctta gcaaaagtgc 17400
 tagaatgtag tgggtgctca gagtgtttgc tgggtgaatg atgtatttgt tgaacgactc 17460
 ttgggacact tgaataaagt ccatccagta tgcaccatta ccatctcttc gctctacaat 17520
 attcttttag gcaagagctt atcttttgag gtgataagat aagctcaaac ttatgtagac 17580
 taagacctca gtctgtaaat gtcatcccta agtcttaaac catcaaaacc agggcctcaa 17640
 ggaatggcat gccttttgca actgtagcaa cctgctgtgc ttattttgccc gtgtttttca 17700
 tttttccccc aaaagctaga gtcccttctc ccatgggcag tgctggaagt gtgctaacia 17760
 attctttctc catactgctt acgattacaa aaaaaacctc cagcatctca tgcagactt 17820
 gagttaaggt tgttttcttt tgtgtgtcag ctgtattctg gtcagtactt cctgatgatg 17880
 ccctatagag attttgctga gatcagaggg tgctccactg ccatcagtag cactgactct 17940
 tgcagaagca cgtttctga agttggctaa tgtcatccct cagttttgtt tgtttgaaat 18000
 ttgttttagt tccagagata gcactttcat ggaatgacgc tatcttctag aatcactttt 18060
 tttttttttt tgagttggag tctgctgtg tgcagaggct ggagtgcagt ggcacaatct 18120
 cagctcactg caatctccac cttccggggt caagtgttc coctgcctca gcctcccgag 18180
 gagctgttac tacaggcgca caccctcact cctggctaatt tttatgtgtt ttagtagaga 18240
 cggggtttca cgtgtttggc caggatgggc tcatctctct gactttgtga tctgctgct 18300
 tcaagctccc aaagtgtgg gattacaggt gtgagtcacc gcgcctggcc tagaatcacc 18360
 tttttatacc ataacgtgag caccactgcc gcgtcaccaa ggaagagag aggcagctac 18420
 tgtgggttta caaatgggta agagtggcac caggaagggt aaagtctcta cttagccaag 18480
 gcttaacaaa atgtcaatca ccaaacattt atttattaag ctacgttcag gataagaaga 18540
 tgaacaagct atctgtacat tcattttctc gtttgaaca aggtaagtat agtgatctat 18600
 cctgcctgcc tctgaggggt attgtgagaa taaaatgaaa tcaagtggaa aagcacttag 18660
 gaaaaagaaa agcattgggt ttcaattgtt agtgtggatc agaaacactg gggcttgttt 18720
 aaaaatcaga ttcttagccc cagtctcagc gattctgatt ctgtatatct gaagtgggac 18780
 tcaggaaatct tgattttcaa caagctgacc agagggtcca atgtgtctat tcttttagtt 18840
 acactttcag aaatattact gtaaatcaaa tggcaagaat aaaatagtta tttagggcag 18900
 ttttagtatg ttggacctgg agtccaaaga cttgggtcaa actccagctt tgtcagttcc 18960
 tagacctgtg accttaacaa gcaaccttct ctgtgaacct tagttccctc aggaacggct 19020
 ctggtcacct cctgctgtac tccattgatg actcaccaca taaggctccc tgggagctcc 19080
 ccaaaccttt gctctcttaa ctccttttac agcctcctac atctcttgca ggtgctgtct 19140
 tctcctcctt tttccaggcc ctgctctgac acagcatcca ttctcctctg ggaagggttc 19200
 cttcaatgtg tctccaagca catcaccccc aggaaggacc ctgtggccat atctgtctat 19260
 caccagatca aactacgtga aggcaggcac taggtactgt cagtgccag cataggcctg 19320
 gcccatacca ggtgtccaca gatgcctagt aaagaaacct atgattcagg acccccatga 19380
 tgagcaacta tagcactaga acagtataa taactaatgt ttataatgca tcttcagttt 19440
 acagagggct tttgtactca tcatctagtt tagttcctgc aacaacctct tgaggaaat 19500
 agcacaaagca ggacaaggga agccacagga tgttaataa tttatccaag tttatgctgc 19560
 tgggaagggc agcactgaaa ttaaaagaaa agttttctga gtcacaaatcc catgcccctt 19620
 cctcaatgtg agctctagca aggtattcag gaatcctgcc tctacagttc agagcctcaa 19680

-continued

attgctgggt atgttgagtt cttgtatctg atttttctag atttctgcc cacattctta 19740
 ctgctcgat atcaggaaag agtttatcaa atgcctgtgg aaatccaaga taagggtcca 19800
 tgatgagtaa ccagtgaaa acatgaagtc aagtcctaact agtcactact atttactac 19860
 tgctgactcc tgatgatcag ctccctttct aagtgtctac tgccactta ttccatcac 19920
 tgcctagaat ttatgtgaag gaatcaaagc aaaaggatca taaggcttcc tttttccagt 19980
 atgttttttc tcccttttga aaactgggcc agttagctat ctccattttt atttcatgaa 20040
 tacatcccca gcgcctggta tatagtagat atggaacatt acactttgga gatattgcac 20100
 ccattctcca gtttctcaa agttactaac aatggttcca tcactgtgcc aacatatttt 20160
 ctttttcaa tatattggga aataattctc ccagtctgaa aatcgaaca catttcatgt 20220
 gacttggtat cctcatatgt cttgggcttc caattctcca ttctagtgtt caagttcatg 20280
 aactgtaaaa caaaggatta gactaaatct cttaaagtct atccagatgc caaattcttt 20340
 tctctttcca tgatacctaa gatagatgcc aaatattgtc tttacctgg tgtttgtgaa 20400
 catgacatca cattacagga gtagcagata ctaaactctc actctgtaaa acactgactg 20460
 agttccatga gccagatact gaagtgaact tgttcacata tgttctcatt taatgctcat 20520
 aacctgtgta agctgggaat tgctgggaca tttatttat ttattattg agacggagtc 20580
 tggctctgtc acctaggctg gtgtgcaatg gcatgatctt ggctcaccgc aacctccgcc 20640
 tccccgggtc aagcgattct cttgcctcag cctccgcagt agctgggatt acggggcaca 20700
 caccaccaca tccagctaatt tttgtatttt tagcagagat ggagtttctc catgttggcc 20760
 aggttggtca cgaacacttg acctcaagtg atctgcctgc ctccagctcc caaagtgtcg 20820
 ggattacagg catgagccac catgcctgcc cgggacctt gttttagaag gatgactgct 20880
 gctataatgt agaaagtgat ttggaagagg ggaggagtgg ggcacgaaag atggtagta 20940
 gatgggggtg gtaatgctta ctttcagta tttggaggct tcggagtcct caaaaattct 21000
 ctctctgat tggagtcctc ccagccaata gagggcttca cacaacagt ttcttgggtt 21060
 ttgaattgtt tgaccagagc tttctccga caaaagggtg ggggtattca ttcacttacc 21120
 acacettgcc tgaacattca cttggggctg ccgggttatga aggtattgt tctccagct 21180
 gtcacagacg ctttgaagac ctgtgcctca gctggttcta aggagtcagt ttgttcagct 21240
 ccgtgccag tttccaact atgaaatgtg ctggagatta acacctctc tgccatttta 21300
 tccctactat aattgccagt caaaggatc ctgcagttgc ctctggcagc cataactgat 21360
 gaatgttctg ccagctgctc tgaggacctga gaagagcagt tttctatcca ggaccagttt 21420
 ccaagggtgg gagggtgaaa tatatcctcc agtgtgacat ttcattctcc agtgatgggt 21480
 ggcttgggcc ctttgaagtt ggctctgagg aaccacacac ttgggtctga gcagccagca 21540
 gcttatcaca tctggtgatc aatccttcaa aggttctctc tgaagtctga atttttggag 21600
 gtcaaatgga ttccacctgg gaggggcttc gcttcaact caggacatgg ggagaaggct 21660
 gttctcttc cagggggagg cagttttcat ggcattgaga tgctcttca cttattcccc 21720
 acccaccac caagtcctt gtaagaggag tagggggaga ggagagcgc tgcagcctcc 21780
 tgctcacatt cctagacacc gactcaactga gcccgctgcc gctggaacag cagagctgtg 21840
 tgaatgtca agaggagta tgctcatagg ctccctggcc tcagtctctt tgtggcttgc 21900
 atattcttcc attagtactg tgttcacac atggaaatca gaggttaca ttaaaagata 21960
 atttgctagt ccagactta atttggggcc ccttcttgc ctgattgaat tacaggggaa 22020
 cataatagat ttttggtag aaatagttgt ctgtgtggct gggagaaaga ttgctcccag 22080

-continued

ctctccagct gggcagccct ttcagtatcc cgtatgttat tccccactt ccagcccacc 22140
tcacctctc tgtggccctt gtgtgtcccc tcggctagga tcctgacctc ctgctcaaga 22200
gtttaaactc aaacttgagc ccaaggaaaa tagagagccc tctgcaacct cataggggtg 22260
aaaaatgtg atgctgggag ctatttagag acctaaccac ggcccagaca gagagagtga 22320
cttgctaaag gccacatagc tagcccacag tagttgtaac aatagtotta atgatattaa 22380
tggctaacat ttatcaacct ttaatgtgtc ccagactttg tgccaagggc ttacatgcag 22440
tgcatgtcg cattcaaac cagacagtct ggctctgggc ccaggctgag ctttggtata 22500
gcatggtaga acgttgtcta taatgtctag tctgggttca aatcctggct tcacttctca 22560
catttacagc tgagtgcct caggcaagtg atttaacctc cctgtacctc agttgcttta 22620
tctgtaaga gaaaatcac agcactgtgg aatagtggg gttaaaattc attcatacaa 22680
gtagtgtgc aagcaatgtt taatacaggg tgagcacctg ttcagtgtt ccttctctg 22740
gctgcctctg gggctagagt gtgtgtctt cgtggtatag atagatagat atggctgagc 22800
tctgcacaaa cacaagagc tgttcttcac tattagaggt agtaacaga gtggttgagc 22860
tctgtggtc tagaacagag gccggcaagc tatggcccat tgcctatatt aatacggcct 22920
gtgattgatt gattttttt ttctttttga gacagagttt cactcttgtt gccaggtg 22980
gaatgcaatg gcacgaactc agctcacgcg aaactctgcc tctgggttc aagcgattct 23040
cctgtctcag cctctcagat agctgggatt acaggcatgt gccaccgcg ctggctaatt 23100
tttgtatttt tagtagagac agggtttctc catgttggtc aggctagtct cgaacttcca 23160
acctcaggtg atctgccgcg ctacgccttc caaagtgtg ggattacagg cgtgagccac 23220
catgactggc ctgattgact gattttttta gtagagatag ggtcttggtt tgttaccag 23280
gctggtctca aacttctggc ttcaagcagt cctccctcct tggcctctcg aatgctggga 23340
ttataggcat gagccactat gcctggccta tatgacctgt gatttttaat ggttagggga 23400
aaaaaagcaa aagaatgctt tgtgacatgt ggaattaca tgaactcaa atatcaggt 23460
cccagcctg gcaacaaagt gagaccctgt ctctacaaa aataaaaaa aataagccag 23520
ggcggggcgc agtggctcac acctataate tcagcacttt gggaggccga ggcaagtga 23580
tcacctgagg tcaggagttc aagaccagcc tgaccaatat ggtgaaaccc tgtctgtact 23640
aaaaacacaa aaattagccg agcatgggtg catgcccctg tagtcccagc tacttgggag 23700
gctgagacaa gagaattgct tgaacctggg aggcggaggt tgcagtgagc caagatcgcg 23760
acactacact gcagcctggg caacagagcg agactccgac acagcacgc acgcacacac 23820
acacacacac acacacacac acgctgggta tggtgccag cacgtgtggt ccaggatgc 23880
actggaggct taggtaggag gatcacttga gcttaggtg ttgagactac aatgaacct 23940
gtttatacca ctgcacttta gccagggcaa cagtgtgaga ctgaatctca aaagaaaaa 24000
aaaaaaaga aaaaatctt tccataagta aatatctgtt ggaacatagc catgtccctt 24060
agtttatgtt ttatatatgg ctgcttttgc cctataatga cacaattgag tggccacgac 24120
agtctgtatg gcctcagag cctaagatat ttgctctctg gccctttaca gaaaagtgc 24180
cttgacctgt gctctagagc catatgtacc aggtttgaaa ctacgcctca cagctgggtg 24240
tgatggcagc catctgtagt ccagctact ctggaggctg aggtgagag atcacttgag 24300
tccagaaggt cgaggtcaag attgtagtga gccatgatgg catcaccgca ctccagcctg 24360
agtgacagag agagaccctg actcaaaaa aaaaaacaa aaaaaaaa caccctcacc 24420

-continued

acttatcagc tatttgcctt gagaatagtg acataacccc tcagaacctt tttcctaate 24480
 tgttaaatga ggctgatgac gtttcctcct tttactggca atttaaacat gatggataat 24540
 aaatgctaag cacttaacac agggcctaga agatattaac tgctcaataa atggtagctt 24600
 cttaacagta ttcaaaccca tgtgctccta tcacatgcat tgttgtccct gtgtccagtt 24660
 ggtggaatgg gaaaaggctc ccttgtaacc ccatctacca tctttatcag actttcctgc 24720
 catggttcac agtaagagat agaagctgca cggtgacttc tggtcttta caatggtgag 24780
 cgggtgtgtc ctggttaagg agagctgatg tcactgcccc aaatccagta gtgagatctg 24840
 agtgttcttg tttcctccag cagccttgct ttttcttta caatcctgca ggcagggaga 24900
 caaggccttt ctacatggtt ggctctggtt tggctatcgt cacaactggg ggctgttcag 24960
 gtgggtcccc attccagata cctaggttta tcaatccctt ttggcacccc aggccttttt 25020
 ctccctcatg ccccatTTTT cagtttgaaa agcatgggta tcacaggaca agtagaagaa 25080
 gtccactgt cactgaggc caatggatgg tgtctgcat gtgaacactc agtgaatagt 25140
 gagtgaatga gactaacctg ggctccatcc tatttgaga gagcttggg aaagattttt 25200
 ctccctaaag agccagaatg aagcctggta gtgggagagc tccagctcta gagtcacatg 25260
 agcctacatt taattccag ccctgccact gactccctt ttgacctga gtgagttacc 25320
 taatctctct gtacctcact tttctgtct gttagtggtg aataattcct gtctcagaga 25380
 aataaaagag tgcatatagt gtttgccaca tggagacaca tcagggtgtag gtttaactc 25440
 tgggctcttg ttccttattt gcaacacagc cctgccctgg agtggaagtg gcacctccca 25500
 ttggtcagct cttgaggctg tcccaggac aggcagaggg aggggaatga tgggagccct 25560
 agtgccagga cagaacagat ggcagctcag agctaggatg gctctctgga cctgtctctc 25620
 ctaccagagg tcccccgct tgggtgtggt ctctcctggc ctggcatcct ctgctttttt 25680
 tttttttcca cctccaagca gaattactgt cctgtaggca gctcctctgc ttgaggacat 25740
 ctggggccag atatgttcac actctatcct gccttgccct tccctgagct caggatggac 25800
 gctcaattgg tcccagttat tgtctgcagc gcctgcctgc agcctcgatc cagccagct 25860
 ccacccttg cctgcaaggt ctgtttccta acagctgctc caaccacaca cctcggttct 25920
 gcgggagccc ctctcttcc tccctccctc cctcattoag ggggtgggact gaagaagaag 25980
 gctaacttga cagcagcgt tctttcttag ctatgcaccg gccctgctc aagaatgcca 26040
 gtgtgtgtgt agcctccaca gagaggtcgt tttctcgag tccagagggg ccgcctgagc 26100
 ttctgagAAC tagggaggag ccatccacag catgagcccc tgtgggaatc tgctgggggc 26160
 caagtggcct ggagtcctca ggctcccgca gctgctccgg agggagaggt gagctcaggg 26220
 cagcctgcct gcagccagag gtgcccggag ccccgggcct gtcattggtg ccatctacag 26280
 ccggcctgag gcagtcacag acggatttgc agctgagcct gtctatctgg tgtgggaaga 26340
 agatggggag ttactgtca gtccccgctt acttcacctc cagagacctg tttcgggtgag 26400
 ttggtctcct agttccctc tccatctctc ctggccctg gtcctgagag gaggggtggtc 26460
 tccctaaatc tctttctc ttagtccttt accatcggtt ctgcccggca gaagccagcg 26520
 gaggttatac ccaaggagaa tcggccttgt gaggtacccc cattatgtcc tggaaagtgt 26580
 gaggggaggg atataccag aaggaaactc ttagggagct ccagctcccc ttctatccca 26640
 gacaaacctg aaggagcctc caaaagatgc cactgacctg cccattgtag atgttactgc 26700
 ttccgggggg aatagcccaa atagagtgtt gtttccagct ctcacatgtc ttacctgcgg 26760
 gccatgctgc ctgcccagga atttgcctca acaagcagga tgggcagggt ttgcccact 26820

-continued

gtggaaactg gcaagtcctg ggtgtgggta gcctgggtaca cagtaggcac cttataaacg 26880
tttgttctct taatggcagg cacatttgcc tctggccttg aagggtctct gagtccacg 26940
gtgaatgtag ttgctgggga aagacctggg cgagtgttct taagactgga gcaatgggct 27000
ttagagtgtt cctgagctgc tgggccagcc cccacacctc ctcagtcctc aggcctaagt 27060
acctccacga gcctctctct gtggggcttc tcagagggag atgtggaaac tctaccteta 27120
acctggcttt ctttgcctat tgccccactc cactctccat agaaactccc caggggggtt 27180
ctggccctct ggggtccctc tgaatggagc cattccaggc taggggtggg tttgttttca 27240
ttctttggga gcagcctgtt gtcccaaaa ggctgcctcc cctcaccag tggctcctgt 27300
cgacttttcc cttctggctt ctctaagcta ggtccagtc ccagatcttg ctgccgggat 27360
actagtccag tggccaggcc ctgggcagaa aagcagtgt ccatgtggtt ttgtggaatg 27420
accggaccct ggtagattgc tgggaagtgt ctggacaggg ggaaggggga aggggaactgg 27480
tcctcaatgc tgactctacc aagcgccctg ctgacactt tatectttaa tctctcaaca 27540
gcctaaagag attatatatc cccattttac agatgaggca accagtttca acagagttaa 27600
catatggagg ctactgggc agctttttct gtcttctga ctttctctca tcttcaggg 27660
ggctgcaggt ttgttttctt ctctagtgg agaggaaatt ctcaggtttg ttttctctc 27720
ctagcagaga gtaaaaaaag ggatagtgtt cctgacttgt tgaagggtg gctgagattg 27780
ttttctaaag agccaatgga aattgatctt gagtttaga gaaagctttt acatgtggaa 27840
ttaagatgcc aagtgttgaa gtagccacat ttcaggctct cattaatttc tcttaactct 27900
gggaaggcag cttaggagaa ggggtgttcc tttaggagcc aggaactata ccccttttac 27960
ccttgagagc gcagggaagc caggaggagc acaacttctc aggaagagga gaagctagag 28020
cagatagtga actctcaacc tgaaccttta agggccagac cactaatgcc acccaagtcc 28080
acctgcctgt tgtcttgttc tgtccaggc tttctggaga acctgatctt cttgcccta 28140
cccccaagct ccgtttgccc agctagagtc tgggggttac tgactgactt tcgtagacat 28200
tcttcccttc cccaaataag agggcacatt cctgaagtca cttctgaaga gatagctgcc 28260
acacagggct ctttccccc agggagggac caccagacc ctctgctctc ccaggtatcc 28320
gttaccacat cactacctgg tcagaaagct gtttctgcca ttagccctc cctctttat 28380
tataggatat cctcaagggc tctcttttg gcctcagttt catccttggc agaaagtaga 28440
agctagactt cttgggtccc tgaacagggt ccttgcctga ttctgtgaaa caaattaagt 28500
tcttgaccct aggcctctgg gggagtacaa agtctatggg agttctgggg ctgtggttc 28560
aaggaaagtg acgcaaccag attccatggg gacatgatca ggcgtgacat gtgaggggag 28620
aagagggagc aagggaatga agaatacaac ttctgtgtcc catacaccct tgcctgacag 28680
gocatacata ctacagagag aatgcactgt ctttccctac acactagcgt gaggagttag 28740
ctgaatttac cactgtgctt ccaagtaaga aaatacctca aattggaatt taaaaagag 28800
gtaaattagg gagtggcttt tgtcggacat ctttaaagca ttttctttt tatagaattt 28860
cacttaatat ccaatactga tttaatgagc ttgggtttac acattatctc ttgaagaaaa 28920
caaatgaacc tttgtgttcc aaagcaatcc atgtttaag ggaataaatt atgcataact 28980
ctgccagct tcacagtaac ctttggcagg tgccctagggt cctctgggac tcttttctt 29040
atctgaaaaa tgaaggactt ggatcagggt aatgggtccc agctctgcaa cttatgtggc 29100
tctcagagg cacacaagct cttttccatt atttgccaaa taatggaggc cctgtcttta 29160

-continued

actgcagtagc aactacacaa aatacttgaa actacagtct tcctgggttt tggttggaac 29220
tgaatcagtg cactctagca acacttattt ctgtctgttc gtaggcttca ttatgtgttt 29280
ggtaattttt ttaaaacaac aataacatat tcataataa ttacagctta attggcagac 29340
tgtttcagtc tataggatct gcaggaagga ggagtaataa agggattttt gactgagctc 29400
ttatggaaca gagtctctct aggccctgt catatctgcc cttctgggcc ctggggaana 29460
gttggcatcc ccagttgttg tgctctccag gtgccctcag gctgtggttg agggagcttc 29520
ccattctctc cttcagccca ctcaattcag aggctagggg ctgaaagaag cttctctaca 29580
actggtgttt cactgggagg ttaagggatg accatccagc caggccttcc tcaggacatg 29640
ggagggctta tgctttaaca tgtgtaaac cactgcaata atgactggtt cttttacccc 29700
ataaggttga gaatttacct gtaaacattt ttgtctgaag aatttgatg taagtgggg 29760
ctgggcctct atcttctctc acttggtctc tctcagcaca gcaccttccc tgctgttct 29820
tacacatcct agatgcacag taactatttc ctaattatta gaaatctatt agaataatt 29880
gatttcagct gggcttggg gctccttctt gtaatcccag cactttggga ggtaaggct 29940
ggaggatcac ctgagtcag gagtttaaga ccagcctggg caacataggg agaccctgtc 30000
tctacaaaaa ataaaaaatt agccaggcat ggtggtgtgc acctgtatg ccagctactc 30060
aggaggctga ggcaggagga tctcttgagc ctgggaggtc agactacagt gagcaatgat 30120
tgtgccactg cactccagcc tgggtgacag agtaagactc tgtctcttaa aaaaaaaaaa 30180
aaaaaagtgt atttctattt gtagatagaa ataattcatt ttaggacctt tctttttcac 30240
ttacagaaat ctgtttcatt ctgggctgag aagcaggtcc atattgctag gcataggaga 30300
aaaaaggggtc tgtctgcatt tgcccttggg ggtctcaaat tggggaggga aagaatgaa 30360
cacttactgg ctaccttctg tgagccaggc atcatgcaag acatctgtac ataattaat 30420
tctcataacc cctaagata ttattagcaa tgtacaagtg aggaactga ggctcagagt 30480
catgaagtaa ctggccttgg gtgacacaga tggtaaatg cagagaagga atatggatcc 30540
aggtcttgaa agagaaaatc tcaactgatt atctttttta aaaaactcat atgttctctg 30600
ctgactcaaa aggtctctgt gtggtatctg gttgaccac tgaactgacc atcagggttc 30660
catgcacttt gtatctgccc aagccctcag aacccctcag taatgttttg gaagtgagt 30720
tttgagggtt gtccttaggc atagcctcag cgtatgtagg cctctagggt atctccccta 30780
acctgaggtt ttcagctcaa ttcactctg ctcctcagga cagtgggatg actgggtcag 30840
acctcagctt taccacctcc cagctgggta ctcttctacc tacagccagg gcagattttg 30900
actttcactt gaaacttcca aaaattgaaa ggtagaaaaa cagccttggc tttgggaaga 30960
acgtatgatg tccatggcct ctaagcatct gaggtgggac atgttcgagt agcaccttac 31020
agttccaaa gtgttctctg gttctttgtt taaaagaaca gagactgctg ggaattgaa 31080
cactgtgaag tatatgaagg aggagaattg tgctatttaa cattcagtag ttgggctaaa 31140
ggagaagcat cacgaagtgt taacactcaa aggggtcttg gctgtcaggg ctccagcttc 31200
cttattttca caggtgagaa tcctgaggct cagctgttga gatgtgctgt ctcactccgg 31260
tgacatagta cagtggatgt ggctttgcag ccaagcacac atagcttcac attccagctc 31320
catcaattat gtattgggca gctttgcaga atgatttgac ttaactctg cttttcagtc 31380
ttctgtaaaa caggataat cctgctaccg taggggtgtc aggattagag ataataaaa 31440
taaggtagct catataggac ctggattatg gctggcattc aataaatagt agctgttaat 31500
tgatagctaa gctagaactc tgaagtctac catggcaact tcttaagtgg tctgagaacc 31560

-continued

cagttgtgtt ctgtggcaaa acacagctta gggatccata cccagccctc ctgtcagctg 31620
ttcaccttcc agttcttcag agacatgtgt ggcagtgaat ttggccacat agctggctgt 31680
gccctttaa ggcattcctt gacacagata tgtggactgg tgacgttctt ctccagccag 31740
gtgttcttcc cagcaggctg gcctggctgt ctctgcatg cctgtacttg tttgtctccc 31800
tgctccctct cctgggcctg gccagagcta cttgcagcaa acaaaagcag gatattggca 31860
atgaaagga ggggtgttct tgggtctccc atgccctgcg gcgcacatac cattgcaagg 31920
gcgtaacaga gccaggcctt gcatttgggt gcaataaagt ctgcacacag aagaaaagaa 31980
ggacctggtg accaggagcc atggaacctt tgtgtctccc tacctgggct actggttctt 32040
gccactctca ccattttcag tttggaata tttgttaagg ctttgcctt ccaggctcct 32100
tgcttggctg tgagtctacc aagagtaagt gggatgctgt ttttgcctc agggagctaa 32160
cagtctagt aagaagaaag atggtgtccc aggaacttct aagtcagaag gcaggaggca 32220
agaaggaag ccctgctcct actgccagcc ctctgttggg caccocatag ttcttcagaa 32280
ccacatttaa tctcactgc aggccaggca tagtggctca cactgtaat cgcagactt 32340
cgggaggcca agggggcag atcacttgag gtcgggagtt cgagaccagc ctcaccaaca 32400
tggggaaacc ccgtctctac taaaaataga aaaattagcc ggggtgtgtg gcatgcgcca 32460
gtaatcccca ctactcagga ggctgaggtg ggaatatcac ttgaactcgg gaagcagagg 32520
ttgcagttag ccgagattgt gccactgcac tccagcctgg gcgataagag caaaattcca 32580
tctcaaaaaa aaaaagaaaa aagaaaaaat cctcactgct accttgaaa taggtgatga 32640
cattgccatt tcacaaatga gaagtgaagg ggctagccca agatcactta ggtggtaaat 32700
gggtgtgcta agattagaac ctcagatcat ctagggaana acacagatat gcacagagtt 32760
aaggggaccc aggggtattgt ttgtctctt ttttcacagg tggggaaca acccagagag 32820
ggaaaggggc ttgtccaagg caatttagca cccaagaact tgaaccata tctctctcct 32880
cctcatttag agctcatccc acatgtatct tatattgaga ggagtgtgag ccacatacca 32940
agaacagtct tcccctctgc ctccaacctc actgtgcagt tttgagacac ttcacagcca 33000
tactctcat gccataccca gcccttaaga cctgaagtt ccccttccat aagacaagta 33060
ggaaaagcta tagggtaaaa atagccatca gtgtttgttg agcaccagag aggaattggg 33120
cactccagaa agataaaggg attctcaggg acttgcttct ctgacttcc ctagctcagc 33180
tgcttcaact cattctctgc cctctctct acctcccga gtgctcagaa gtagtagaac 33240
tcactgtggc ctctcactt gcattgttga gttttattta gactttctt tctcaactc 33300
ttcataagct catgaaaggt gaagttaggt gccctgtgta tttatcttt atatctcag 33360
tgcttagcaa gttataataa tgcacttgcc tggcaaaagg cttctctca tacattagct 33420
tattctctct tcacattggc tctttgtagt aataggatgc tattagtat tttcaatgag 33480
agaaagctac taagagaagt gtgccagcta gtgacagtaa gtggctgata aagtgaagctg 33540
ccattacatt gtcatcatct ttaatagaag ttaacacata ctgagtttct actatattgg 33600
gtctttttt ttttttttt tttttttta gagacggaat cttgctctgt tgtccaggct 33660
ggaaagcagt ggtgcaattt tgggtcacca caacctccg tcccagggt caagcgattc 33720
tcctgctca gccctctgag tagctgggac taccagtga cgcaccacg cccggctaatt 33780
ttttgtatt ttagtagaga cagggtttca ccatgttggc caggctggtc ttgaactcct 33840
gacctgtga tctgcccgcc tcagcctccc aaagtgtgg gattacaggt gtgagccacc 33900

-continued

gcgcctgcc tatattagga cttttatata agctatctct agctagctag ctgctagct 33960
ataatgtttt ttgagacaga gtctgactct gtcacccagg ctggagtga gtggcgtgat 34020
ctcgactcac tgcaacctcc acctcctggg ttccagtgat tctcctgctc cagcctccc 34080
agtagctggg attatagggt catgccacca cgccagcta attttttgta tttttagtag 34140
accaggtttc accatgttgg ccaggctggt ctgcaactcc tgacttcaag tgatccaccc 34200
gcctcgctcc cccaaagtgc tgggattata agcataagcc actgtgcccc gctgctctct 34260
atatttttta tacatattat ttccattaat ttccacagca gttcatttta tagatgagga 34320
aactaggcca gagaagtaaa atatcttgcc caagatgatg taactagtaa gtggcaggat 34380
caagattcaa accaagcaat gttcaaacct cttggaagca agaattgggc cactgtggaa 34440
ggtgcaaggc cttgacaaca agaattagga aaagaaggaa ctagaaggaa agagatggca 34500
tgggctcagc agggcaggga gctcctagct gtgtgtgttg ggaagctcag aaggaggaa 34560
gaggttgtct gtgcaggtaa gtcctgagaa cacaccagac ttttgagagg tggagcttca 34620
tagccaggct attaggggag aaggagagta tagatTTTTT tttttttttt 34680
tttttttagc agacgggggc ttactatgtt gccaggctg gtcttgaact cctgggctca 34740
agtgtcctc ccaactcagc ctcccaaagt gctgggatta gaggcacag ccaccccgcc 34800
cagcgagcta tggatctaac atgtacatct tacacagtgc taatagaatg ttgggtttct 34860
tccccaatat tttattttga aaaaaattc aaatatatag aaaagttgaa aaatgtagtt 34920
caaagaacac ctacatacct ttacataga ttcatgattt gttaatgta tgccactttg 34980
tatatatctc tctccctcct atctgtatac ttttatttat ttatttttgc tgaactattt 35040
cagagtaact taaaggcata ttgattttac ccttgaacag ttcaatatgt ttctgctaag 35100
aattctccta tataagtcag atatcattac atctaagaaa attcacggca attttacaat 35160
ataatattat agtccaaac catatttctc cagttgttcc aaaaaatgtt catggctgtt 35220
tcctttttta atctaattt gaatccaagt ttgaggcatt gtatttggtt gctgtgtctc 35280
taggggtttt aaatctgtg ccttttcttc tcccatgac tttttagaag agtcaagacc 35340
ggttattctt atagaataac ccacattcta gatttgctg attagttttt ttatacttaa 35400
cgtatttttg gcaagaacat tacattgga acgctgttgg tgatgggtoa gttttgaaga 35460
gtggagatga ttaaactgct tttgttcatt gaagtatctg tcaagaccag agatccttaa 35520
ctggtgccat aaatagttt cagagaatcc tttatatata caccctgtcc cccacctaaa 35580
ttatatacac atcttcttta tatattcatt ttctagggg aggtctcttg gcttttatca 35640
aattctcaga gggcccaag acccaagag gttatgaac actagtctgt ccactgaggc 35700
aggcaacaca gagctgggtt ctggggcctt gttcagctg aaccagcttc ccttggggag 35760
atagcacaa gctgtaactt tgccccatct tggctttgga tcaaaggaga ctgtccattt 35820
tgttgtcata cctaggaacc agggacagct tatgtggcct ggttccagg atccaggaga 35880
atttcagttc ttgtcttgc tttcaggtgt tcagaatgcc aggatccct caccaactgg 35940
tactatgaga aggatgggaa gctctactgc cccaaggact actgggggaa gtttggggag 36000
ttctgtcatg ggtgtccct gctgatgaca gggcctttta tggtagtga atcccttcct 36060
atctgcccc ctgtgtcttc agagtccatt gacagtgtt ccagttccct gtggcctgtt 36120
aatcttttag tctttccatc agccaggga tctcccttta tttattcatt cattcaacta 36180
gcaggatata attgagcacc tactaagtga aaggtaagat ccttccctca aagacttaat 36240
agttgaacgt tgggagtggt aggagaggga ggcagagagg agacacaata tagttggata 36300

-continued

aggacctcca aggagagtgt tacaggctga gaggaggata tacttaggtt gtcttaggg 36360
aatcagaaaa ggagactctg gaataggctg gcagagagag gggctacctc ctataacctg 36420
tctggacaaa cgactttaag catagtga caatttccaa cctgtattg gaagaactga 36480
tcttttttag tggggatgat tacttctggg gatttcttct cataactgag accaaaacag 36540
ttttgtgcag tctcagaaat gacaggaggt accaatctga cacttccttt ggaagctcta 36600
gggcagagag tgaagagtgt gattttgacg ggggccttgc ttggaggcca ttcaccacc 36660
cctgtcctca ctccagcaac agtgataact cacttccttc ctcccttctg acaccctct 36720
ccccacctgc tcacaggtgg ctggggaggt caagtaccac ccagagtgtt ttgcctgtat 36780
gagctgcaag gtgatcattg aggatgggga tgcatatgca ctggtgcagc atgcccct 36840
ctactgtaaa gatagtggtc ctttgtctat cctctcccat ataagagtgg ctggcgggga 36900
gggcagagtgt cagggtagt tgggcagaag gagtgtaggt gtagtcagag cattggattc 36960
ttaccacagc agtgcctta accagctctt taactgttaa gcagaatgat ttacacatgt 37020
ctctacctt tttcttacc aacctgaaa atgtcttcac tctgcctgc aatcctccca 37080
gtgggaggga ctctcaagg acgatccag aacattaaag tcaaagacc cttagagctc 37140
acctgtcca accaccttg ttgataaaag aagtcagcct ggggcccatg gaatagaata 37200
gtacaagggt aaggttctca ttgtgagtc aaggtagagt gaagagaacc cagaccatct 37260
caccccaacc caggccagt tttttccaaa tataccactt gctgcagatc tagctcagca 37320
ccccagctcc cagcccccag tgagaacca ggctcctcat tctgagcagc cagctagaat 37380
catgacaaa aggggtgtag tgagactatg ggtactgtt cttaaagcca catggtgcag 37440
tgggtgctgg ggggctctg tgtgggactc tagcatctta tccccctg tgccctctcc 37500
ccagtgggaa gtgccacaat gaggtggtgc tggcaccat gtttgagaga ctctccacag 37560
agtctgttca ggagcagct cctactctg tcacgctcat ctccatgccg gccaccactg 37620
aaggcaggcg gggcttctcc gtgtccgtgg agagtgcct ctccaactac gccaccactg 37680
tgcaagtga agagttaag ttttgagaac ccttcagcag ggggtcttga gcagagtctg 37740
taaatggggt tcagagggt tagacctcca aagtctcat cagaactccc ttattctca 37800
tctcatatct tctcctgga cccactatg ctgtaacgt acctgggctc tggcacttac 37860
tgttctctct gccaggtca cttctaccc gatacttaag gcaagaatca ctcccttcc 37920
aggtgtcagg tttcaggtca tgtttgtct ttgaaatcat ctggcttgat tatgtgtatt 37980
agtgtttat cttctatccc ctccactaga atgtaattc cagaagaac ttgctgtctt 38040
attcagtgtc gcatgccag ggcttggag agtacctggc atatagtagg agttgattga 38100
ttattatttt gtcagtcgag agaataatg gagaaaatgt ggtccatggc ccaaaagaag 38160
ttaagacct atcctagatt caggccagag accagatgga gaaagagtct gtgtctatct 38220
aataccagta atgtctgacc tctggccgct taccatgtaa atattgattg tgtatctacc 38280
atgtgttga cactaggcta gtgcttgac agcaggtgaa agatactaga gtttgggaag 38340
tcaggaggag ctaaggtctg ttctacaacc ttattagatg aagaggagag ggaattgtgt 38400
tcagggcaga gggagaagca tttctccaaa agtaggagtc ttaatcatgt ctgatgtagg 38460
ttgagtgtgg ccagaaaagg ggctgttaag tatagagggc ctggattatg aaaatccagc 38520
agatccattg agagttaag cagcaagggt ttgtgaccaa gttacattt tagaaggatc 38580
actggtatgg aggttgatt ggagagggga aagcctaaag gtatagagac tagttaggaa 38640

-continued

gctattgtag gctgggcatg gtggttcacg cctgtaactc cagcactttg ggaggctgag 38700
gtgggaggat tgcttgaggc caggagttga agaccaacct ggccaacata gcaagacccc 38760
gtctctgttt ttcttaatta aaagaaaagt ccagacgtag acatagtggc tcacgcctgt 38820
aatgccagca ctttgggagg coaagggtgg cagattgctt gaggtcaaga gtttgggatt 38880
aggccaggcg cagtggctca cgctgtaat cccagcactt tgggaggccg aggtgggagg 38940
atcacagggt caggagatca agaccatcct ggctaacaca atgaaccccc gtctctacta 39000
aaagtacaaa aattagccgg gcatggtggc ggacgcctgt agtcccagct actcgggagg 39060
ctgaggcagg agaattggct gaacctagga ggcggagctt gctgtgagca gagatcacgc 39120
cactgcactc cagcctgagc gacagagcga gactccatct caaaaaaaaa aaagagtttg 39180
ggattagcct ggccaacatg gcaaaacccc atctctacaa aaagtacaaa aaaattagct 39240
gggtatgggt gtgcgcgctt gtaatcccag ttactcagga ggctgaggca tgagaattgc 39300
ttgagcctgg gaggtggagg ttgcagtgag cccagatcat gccactgcac tccagcctgg 39360
atgacagagt aagatgccat ctcaataaaa aattaaaaac aaagttaaaa aaaaaaatag 39420
aagctattac cgtgatccag gtaagagatg tgaataacta caatgatgga aagaaggcag 39480
agttcttaga gatgggagta ggagagatga gggaactcca gattgggaag atgatgttca 39540
agttctggc ttaggccaca gggtgagtg caattccctt cactgagatg gggcatcctg 39600
gaaaagggtg tgctttctg tgtgggtatc ctgggcccct taggggccac tggtggcctg 39660
ggacctggta aaccttcctt gcacaagcag aattgggtcaa gcagggtttt aggacatctt 39720
tacctgcct caactctgtt ctggcccagg gtcaaccgga tgccacatcag tcccaacaat 39780
cgaaacgcca tccacctggg ggaccgcac ctggagatca atgggacccc cgtccgcaca 39840
cttcagtggt aggaggtaga gtgtgtgtct aatctgtctt gtgaggggtg gacatggaac 39900
agatcctctg ggaaatcagg ctgtagcctt taccttttcc tacccccagc ccactctctt 39960
gtcttagcat tgagcctgtg accactgggt acctatttca gcgtaacagg tteccagggt 40020
agcagggatg gttgatggac gggagagctg acaggatgcc aggcagaggg cactgtgagg 40080
ccactggcag ctaaaaggca ccattagaca agttgagcac tggccacact gtgcctgagt 40140
catctgggtt ggccatgggt ggccctgggt ggggcagcct gtgggagcct tatactgtct 40200
ttggccacag gtggaggatg caattagcca gacgagccag acaactcagc tgttgattga 40260
acatgacccc gtctcccaac gcctggacca gctgcggctg gagggccggc tcgctcctca 40320
catgcagaat gccggacacc cccacgcctt cagcaccctg gacaccaagg agaactctga 40380
ggggacactg aggagacgtt ccctaagggt ccacctccca cctggctctt gttctgtcct 40440
atgtctgtct ctgggatgaa gctgagctgg ctttcagaag cctgcagagt taggaaagga 40500
accagctggc cagggacaga ctatgaggat tgtgctgacc cagctgcccc tgtggggatc 40560
acagtttaca gccagagcct gtgcggaccc agctgtctgc caggtttcct tagaaacctg 40620
agagtcagtc tctgtccact gaactcctaa gctggacagg aggcagtgat gctaaacctt 40680
gaagggcaac atggcctatg gaaaaagcat ggagctcaga gcctggagta cgggcacaga 40740
taggattgaa taaattgtgt agaaagactt tgaaaacaat aaagcaaaag atgaatgaac 40800
gtttttttta gacttgaggg accaacaacc cccaaacccc agattctgcc aggtccatgg 40860
ggaaggagaa gttgccttga gtggaagccc caagtaggga gacttacaga aaagaagtca 40920
agagcactgg ctcccaggca gaaatactga taccctactg gggcttcagg ctgagctcct 40980
cccttcacaa atcacttcat ctctctgagc ctgtttctgc atctgtgaca taagatggta 41040

-continued

agataaagggt ggctgtctca ccaattatgt aaggattaaa tgtggaaaag gacataaagt 41100
tgtatagtgc tgccataggg acagtgttca gtaaacgtga cacattctta gtatcactaa 41160
gaatcagggt cttggccagg caccgtggct catgcctgta atcccaacac tctgggaggc 41220
ctaggtcggg ggatggcttg aacacaggag tttgagacca gcctgagcaa catagtgaga 41280
cactgtctct acaaaaaaaa aataataata ataattgttt ttaattagat gggcagggca 41340
ctgtggctca caccgtgaat ccagcactt tgggaggcca aggcggagg attgcttgag 41400
gccaggaggt caggagcagc ctgggccaca ttctgtctc tacaaagaat aaaaaagtta 41460
actgggcatg gtggcacatg cctgtaatcc cagctactca agaggctgag gaggagatt 41520
gcctgagccc aggagttcaa gactgcagt agccttgatc acaccactgt actacagctt 41580
gggcaacaga gtgagacctt gtctccaaaa aaaaagttt gttttttttt atccactctc 41640
ctcaccaaac aaactgagta agtttagagc ctctcagctg gcatgtgttg gaaacagtgc 41700
cctctcatta aagtgtgcc ctactccca ttgctcttg gccttggtca gtatgatgaa 41760
attagtggga ggcagggcaa cagagggcag ggaagagcta gaaatccatg gcctggaaaa 41820
gggaagattt gggagtggcc aggtatctgt agagccacca tgcagaggag gggggcagct 41880
agccttgtgt gctctgttg gcatggtcag caggaggcag agcaaaagga caagggttaag 41940
taaacctgta ggtcgggaca agccaagagc catccagcgt cagtcctctc tgggtagccc 42000
aagtaagaca ggagcatacc ccagagagaa agttcgagg gctgttcacc tgcagtgtctg 42060
tggacttcaa ccttcttgtt ccttcttcag taagtgaana taacagtcac tgaccatgac 42120
tattatcgac cgcttttgaa aatgtaaaca tagtgacttt attgctgtaa aaatcatatc 42180
tgtttatcat cttaaaaatc aggaacatg gacaggtaca aagatgtgca aaatatcatc 42240
caaaatccca tttgtggcc aggcacggtg gtcacgcct gtaatccca cacttggtga 42300
ggcggaggcg ggcaaatcac ttgaggtcag gagtttgaga ccagcctggc caacatgggtg 42360
aaacctatc tctactaaaa atacaataat taggctgggc gcagtggctc acgcctataa 42420
tcccagcact ttgggaggcc gaggtgggag aatcacagg tcaggagttt gagactagcc 42480
tggccaatat ggtgaaaccc catctctact aaaaatacaa aaattagggc cgggtgtggt 42540
ggctcacgcc tgtaatccca gcaactaggg aggcggagac agatggatcg cgagatcagg 42600
agttcgagac caacctagcc aacatggtga aaccccatct ctactaaaaa aatacaaaaa 42660
ttattcggtt tgggtggcac acgcctgtaa tcccagctac ttgggaggct gaggcaggag 42720
aatctcttga acctgggagg cagagggttg agtgagtgga gatccgcgg ttgcactcca 42780
gcctgggcca cagagtgaga ctccatcaaa aaaaaaaaaa aaattagccg 42840
ggcgtggtgg cgtgcaccta tactccagc tacttgggag gctgaggcag gagaatcgct 42900
tgaacctgga aggcggagggt cgcagtgagc cgagatcgtg ccattgcaat tcagcctggg 42960
cgacagagcg agactctgtc tcaaaaataa taataataac aataactagc cgggcctggt 43020
ggcacatgcc tgtagtccca gttactcagg aggcggaggc atgagactca ggtgaactag 43080
ggagacagag gttgcagtga gccaaagatc caccactgca ctccagcctg gttgacagag 43140
cgagactctg tctcaaaaaa aaaaaaatcc catttgctca ttttttgat actagtataa 43200
ctatcactct aaacagtta gtacttaaat caagcagata tgggagatgg tgaattacca 43260
tctacagtgt tgtcatatat gtcacatact gagcattatc agctagtata atctagttaa 43320
ttgttctatg tgtgatgtat gcagagttcc cattttgaat gtgtttttac tatgcttaa 43380

-continued

taaatgactg atgtcagcaa ccccaaatg atacatctga tgtaagagcc cctgttcccc 43440
 aataataaca tctaaactat agacattgga atgaacaggt gccctaagt ttctccctc 43500
 cagggtttct tggccgtct ctgaggacta cacatcccta ctccgtctt tcctcatctt 43560
 caggcgagct aacagtatct ccaagtcccc tggccccagc tccccaaagg agccccgtct 43620
 gttcagccgt gacatcagcc gctcagaatc ccttcgtgtg tccagcagct attcagagca 43680
 gatcttccgg ccctgtgacc taatccatgg ggaggtcctg ggaagggct tctttggca 43740
 ggctatcaag gtgagcgag gcaacaattg ctttgcctt ctgccccag tccctctgtc 43800
 actgtcttc ggggatttct catcacttgg cccacccca caccatgag gatgccaggc 43860
 ctctctctg gctttgggtg ttggtgtgag aggtatcctt cccccccac caggccacct 43920
 aaggtaaatg ttgctgttac agtgagcttg tggacctgga gatccaggtt ggggtgagct 43980
 gtgcctgtgg ccctcctgcc tccagtcagt ggggtttgt taggtgcctg cagacctcag 44040
 taccgggcat gctacaagga gcacacaggg gaatggctcc tgcctccctg gtgaacagtc 44100
 tcagggacta acctctctct ttctctctc ctctctctt tctgtgaga actggggagg 44160
 ggggtcaggt aagactgtg tctcagcttg ggggcagcag ggctggagag ctacccccg 44220
 atccaccag ctccctgggt catgtcttg gcaactgacct tctgcccc agacttctgt 44280
 tcactcagga gactcacttc tatgccaat gaccagagcc cctgcttggc ttggcagcat 44340
 cccctctgc cttcttcccc acttccctt tctgggttct tgcctgtcct ctgtgcatgc 44400
 ccagctctcc aggaagagg gtttgcctc gtgtgagtc catgttctc cagctgcat 44460
 cttccacaca tgaactctgt cattctgacc cggctcagtg tgcctccaa gggatgggat 44520
 ggccagctgc atagatttct tcaaacagtt ctccagaact tctctggtc tcagcccat 44580
 taacagtcac cctccctgta ggtgacacac aaagccacgg gcaaagtgat ggtcatgaaa 44640
 gagtaattc gatgtatga ggagaccag aaactttt tgactgaggt aagaagatgg 44700
 agggggcccg ggaggttgg gtcaccattg gaagagagaa gacctacaa ataattggct 44760
 caagagaaaa tacagtttg aattactgtc ttaagacta agcagaaaag agccctagag 44820
 gaatatccca ctccctctaa attacagcgt aattatttgt tcaatgaaca ctactaaaa 44880
 gcaacacaaa cagggtacaa gggatgcagt aacaaaagat acagggttca gaagagctct 44940
 caggttatga ggatgatga catgaanaca ctccaattta gtacaactca atgttataat 45000
 cctcacctga acgcccgtct aaggagacct ggaggggagc tcctgagca ctcacactcc 45060
 ttgggcattt acagttttca ctaccctcc caagtactt catggagtaa cttagtttg 45120
 ggacacctgt ggtctgggtg ttgcctcca agccacttg ccactccac ccagttctc 45180
 ccaatgcagt tcaagggta aggcctatga agccatctc atctatatgg tgggtgtctt 45240
 ccctcatctt gatcttagtg ccctgtcata tcacaagata ggaggtagga gatacaggtg 45300
 gtaacacttg tcaagctgat tccctggagg gaagaggtaa ggaagacagt gagaagtaa 45360
 ccaccagctt tccctggctt ccccccccc caggtgaaag tgatgcgag cctggaccac 45420
 cccaatgtgc tcaagttcat tgggtgtctg tacaaggata agaagtgaa cctgctgaca 45480
 gagtacattg aggggggac actgaaggac tttctgcgca gtatggtgag cacaccacc 45540
 catagtctcc aggagccttg gtgggtgtc agacacctat gctatcata ccttaggagc 45600
 ttaagggca gaggggccct gcttgcctc caaaggacca tgctgggtg gactgagcat 45660
 acatagggag gcttcaactg gagaccacat tgacctagg ggcctggacc acgagtgga 45720
 cagggtctca cagcctctga aaatcattcc ccattctgca ggatccgtt cctggcagc 45780

-continued

agaaggtcag gtttgccaaa ggaatgcct ccggaatggt gagtcccacc aacaaacctg 45840
ccagcagggc gagagtaggg agaggtgtga gaattgtggg cttcactgga aggtagagac 45900
cccttcctat gcaacttgtg tgggctgggt cagcagctat tcattgagtt tgtctgtgtc 45960
actgaaactg accccagcca actgtttctca gttcacagcc ctgttttcaa agaattacac 46020
atctctaaag gcaaacaggc caccgacaag gcaaaactgga gaggcacact gtagcctgag 46080
atggcctggg cttgccatca cagggtattca ggtgctgagg gccttagac caactagagc 46140
acctcactgc ctaggaaatc aatgaagggg aaatgagttc tagcggagcc ctgaaggatc 46200
agaattgat aaagtctta ttggcagaga ggcaccagga ttgaagtgc agggacaaag 46260
acctgggagg aaagaggaga aaatcatcta tttcacctgg aaacaaatga ttccaagcat 46320
agaaataata acagctgaca agtactgagt gccctctata tgctaggcac tgggctgagg 46380
gattaacatg catgtgatg tttattcttc atgacaacct tggtttccag ataagctgga 46440
ctggaaaggg acagagctgg gatcctgggc taatcagtct ggtcgccaag cctgagactt 46500
tagccactgc cttcacatg ggggtccatg aaaatagtag tagtctgga cagtttgggg 46560
gtacatcaag gtcgctgtgt ttaagctat ggagcttgga ctataggaga caaatgtaaa 46620
agagttttt ggtgactgg ctttttggtt tttttgttg tttgtttgtt tgtttgttg 46680
tttgtttgtt ttttctgtt tctggggctt gaatcaggaa ggaggtttt ttgtgttgt 46740
tgttttgaga aaggatattg ctctgttgcc cagactggag tgcatgtgga cgatcatggc 46800
tcactacagc ttcgacctcc tgggtcgaag caatcctct gccttagcct cccaagtagc 46860
tggactacag gtgtgtacca ccacacctaa ttttttgaat tttttttct tttttttt 46920
ttttttttt ggtagagaca ggttctcact ttgttgccca ggctgaatc tcaaaacctc 46980
gggctcaagc attcctctg cctcgccctc ccaagtggt gggattacag ttgtgagcca 47040
ccatgcccgg caggaaaaga tttttaagca agaaagctta agagctgtgg tttttccaaa 47100
atgagctctg gctggcacag tggctcatgc ctgtaatccc agcactttt tgggaggccg 47160
aggtgagtg atcacttgag gtcaggagtt tgagaccagc ctggccaact ggtgaaacct 47220
ctgtttctac taaagaaaaa aatgcaaaaa ttagctgggc gtggtggtgc acgcctgtag 47280
tcccagctac tcaggaggcc gaggcaggag aatagcttga acctgggagg cagaagttgc 47340
agttagccaa gatcacacca ctgcattcca gcctgggtga cagagtgaga cttcatctca 47400
aaaaaaaaa aaaaagagga ctgatatggt tagtacattg ggtggaatg cggagggtcc 47460
agggaatgga gccctgcata gggggctaat gaaacattc agatttctga attaaggtag 47520
tggctgtggg gacaggagcc tgggaggcag ggtggagtca gaatggagag actggtggc 47580
aatgagggaa caggaggagg aggaggagga gttacgagt gcttgagggt tcacttacca 47640
gacatttggg ggaatgggga tagccgtgat tgttgagcaa ctggtttggg aagagctagc 47700
attgatccct gctgttctgt gctagcagaa cctatcagca tcttctgggc aggaactgg 47760
ctccatgaga ctggcttagg gagaggctgc tagtcacctc atctgcagag aaggggcagc 47820
tggagctgtg ggacagaaga ggcattcatg tagctgtgg ggtgtctca gcttgtaag 47880
aggagatggc tttagcagc gctgacactg aaaaaggctg aagaaaaaa cagacacaca 47940
agagtctcag gatcaggtag cataggaaag ttgtggacag tctttgagga gcaactcctc 48000
aggcaggcag gcaggcaggt catgagctat agcgattcag gaagagctcc ctgggtgtgt 48060
gagcagctcc aggagcctaa gggatgaaag tagtattgca gggggctgga gagcaaggag 48120

-continued

tggctccttc tacatttgca agggaaaggag aaaggaagtt gctcctgaga gtggtaaagag 48180
tcagtggtgg aggcctggag aggagacata acaaacaaat ttgttgacaa acattttggt 48240
aggaaggggg agagcttaaa gtttagacag tggggaaggt ggagtcttag aggaggtgaa 48300
tgtctgaaag acagagctag ctggagcaag aagtcacttc tctgttgacg gcaggaagga 48360
tccaaagtgg ctcaagccag agattgggag agtggggagg agggagcagc ctggatctaa 48420
gtaaaatggg tagaggtgga ggggggtgctg caacggccag ggttttctga agttggggac 48480
attaggagag agctgtgagg gctttggcca gccactgtgc tagtgattgg tgaaccaaag 48540
gatgggcagg agatggcagc agggaaagcag aggaagtcca ggcttcctgt tggatttggg 48600
acaaggaga gggccatagga gggcctggcc ctgttgcca ggttgggttc tgaagctggg 48660
tgggcatggc ctggtaggag agcatctatg gcgccaatt ccagattcag ggtctagtgt 48720
atttgctggc cctgtagcct cagctcatgc ttctgttcca ggcctatttg cactctatgt 48780
gcatcatcca ccgggatctg aactgcaca actgcctcat caagttggta tgtccactg 48840
ctctgggctt ggctccagg gtcctatcct tcctggcttc ctgtcacaa aggaggctga 48900
cttgccctct ctggctagag ggcagagggt ttgcctagga gctcctatct ttcccttct 48960
gcttcttcca atgcccctct ctgtcctctg ggagctccga gacacacaca gacataattt 49020
cacctctctc cattagcaac ctttgaata atttgattag aagggacttc agaagtttgt 49080
tgactatatg tagaaaacc ttgtatttta cctgcttttg ccccatagta gtcttgtaaa 49140
acagttcatt gctgaccca tttacagtgt gtggcacctg aagcctcagc ctgaggccac 49200
cgagctagta aatttacagg gaccagtttg agaccagcat tcctcccact gccctcagc 49260
tgtggtggtt acaatgttgt ttgtcttact gacttgctat ctggtctcct ggggtctctac 49320
cggctggccc tggctctgcc ctctagacct acaccacgca atcttcattc cttccacaca 49380
tgactgccct gtagctatc aaagagcttg tctcccccac gtctcccact ctactgcctc 49440
caccttgctt ttttctgtct tatcctggtt ctgaccactg cctgaatca ttttaggaat 49500
aagacaggag agggaaaaac aaaagcaacc cctgtccca cctctgagtt ccactctcca 49560
agtccctgag cctcaccctc agggctccag tggctctgcc atgaaccac tgtgggctgg 49620
gagtgctgtg tgcacagata ccagaccctc agaaacacaa atgccaaagt tgtctgtttt 49680
tttgttttgt tttgttttgt ttttttagatg gagtctcatt ctgtttccca ggtggagtg 49740
cagtggtgca atcttggtt actgcagcct ctactcccg ggtctagtgt attgttctgc 49800
ttcagcctcc cagtagctag gactacaggc gtgtgccacc acgcccagct aattttttt 49860
ttttttttt tgtattttta gtagagacag ggttttgcca tgttgccag gctggtcttg 49920
aactcctgac ctgagtgat tcacccgctt tggcctccca aagttctggg attacaggtg 49980
gaagccaccg tgcctggcct gagtgtgtct atttgataga gctttctgct ctgattctcc 50040
cttgctatac accttttctc cccttctcag tggcttctct tgcctatgct tcctcccag 50100
ggccaggttt gagaacatcc ccatgaagtc ctgacctgtc ttttatacta ccaggacaag 50160
actgtgtgtg tggcagactt tgggctgtca cggctcatag tggaaagag gaaaagggcc 50220
cccatggaga agggccaccac caagaaacgc accttgcca agaagaccg caagaagcgc 50280
taacaggttg tgggaaaccc ctactggatg gccctgaga tgcgaacgg tgaagcctga 50340
agccctggag gggacaccg cagagggagg acagatgctg cccttgcatc agagccctgg 50400
gaattccagg ggaggcctgt gaagcgtagg accggatacc cagagctgag gatatttttc 50460
ccttgccagg tggggcctca cgatttagct cctgagctca gggggctggg aactgatcag 50520

-continued

tgtcccatca tgggggataa ggtgagttct gactgtggca tttgtgcctc agggatcgct 50580
aagagctcag gctattgtcc cagcttttagc cttctctctc catggtgaga actgaagtgt 50640
ggtgccctct ggtggataat gctcaaacca accagagatg ctggttggga ttcttgaat 50700
cagggttggt aggcctcaga aatggtctga atacaatcca ttttgagtc tgaggccag 50760
agaagttcag tgaattgcct aggagcatatc agctgcctaa tggcagaggc tagatgaacc 50820
ctagtctggt tcttttccac tttaacgtgc agtttcatcc taggcagtgt tatgttataa 50880
gggctctcca aggcagttca cctacggctg aggaaggact attttcaggt ggtgtctgctg 50940
caggacagcc tgtgggtgt cctcacagaa cctgttctag cctagtctct tagctgtggc 51000
ttagattgac cctagacca gtgcagagca ggtaagggat gtaaaactaa cagtgtgctc 51060
tcctgtgttc cccaaggaaa gagctatgat gagacggtg atatcttctc ctttgggac 51120
gttctctgtg aggtgagctc tggcaccag gccatgccc aggcagcagg cctagcagct 51180
ctgecttccc tcggaactgg ggcatctcct cctaggatg actagtctga ctaaatcaa 51240
catgggtgta gggttttatg gtttataacg catctgcaca tctttgccac gttcgtgttt 51300
cattgtctct aagagaagga ctggcagggt tttttgttt tagatggagc ctcacttctg 51360
tgccaggct ggagtgcagt ggcacatct gggctcactg caacctctgc cttctgggt 51420
caagtgtatc tcctgctca gccctccag tagctgggac tacggcaca caccaccatg 51480
cccggctaatt tttgtatgt ttagtagaga cagggtttca ccatgttggc caggctggc 51540
ttgaactccg gacctcaggt gatccgctg cctcagcctc taaaagtgt ggaattaata 51600
ggcgtgagct acctgcccg gccaggtttt ttttttttt tttttagttg aggaaactga 51660
ggcttggaa agggcagtg cttgcacatg gtcgataagg ggcagatgag actcagaatt 51720
ccagaaggaa gggcaagaga ctgttcattg ggctgtctag ctagtcttg ggcctaatgt 51780
agcccttctc agttccctc aagtagaagt agccactcta ggaagtgtca gccctgtgcc 51840
aggtagcagc tggacagagt gaggaatctt ggaagattc ctaccttag gagtttagtc 51900
aggtagcagc atatctcagc gactcaaac cacaacatt caaagccttc tgtaattcct 51960
acaaagtgtg gaggggtaga ggagaggaga gacaaggat ggttaggata atgaaggat 52020
gtttttgttt tttttgttt tttgagatg agtttctc tgtaaccag gctggagtgc 52080
agaggtgcaa tcttggctca ctgcagcctc cgccctccag gttcaagcaa tcctcctgcc 52140
tcagcctccc aagtagctgg gactacaggt gtgcgccacc acgctctgct aatttttga 52200
ttttcagtag agacagggt tcgcatatt ggcagggctg gtctcaaatg cctgacctca 52260
ggtgatacac ccgcttcagc ctcccaaagt gctgagatta caggcatgag ctaccgtgcc 52320
tggccatgaa ggaagatttg ttttaaaaaa ttgttttctt taatattaat tgaacacctc 52380
tggtcagagc actgggctgg tgccagaggg ttccagacat gaatcagatc cagcacctca 52440
tagagcetta atctggcaca cacacacagc cacaaggaga cacagacaag gcagggtagg 52500
atgagtggaa ctgaggagca gatgctgatt tggaaacatt ggcttctgca gtgaagcccc 52560
ttcttagtcc tcttcagtaa ccagctctc agtgatata ggtctggatt agtaagattt 52620
ggagagatga ttggggattg gggagagctc tctaactat tttaccact cctcttctgc 52680
cattcttct gtccacatcc coagcatccc tttccctgc caagtatctg tggcctctgt 52740
agtctttgt aaacagctgt cttcttacc tacagatcat tgggcagggt tatgcagatc 52800
ctgactgcct tccccgaaca ctggactttg gcctcaactg gaagcttttc tgggagaagt 52860

-continued

ttgttccac agattgtccc cggccttct tcccgtggc cgccatctgc tgcagactgg 52920
agcctgagag caggttgga tectgccttt ttctcccagc tcacagggtc ctgggacgtt 52980
tgctctgtc taaggccacc cctgagccct ctgcaagcac aggggtgaga gaagccttga 53040
ggtcaagaat gtggctgtca acccctgagc catctgacaa cacatatgta caggttgag 53100
aagagagagg taaagacata gcagcaagta atctggatag gacacagaaa cacagccatt 53160
aaaagaaagt ttaaaagaag gaaattcacc caaacattt gaatacagta agtgatttca 53220
tctttcgata ttcccctgtc catatctaca catatacttt tttttatagt aaatagttct 53280
gtattttgcc ctgcatttcc ctgtgttta ctatccagtc ttcctgttta tcatTTTTgt 53340
cgacaacatg aaattctatt gagagactgt ctgaacatat tgtaatgtag atgttcaggt 53400
ttttccagtt tctctttaca ataggtattt aactacagtg agcagtttta tgcatttagc 53460
taatttctcc tttgaggaag tattttcaaa attaccttta ttcttctcag gtaataattt 53520
cattattacc aaagtaccct taggtctttt caagtgtgtg gtaaaaaac gagaatcttg 53580
ctggcgcgga tggctcacac ctgtaatccc agcactttgg gaggtgagg ctggtggatc 53640
acctgaggtc tggagttcga gaccagcctg gccaacatgg tgaacccca tctctactaa 53700
aaatacaaaa cttagccagg catggtggca ggtgcctgta accccagcta cttgggaggc 53760
tgaggcagga gaattgcttg aaccagggg cggaggttgc agtgagccga tatcacgcca 53820
ttgcactcca gccctggcaa caagagtga aactctgtct aaaaatggg tcttttct 53880
gccatcaaaa atcatgttct ttttaaaac aagtcaaac attaccaaa tttatagcac 53940
aggaaatagc tcttctgtaa tctccctaa ccaatatatc cctcaacatt ctctcacc 54000
ccaactccac cctcccagga taaccagttg ggacataatc tttatttaa aatggtttcc 54060
ggatagagaa agcgttctgg cggcgccagc cccggcgccg gccgcagggg acaagggcg 54120
ggcgatcgg cggggagggg gcggggcgcg accagccag gcccgggggc tccgcatgct 54180
gcagctgcct ctggcgccgc cccgcgcgcg cctcgcgcg ggagccggcg agctaactg 54240
agccagccgg cggcgctcac ggagcgcgcg gcacaaggag gggcccccag cgcgcacgtg 54300
gccccgagg ccgcgtggc ggacagcggc accgcgggg gcgcggcggt ggcgccccg 54360
gccccggccc ccaggccagg cagtggcggc caaggaccac gcactactt tcagagcccc 54420
ccccggggcc gcaggagagg gcccgggctg ggcggatgat gagggcccc tgaggcgcca 54480
agggaaggtc acctcaagt atgacccaa ggagctacgg aagcacctca acctagagga 54540
gtggtcctg gagcagctca cgcgcctcta cgactgccag gaagaggaga tctcagaact 54600
agagattgac gtggatgagc tectggacat ggagagtgc gatgcctggg cttccaggtt 54660
caaggagctg ctggttgaat gttacaaacc cacagaggcc ttcactctg gcctgctgga 54720
caagatccgg gccatgcaga agctgagcac accccagaag aagtgaaggc ccccgaccca 54780
ggcgaacggt ggctccata ggacaatcgc tacccccga cctcgtagca acagcaatac 54840
cgggggaccc tgcggccagg cctggttcca tgagcagggc tectcgtgcc cctggcccag 54900
gggtctcttc cctgcccccc tcaattttcc acttttggat tttttattg ttattaaact 54960
gatgggactt tgtgtttta tattgactct gcgcacagg ccttttaata aagcgaggta 55020
gggtacgcct ttggtgcagc tcaaaaaaa aaaaaaat gatttccagc ggtccacatt 55080
agagttgaaa ttttctggtg ggagaatcta taccttggtc ctttataggc caaggaccgc 55140
agtccttcag taacaccagt gtaaaagctt gaggagaaat tgtgaagcta cacagtattt 55200
gttttctaata acctcttgc attctaaata tctttaattt attaaaaat atatataac 55260

-continued

agtattgaat gcctactgtg tgctaggtag agttctaaac acttgggtta cagcagcga 55320
caaaataaag gtgcttacc ccatagaaca tagattctag catggtatct actgtatcat 55380
acagtagata caataagtaa actatattga atattagaat gtggcagatg ctatgaaaa 55440
agagtcaaga caagtaaaga cgattgttca gggtagcagt tgcaatttta aatatggctg 55500
tcagagcagg cctcactgag gtgacatgac atttaagcat aaacatggag gaggaggagt 55560
aagcctgagc tgtcttaggc ttccggggca gccaaagccat ttccgtggca ctaggagcct 55620
ggtgtttccg attccacctt tgataactgc attttctcta agatatggga gggaagtttt 55680
tctcctattg tttttaagta ttaactccag ctagtccagc cttgttatag tgttacctaa 55740
tctttatagc aaatatatga ggtaccggtt acattatgcc catttctcac agaggcacta 55800
ctaggtgaag gagtttgctt gacgttatac aaccagggaag tagctgagcc tagatccctt 55860
ccaccacccc catggccctg ctcatgttcc acctgctctt aatttacctc ttttctctct 55920
agaccagcat tctcgaatt ggaggactcc tttagggccc tctccctgta cctgggggag 55980
ctgggcaccc cgctgctgc agagctggag gagttggacc acactgtgag catgcagtac 56040
ggcctgaccc gggactcacc tccctagccc tggcccagcc cctgcaggg ggggtttcta 56100
cagccagcat tgccctctg tgcccatc ctgctgtgag cagggccgtc cggtcttctt 56160
gtggattggc ggaatgttta gaagcagaac aagccattcc tattacctcc ccaggaggca 56220
agtgggcgca gcaccaggga aatgtatctc cacaggttct ggggcctagt tactgtctgt 56280
aaatccaata cttgctgaa agctgtgaag aagaaaaaa cccctggcct ttgggcccag 56340
aggaatctgt tactcgaac caccaggaa ctccctggca gtggattgtg ggaggctctt 56400
gcttactact atcagcgtga cctggacctg ctgggcagga tccagggtg aacctgcctg 56460
tgaactctga agtactagt ccagctgggt gcaggaggac ttcaagtgtg tggacgaag 56520
aaagactgat ggtcaaagg gtgtgaaaa gtcagtgtg ctccccctt ctactccaga 56580
tctgtcctt cctggagcaa ggttgaggga gtaggttttg aagagtcctt taatatgtg 56640
tggaacaggc caggagttag agaaagggtt ggctctgtt tactgtctca ctggctctag 56700
ccagcccagg gaccacatca atgtgagagg aagcctccac ctcatgttt caaacttaat 56760
actggagact ggtgagaac ttacggacaa catcctttct gtctgaaaca aacagtcaca 56820
agcacaggaa gaggtgggg gactagaaag aggccctgcc ctctgaaag ctcatgctt 56880
ggcttctgtt actcactac ggggtgggtc cttagtcaga tgccataaac attttgctta 56940
aagctcagat ggttctggag gacagtgtg cttgtcacag gcctagatc tgaggggagg 57000
gagtgaggat ctacgaatc tottggtctt ggcttcatgg caaccactgc tcaccttca 57060
acatgcctg tttaggcagc agcttgggtt gggaagaggt ggtggcagag tctcaaagct 57120
gagatgctga gagagatagc tccctgagct gggccatctg acttctacct cccatgttg 57180
ctctcccaac tcattagctc ctgggcagca tctcctgag ccacatgtgc aggtactgga 57240
aaacctccat cttgctccc agagctctag gaactcttca tcacaactag atttgctct 57300
tctaagtgc tatgagctt caccatattt aataaattgg gaatgggtt ggggtattaa 57360
tgcaatgtgt ggtggttga ttggagcagg ggaattgat aaaggagagt ggtgtctgtt 57420
aatattatct tatctattg gtggtatgtg aaatattgta catagacctg atgagttgtg 57480
ggaccagatg tcactctg tcagagtta cttgctatat agactgtact tatgtgtgaa 57540
gtttgcaagc ttgctttag gotgagccct ggactcccag cagcagcaca gttcagcatt 57600

-continued

gtgtggctgg ttgtttcctg gctgtcccca gcaagtgtag gagtgggtgg cctgaactgg 57660
 gccattgac agactaaata aattaagcag ttaacataac tggcaatatg gagagtgaag 57720
 acatgattgg ctgagggaca taaatgtaga gggctgcta gccacottct ggcctagccc 57780
 acacaaactc cccatagcag agagtattca tgcacccaag tctaaaacc tcaagcagac 57840
 acccatctgc tctagagaat atgtacatcc cacctgaggc agccccctcc ttgcagcagg 57900
 tgtgactgac tatgaccttt tcttgccctg gctctcacat gccagctgag tcattcotta 57960
 ggagccctac cctttcatcc tctctatatg aatacttcca tagcctgggt atcctggctt 58020
 gctttcctca gtgctgggtg ccacctttgc aatgggaaga aatgaatgca agtcacccca 58080
 ccccttgctg ttctttacaa gtgcttgaga ggagaagacc agtttcttct tgctttctgca 58140
 tgtgggggat gtcgtagaag agtgaccatt gggaaggaca atgctatctg gttagtgggg 58200
 ccttggggc aatataaatc tgtaaaccca aaggtgtttt ctcccaggca ctctcaaac 58260
 ttgaagaatc caacttaagg acagaatatg gttcccgaaa aaaactgatg atctggagta 58320
 cgcattgctg gcagaaccac agagcaatgg ctgggcatgg gcagaggcca tctgggtgtt 58380
 cctgaggctg ataacctgtg gctgaatatc cttgctaaaa gtccaggaga cactcctgtt 58440
 ggatctcttt cttctggagt catagtagtc accttgacgg gaacttctct agcccagggc 58500
 tgctgcaggc agcccagtga cccttctctc tctgcagtta tcccccttt ggctgtctgca 58560
 gcaccacccc cgtcaccac caccacaacc ctgccgact ccagccttta acaagggtg 58620
 tctagatatt cattttaact acctccacct tggaacaat tgctgaagg gagaggattt 58680
 gcaatgacca accacctgtg tgggacgcct gcacacctgt ctttctctgt tcaacctgaa 58740
 agattcctga tgatgataat ctggacacag aagccgggca cggtggtctt agcctgtaat 58800
 ctacgacctt tgggaggcct cagcagggtg atcacctgag atcaagagtt tgagaacagc 58860
 ctgaccaaca tggtgaaacc ccgtctctac taaaaataca aaattatgcc aggtgtgggtg 58920
 gcacatacat gtaatccag ctactctgga ggctgaggca ggagaatgc ttgaaccac 58980
 aaggcagagg ttgcagtga gcgagatcat gccattgcac tccagcctgt gcaacaagag 59040
 ccaaaactcca tctcaaaaa aaaaa 59065

<210> SEQ ID NO 4
 <211> LENGTH: 265
 <212> TYPE: PRT
 <213> ORGANISM: Human

<400> SEQUENCE: 4

Leu Thr Glu Val Lys Val Met Arg Ser Leu Asp His Pro Asn Val Leu
 1 5 10 15

Lys Phe Ile Gly Val Leu Tyr Lys Asp Lys Lys Leu Asn Leu Leu Thr
 20 25 30

Glu Tyr Ile Glu Gly Gly Thr Leu Lys Asp Phe Leu Arg Ser Met Asp
 35 40 45

Pro Phe Pro Trp Gln Gln Lys Val Arg Phe Ala Lys Gly Ile Ala Ser
 50 55 60

Gly Met Ala Tyr Leu His Ser Met Cys Ile Ile His Arg Asp Leu Asn
 65 70 75 80

Ser His Asn Cys Leu Ile Lys Leu Asp Lys Thr Val Val Val Ala Asp
 85 90 95

Phe Gly Leu Ser Arg Leu Ile Val Glu Glu Arg Lys Arg Ala Pro Met
 100 105 110

-continued

Glu	Lys	Ala	Thr	Thr	Lys	Lys	Arg	Thr	Leu	Arg	Lys	Asn	Asp	Arg	Lys
	115						120					125			
Lys	Arg	Tyr	Thr	Val	Val	Gly	Asn	Pro	Tyr	Trp	Met	Ala	Pro	Glu	Met
	130					135					140				
Leu	Asn	Gly	Lys	Ser	Tyr	Asp	Glu	Thr	Val	Asp	Ile	Phe	Ser	Phe	Gly
	145				150					155					160
Ile	Val	Leu	Cys	Glu	Ile	Ile	Gly	Gln	Val	Tyr	Ala	Asp	Pro	Asp	Cys
			165					170						175	
Leu	Pro	Arg	Thr	Leu	Asp	Phe	Gly	Leu	Asn	Val	Lys	Leu	Phe	Trp	Glu
			180					185						190	
Lys	Phe	Val	Pro	Thr	Asp	Cys	Pro	Pro	Ala	Phe	Phe	Pro	Leu	Ala	Ala
		195					200						205		
Ile	Cys	Cys	Arg	Leu	Glu	Pro	Glu	Ser	Arg	Pro	Ala	Phe	Ser	Lys	Leu
	210					215					220				
Glu	Asp	Ser	Phe	Glu	Ala	Leu	Ser	Leu	Tyr	Leu	Gly	Glu	Leu	Gly	Ile
	225				230					235					240
Pro	Leu	Pro	Ala	Glu	Leu	Glu	Glu	Leu	Asp	His	Thr	Val	Ser	Met	Gln
				245					250						255
Tyr	Gly	Leu	Thr	Arg	Asp	Ser	Pro	Pro							
			260				265								

That which is claimed is:

1. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
 - (b) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:1;
 - (c) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:3; and
 - (d) a nucleotide sequence that is completely complementary to a nucleotide sequence of (a)-(c).
2. A nucleic acid vector comprising a nucleic acid molecule of claim 1.
3. A host cell containing the vector of claim 2.
4. A process for producing a polypeptide comprising culturing the host cell of claim 3 under conditions sufficient for the production of said polypeptide, and recovering the peptide from the host cell culture.

5. An isolated polynucleotide consisting of a nucleotide sequence set forth in SEQ ID NO:1.

6. An isolated polynucleotide consisting of a nucleotide sequence set forth in SEQ ID NO:3.

7. A vector according to claim 2, wherein said vector is selected from the group consisting of a plasmid, virus, and bacteriophage.

8. A vector according to claim 2, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that the protein of SEQ ID NO:2 may be expressed by a cell transformed with said vector.

9. A vector according to claim 8, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.

* * * * *